NO324932B1 - 1,2,3,4-Tetrahydroisokinolin-derivater, fremgangsmate for fremstilling av slike, farmasoytiske preparater inneholdende slike samt slike forbindelser anvendt til fremstilling av medikament for behandling av sykdommer - Google Patents
1,2,3,4-Tetrahydroisokinolin-derivater, fremgangsmate for fremstilling av slike, farmasoytiske preparater inneholdende slike samt slike forbindelser anvendt til fremstilling av medikament for behandling av sykdommer Download PDFInfo
- Publication number
- NO324932B1 NO324932B1 NO20024339A NO20024339A NO324932B1 NO 324932 B1 NO324932 B1 NO 324932B1 NO 20024339 A NO20024339 A NO 20024339A NO 20024339 A NO20024339 A NO 20024339A NO 324932 B1 NO324932 B1 NO 324932B1
- Authority
- NO
- Norway
- Prior art keywords
- benzyl
- dimethoxy
- acetamide
- dihydro
- isoquinolin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 230000008569 process Effects 0.000 title claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 11
- 238000011282 treatment Methods 0.000 title claims description 11
- 239000003814 drug Substances 0.000 title claims description 9
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 7
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical class C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 title abstract description 16
- 201000010099 disease Diseases 0.000 title description 5
- 239000004480 active ingredient Substances 0.000 claims abstract 4
- 238000006243 chemical reaction Methods 0.000 claims description 157
- 239000000203 mixture Substances 0.000 claims description 34
- -1 lower-alkenyl Chemical group 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 28
- 125000000623 heterocyclic group Chemical group 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 22
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 19
- 102000002512 Orexin Human genes 0.000 claims description 17
- 108060005714 orexin Proteins 0.000 claims description 17
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 208000008589 Obesity Diseases 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 7
- 235000020824 obesity Nutrition 0.000 claims description 7
- 208000019116 sleep disease Diseases 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- UZJLYRRDVFWSGA-UHFFFAOYSA-N n-benzylacetamide Chemical compound CC(=O)NCC1=CC=CC=C1 UZJLYRRDVFWSGA-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 125000002619 bicyclic group Chemical group 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 125000002950 monocyclic group Chemical group 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052717 sulfur Chemical group 0.000 claims description 3
- 239000011593 sulfur Chemical group 0.000 claims description 3
- GEYCZKOLGCILBP-UHFFFAOYSA-N 2-[1-[(3,4-dichlorophenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-3-ylmethyl)acetamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1CC1C=2C=C(OC)C(OC)=CC=2CCN1CC(=O)NCC1=CC=CN=C1 GEYCZKOLGCILBP-UHFFFAOYSA-N 0.000 claims description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 238000006482 condensation reaction Methods 0.000 claims description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 2
- 238000005580 one pot reaction Methods 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- BFYOCLKGJYHCMY-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(naphthalen-1-ylmethyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NCC1=CC=CC2=CC=CC=C12 BFYOCLKGJYHCMY-UHFFFAOYSA-N 0.000 claims 1
- ASOAAMJIFYSJEV-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-8-ethoxy-5-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-2-ylmethyl)acetamide Chemical compound C=1C=C(OC)C(OC)=CC=1CC1C=2C(OCC)=CC=C(OC)C=2CCN1CC(=O)NCC1=CC=CC=N1 ASOAAMJIFYSJEV-UHFFFAOYSA-N 0.000 claims 1
- 239000012876 carrier material Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- ACOHAEBNFWGQCL-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)acetamide Chemical compound CC(=O)NCC1=CC=CC=N1 ACOHAEBNFWGQCL-UHFFFAOYSA-N 0.000 claims 1
- FYSUZYYFUUADES-UHFFFAOYSA-N n-benzyl-2-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NCC1=CC=CC=C1 FYSUZYYFUUADES-UHFFFAOYSA-N 0.000 claims 1
- 229940123730 Orexin receptor antagonist Drugs 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 252
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 151
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 50
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 46
- 238000007363 ring formation reaction Methods 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 23
- YXWQTVWJNHKSCC-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1 YXWQTVWJNHKSCC-UHFFFAOYSA-N 0.000 description 21
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 19
- ANOUKFYBOAKOIR-UHFFFAOYSA-N 3,4-dimethoxyphenylethylamine Chemical compound COC1=CC=C(CCN)C=C1OC ANOUKFYBOAKOIR-UHFFFAOYSA-N 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- PXJACNDVRNAFHD-UHFFFAOYSA-N (2-methoxyphenyl)methanamine Chemical compound COC1=CC=CC=C1CN PXJACNDVRNAFHD-UHFFFAOYSA-N 0.000 description 14
- LAUPTNYHVCVPFH-UHFFFAOYSA-N (2-ethoxyphenyl)methanamine Chemical compound CCOC1=CC=CC=C1CN LAUPTNYHVCVPFH-UHFFFAOYSA-N 0.000 description 13
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical class NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 239000000460 chlorine Substances 0.000 description 12
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000008346 aqueous phase Substances 0.000 description 11
- AKEYUWUEAXIBTF-UHFFFAOYSA-N n-methylnaphthalen-1-amine Chemical compound C1=CC=C2C(NC)=CC=CC2=C1 AKEYUWUEAXIBTF-UHFFFAOYSA-N 0.000 description 11
- XASGBYOFEJTAPK-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-5,8-dimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound N1CCC=2C(OC)=CC=C(OC)C=2C1CC1=CC=C(OC)C(OC)=C1 XASGBYOFEJTAPK-UHFFFAOYSA-N 0.000 description 10
- QBJIMTPENIGDOG-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)acetyl chloride Chemical compound COC1=CC=C(CC(Cl)=O)C=C1OC QBJIMTPENIGDOG-UHFFFAOYSA-N 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 10
- KPWTVVBDJMLSJG-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6-methoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound N1CCC2=CC(OC)=CC=C2C1CC1=CC=C(OC)C(OC)=C1 KPWTVVBDJMLSJG-UHFFFAOYSA-N 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 239000012981 Hank's balanced salt solution Substances 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 description 8
- YXWQTVWJNHKSCC-INIZCTEOSA-N (1s)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=C(OC)C(OC)=CC=C1C[C@H]1C2=CC(OC)=C(OC)C=C2CCN1 YXWQTVWJNHKSCC-INIZCTEOSA-N 0.000 description 7
- ZWXFFJWOZVUYKB-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7,8-trimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=C(OC)C(OC)=C(OC)C=C2CCN1 ZWXFFJWOZVUYKB-UHFFFAOYSA-N 0.000 description 7
- WMWYGDZKGRHADI-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6-methoxy-7-propan-2-yloxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC(C)C)=C(OC)C=C2CCN1 WMWYGDZKGRHADI-UHFFFAOYSA-N 0.000 description 7
- NRJCAOCPBSXOGP-UHFFFAOYSA-N 6,7-dimethoxy-1-[(3-methoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline Chemical compound COC1=CC=CC(CC2C3=CC(OC)=C(OC)C=C3CCN2)=C1 NRJCAOCPBSXOGP-UHFFFAOYSA-N 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- LRFWYBZWRQWZIM-UHFFFAOYSA-N (2-fluorophenyl)methanamine Chemical compound NCC1=CC=CC=C1F LRFWYBZWRQWZIM-UHFFFAOYSA-N 0.000 description 6
- ANWKSRMTENFMAJ-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-5,6,7-trimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=C(OC)C(OC)=CC=C1CC1C(C=C(OC)C(OC)=C2OC)=C2CCN1 ANWKSRMTENFMAJ-UHFFFAOYSA-N 0.000 description 6
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- BGXHKISGQNWFOY-UHFFFAOYSA-N 4-[(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]-n,n-dimethylaniline Chemical compound C1=2C=C(OC)C(OC)=CC=2CCNC1CC1=CC=C(N(C)C)C=C1 BGXHKISGQNWFOY-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 102000008834 Orexin receptor Human genes 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 150000002989 phenols Chemical class 0.000 description 6
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- PFYXGKHVNOPDHU-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-ylmethyl)-5,8-dimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=C2OCOC2=CC(CC2C=3C(OC)=CC=C(C=3CCN2)OC)=C1 PFYXGKHVNOPDHU-UHFFFAOYSA-N 0.000 description 5
- SRKDGMYMABXBMA-UHFFFAOYSA-N 1-[(2,5-dimethoxyphenyl)methyl]-5,8-dimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound COC1=CC=C(OC)C(CC2C3=C(OC)C=CC(OC)=C3CCN2)=C1 SRKDGMYMABXBMA-UHFFFAOYSA-N 0.000 description 5
- DQLMJULGOGAQCH-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,8-dimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=2C(OC)=CC(OC)=CC=2CCNC1CC1=CC=C(OC)C(OC)=C1 DQLMJULGOGAQCH-UHFFFAOYSA-N 0.000 description 5
- HWNSTGWDEVWFNH-UHFFFAOYSA-N 1-benzyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=2C=C(OC)C(OC)=CC=2CCNC1CC1=CC=CC=C1 HWNSTGWDEVWFNH-UHFFFAOYSA-N 0.000 description 5
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 5
- FPWLTKFZPJGKSX-UHFFFAOYSA-N 2-methoxy-2-(3-methoxyphenyl)ethanamine Chemical compound COC(CN)C1=CC=CC(OC)=C1 FPWLTKFZPJGKSX-UHFFFAOYSA-N 0.000 description 5
- HSNRSHBFNHIQQL-UHFFFAOYSA-N 6,7-dimethoxy-1-(naphthalen-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=CC2=CC(CC3NCCC=4C=C(C(=CC=43)OC)OC)=CC=C21 HSNRSHBFNHIQQL-UHFFFAOYSA-N 0.000 description 5
- NCBLMBAELRCUHD-UHFFFAOYSA-N 6,7-dimethoxy-1-[(2,3,4-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=2C=C(OC)C(OC)=CC=2CCNC1CC1=CC=C(OC)C(OC)=C1OC NCBLMBAELRCUHD-UHFFFAOYSA-N 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- OFNHNCAUVYOTPM-IIIOAANCSA-N orexin-a Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N2)[C@@H](C)O)=O)CSSC1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NC(=O)CC1)C1=CNC=N1 OFNHNCAUVYOTPM-IIIOAANCSA-N 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- YRYCIFUZSUMAAY-UHFFFAOYSA-N (RS)-1-benzyl-1,2,3,4-tetrahydroisoquinoline Chemical group N1CCC2=CC=CC=C2C1CC1=CC=CC=C1 YRYCIFUZSUMAAY-UHFFFAOYSA-N 0.000 description 4
- YSOCJYPSQCCGNA-UHFFFAOYSA-N 1-[(3-bromo-4-methoxyphenyl)methyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=C(Br)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1 YSOCJYPSQCCGNA-UHFFFAOYSA-N 0.000 description 4
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 4
- ZSTCPHVBMNDKEB-UHFFFAOYSA-N 6,7-dimethoxy-1-(2-phenylethyl)-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=2C=C(OC)C(OC)=CC=2CCNC1CCC1=CC=CC=C1 ZSTCPHVBMNDKEB-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 108050000742 Orexin Receptor Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 150000001347 alkyl bromides Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 150000002527 isonitriles Chemical class 0.000 description 4
- 239000010502 orange oil Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- KDDNKZCVYQDGKE-UHFFFAOYSA-N (2-chlorophenyl)methanamine Chemical compound NCC1=CC=CC=C1Cl KDDNKZCVYQDGKE-UHFFFAOYSA-N 0.000 description 3
- CJAAPVQEZPAQNI-UHFFFAOYSA-N (2-methylphenyl)methanamine Chemical compound CC1=CC=CC=C1CN CJAAPVQEZPAQNI-UHFFFAOYSA-N 0.000 description 3
- RGXUCUWVGKLACF-UHFFFAOYSA-N (3-methylphenyl)methanamine Chemical compound CC1=CC=CC(CN)=C1 RGXUCUWVGKLACF-UHFFFAOYSA-N 0.000 description 3
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 3
- JPQWLBDPQWBRPV-UHFFFAOYSA-N 1-[(3,4-dichlorophenyl)methyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=2C=C(OC)C(OC)=CC=2CCNC1CC1=CC=C(Cl)C(Cl)=C1 JPQWLBDPQWBRPV-UHFFFAOYSA-N 0.000 description 3
- FEBIPJYPQVUYPH-UHFFFAOYSA-N 1-[(3,4-diethylphenyl)methyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=C(CC)C(CC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1 FEBIPJYPQVUYPH-UHFFFAOYSA-N 0.000 description 3
- FNSGPTFLDDASLF-UHFFFAOYSA-N 1-[(3,4-dimethylphenyl)methyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=2C=C(OC)C(OC)=CC=2CCNC1CC1=CC=C(C)C(C)=C1 FNSGPTFLDDASLF-UHFFFAOYSA-N 0.000 description 3
- MOOMGAOQWHKDSC-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=2C=C(OC)C(OC)=CC=2CCNC1CC1=CC=C(Cl)C=C1 MOOMGAOQWHKDSC-UHFFFAOYSA-N 0.000 description 3
- IGWXUFJDUPHOHK-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=2C=C(OC)C(OC)=CC=2CCNC1CC1=CC=C(F)C=C1 IGWXUFJDUPHOHK-UHFFFAOYSA-N 0.000 description 3
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 3
- UPSXAPQYNGXVBF-UHFFFAOYSA-N 2-bromobutane Chemical compound CCC(C)Br UPSXAPQYNGXVBF-UHFFFAOYSA-N 0.000 description 3
- RUJHATQMIMUYKD-UHFFFAOYSA-N 2-naphthalen-1-ylethanamine Chemical compound C1=CC=C2C(CCN)=CC=CC2=C1 RUJHATQMIMUYKD-UHFFFAOYSA-N 0.000 description 3
- IGPYNHMMDJOIQN-UHFFFAOYSA-N 6,7-dimethoxy-1-(1-phenylpropyl)-1,2,3,4-tetrahydroisoquinoline Chemical compound N1CCC2=CC(OC)=C(OC)C=C2C1C(CC)C1=CC=CC=C1 IGPYNHMMDJOIQN-UHFFFAOYSA-N 0.000 description 3
- GXTUEUWFEKEQHJ-UHFFFAOYSA-N 6,7-dimethoxy-1-[(4-methoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1 GXTUEUWFEKEQHJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical class NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000004454 Hyperalgesia Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001408 amides Chemical group 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 230000002267 hypothalamic effect Effects 0.000 description 3
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- OHOWSYIKESXDMN-WMQZXSDYSA-N orexin-b Chemical compound C([C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCSC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)C1=CNC=N1 OHOWSYIKESXDMN-WMQZXSDYSA-N 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- GDFBHCMFIUBEQT-UHFFFAOYSA-N (2,5-difluorophenyl)methanamine Chemical compound NCC1=CC(F)=CC=C1F GDFBHCMFIUBEQT-UHFFFAOYSA-N 0.000 description 2
- IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 2
- QUKGLNCXGVWCJX-UHFFFAOYSA-N 1,3,4-thiadiazol-2-amine Chemical compound NC1=NN=CS1 QUKGLNCXGVWCJX-UHFFFAOYSA-N 0.000 description 2
- HOFWLPPBIBQUCV-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-ylmethyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=C2OCOC2=CC(CC2NCCC=3C=C(C(=CC=32)OC)OC)=C1 HOFWLPPBIBQUCV-UHFFFAOYSA-N 0.000 description 2
- LUBJCRLGQSPQNN-UHFFFAOYSA-N 1-Phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 description 2
- HYHOBLFHBFTVGR-UHFFFAOYSA-N 1-[(2,5-dimethoxyphenyl)methyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound COC1=CC=C(OC)C(CC2C3=CC(OC)=C(OC)C=C3CCN2)=C1 HYHOBLFHBFTVGR-UHFFFAOYSA-N 0.000 description 2
- XUGXVRXTSBIUON-UHFFFAOYSA-N 1-[(3,4-difluorophenyl)methyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=2C=C(OC)C(OC)=CC=2CCNC1CC1=CC=C(F)C(F)=C1 XUGXVRXTSBIUON-UHFFFAOYSA-N 0.000 description 2
- WKMNJFHMNUVFSX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-5-methoxy-8-phenylmethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=2C(CC=3C=C(OC)C(OC)=CC=3)NCCC=2C(OC)=CC=C1OCC1=CC=CC=C1 WKMNJFHMNUVFSX-UHFFFAOYSA-N 0.000 description 2
- RZUZZVWHTNDQOV-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6-methoxy-7-phenylmethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OCC=3C=CC=CC=3)=C(OC)C=C2CCN1 RZUZZVWHTNDQOV-UHFFFAOYSA-N 0.000 description 2
- HLIQXYYZPCEECQ-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-7-methoxy-6-phenylmethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OCC=3C=CC=CC=3)C=C2CCN1 HLIQXYYZPCEECQ-UHFFFAOYSA-N 0.000 description 2
- XMKIJBZKRPJLGX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-8-methoxy-5-phenylmethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=C(OC)C=CC(OCC=3C=CC=CC=3)=C2CCN1 XMKIJBZKRPJLGX-UHFFFAOYSA-N 0.000 description 2
- UCOSRTUSVXHIMK-UHFFFAOYSA-N 1h-benzimidazol-2-ylmethanamine Chemical compound C1=CC=C2NC(CN)=NC2=C1 UCOSRTUSVXHIMK-UHFFFAOYSA-N 0.000 description 2
- CZOZLTKKYXGUOF-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)-n-[2-(2,5-dimethoxyphenyl)ethyl]acetamide Chemical compound COC1=CC=C(OC)C(CCNC(=O)CC=2C=C3OCOC3=CC=2)=C1 CZOZLTKKYXGUOF-UHFFFAOYSA-N 0.000 description 2
- RPDXVMBCIRAVCV-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)-n-[2-(3,4-dimethoxyphenyl)ethyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)CC1=CC=C(OCO2)C2=C1 RPDXVMBCIRAVCV-UHFFFAOYSA-N 0.000 description 2
- ODVLMCWNGKLROU-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)acetic acid Chemical compound OC(=O)CC1=CC=C2OCOC2=C1 ODVLMCWNGKLROU-UHFFFAOYSA-N 0.000 description 2
- GJBVKWQIHCHNBO-UHFFFAOYSA-N 2-(2,5-dimethoxyphenyl)-n-[2-(2,5-dimethoxyphenyl)ethyl]acetamide Chemical compound COC1=CC=C(OC)C(CCNC(=O)CC=2C(=CC=C(OC)C=2)OC)=C1 GJBVKWQIHCHNBO-UHFFFAOYSA-N 0.000 description 2
- YSSRPZDIPQMYDW-UHFFFAOYSA-N 2-(2,5-dimethoxyphenyl)-n-[2-(3,4-dimethoxyphenyl)ethyl]acetamide Chemical compound COC1=CC=C(OC)C(CC(=O)NCCC=2C=C(OC)C(OC)=CC=2)=C1 YSSRPZDIPQMYDW-UHFFFAOYSA-N 0.000 description 2
- RAPIPBRHRYSAHQ-UHFFFAOYSA-N 2-(2,5-dimethoxyphenyl)acetyl chloride Chemical compound COC1=CC=C(OC)C(CC(Cl)=O)=C1 RAPIPBRHRYSAHQ-UHFFFAOYSA-N 0.000 description 2
- AAQIRQUMPMWERW-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-n-[2-(3,4-dimethoxyphenyl)ethyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)CC1=CC=C(F)C(F)=C1 AAQIRQUMPMWERW-UHFFFAOYSA-N 0.000 description 2
- LMBCEKZJBDMWCI-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-[2-(2,5-dimethoxyphenyl)ethyl]acetamide Chemical compound COC1=CC=C(OC)C(CCNC(=O)CC=2C=C(OC)C(OC)=CC=2)=C1 LMBCEKZJBDMWCI-UHFFFAOYSA-N 0.000 description 2
- WKMPNMHAVRYZFG-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-[2-(3-methoxyphenyl)ethyl]acetamide Chemical compound COC1=CC=CC(CCNC(=O)CC=2C=C(OC)C(OC)=CC=2)=C1 WKMPNMHAVRYZFG-UHFFFAOYSA-N 0.000 description 2
- LPBNXHIAXFOGEN-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-[2-(5-methoxy-2-phenylmethoxyphenyl)ethyl]acetamide Chemical compound C=1C=C(OC)C(OC)=CC=1CC(=O)NCCC1=CC(OC)=CC=C1OCC1=CC=CC=C1 LPBNXHIAXFOGEN-UHFFFAOYSA-N 0.000 description 2
- XPHIFDXVOGTFLO-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-[2-(3,4-dimethoxyphenyl)ethyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)CC1=CC=C(Cl)C=C1 XPHIFDXVOGTFLO-UHFFFAOYSA-N 0.000 description 2
- NBICEVBGTVHJCK-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-[(3-methylphenyl)methyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NCC1=CC=CC(C)=C1 NBICEVBGTVHJCK-UHFFFAOYSA-N 0.000 description 2
- JOFJQVWIZBJLIW-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-[(4-fluorophenyl)methyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NCC1=CC=C(F)C=C1 JOFJQVWIZBJLIW-UHFFFAOYSA-N 0.000 description 2
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical class NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 2
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 2
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 2
- KYHMEWQGAKQCIM-UHFFFAOYSA-N 3-naphthalen-1-ylpropanamide Chemical compound C1=CC=C2C(CCC(=O)N)=CC=CC2=C1 KYHMEWQGAKQCIM-UHFFFAOYSA-N 0.000 description 2
- FUTZESSLBXJDFG-UHFFFAOYSA-N 4-[(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC(CC2C3=CC(OC)=C(OC)C=C3CCN2)=C1 FUTZESSLBXJDFG-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 206010002653 Anosmia Diseases 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101000598921 Homo sapiens Orexin Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 206010021067 Hypopituitarism Diseases 0.000 description 2
- 208000028482 Hypothalamic disease Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 208000006199 Parasomnias Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 206010036832 Prolactinoma Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000024732 dysthymic disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 238000012632 fluorescent imaging Methods 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 2
- 208000031424 hyperprolactinemia Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- GCYIIFMWMWWCQR-UHFFFAOYSA-N methyl 2-[1-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-yl]cyclohexa-2,4-dien-1-yl]acetate Chemical compound C1CC2=CC(OC)=C(OC)C=C2C(CC=2C=C(OC)C(OC)=CC=2)C1C1(CC(=O)OC)CC=CC=C1 GCYIIFMWMWWCQR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- JEMCXCMZAJPLLR-UHFFFAOYSA-N n-[2-(2,5-dimethoxyphenyl)ethyl]-2,2-diphenylacetamide Chemical compound COC1=CC=C(OC)C(CCNC(=O)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 JEMCXCMZAJPLLR-UHFFFAOYSA-N 0.000 description 2
- MDDIUSXQWPNOCY-UHFFFAOYSA-N n-[2-(2,5-dimethoxyphenyl)ethyl]-2-phenylacetamide Chemical compound COC1=CC=C(OC)C(CCNC(=O)CC=2C=CC=CC=2)=C1 MDDIUSXQWPNOCY-UHFFFAOYSA-N 0.000 description 2
- HQDGRCBVDVPNBF-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-2-(2,3,4-trimethoxyphenyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)CC1=CC=C(OC)C(OC)=C1OC HQDGRCBVDVPNBF-UHFFFAOYSA-N 0.000 description 2
- FGPUFQRNZGCKQV-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-2-(3,4,5-trimethoxyphenyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)CC1=CC(OC)=C(OC)C(OC)=C1 FGPUFQRNZGCKQV-UHFFFAOYSA-N 0.000 description 2
- JXUNQKVJRZBSER-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-2-(3-methoxyphenyl)acetamide Chemical compound COC1=CC=CC(CC(=O)NCCC=2C=C(OC)C(OC)=CC=2)=C1 JXUNQKVJRZBSER-UHFFFAOYSA-N 0.000 description 2
- FAMYMMVKOXQHTC-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-2-(4-fluorophenyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)CC1=CC=C(F)C=C1 FAMYMMVKOXQHTC-UHFFFAOYSA-N 0.000 description 2
- FBMGZFDOFQXQKX-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-2-(4-hydroxy-3-methoxyphenyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)CC1=CC=C(O)C(OC)=C1 FBMGZFDOFQXQKX-UHFFFAOYSA-N 0.000 description 2
- WZZFLNQCSFTAQT-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-2-(4-methoxy-3-phenylmethoxyphenyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)CC1=CC=C(OC)C(OCC=2C=CC=CC=2)=C1 WZZFLNQCSFTAQT-UHFFFAOYSA-N 0.000 description 2
- VXBDJWHXZMSPEZ-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-2-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NCCC1=CC=C(OC)C(OC)=C1 VXBDJWHXZMSPEZ-UHFFFAOYSA-N 0.000 description 2
- HVABELWWEQMYIB-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-2-phenylacetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)CC1=CC=CC=C1 HVABELWWEQMYIB-UHFFFAOYSA-N 0.000 description 2
- NEFROOCEKFXOJH-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-2-phenylbutanamide Chemical compound C=1C=CC=CC=1C(CC)C(=O)NCCC1=CC=C(OC)C(OC)=C1 NEFROOCEKFXOJH-UHFFFAOYSA-N 0.000 description 2
- NKTXVHNEQLENPU-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-2-phenylmethoxyacetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)COCC1=CC=CC=C1 NKTXVHNEQLENPU-UHFFFAOYSA-N 0.000 description 2
- XZQORMQJAFYPRT-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-3-phenylpropanamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)CCC1=CC=CC=C1 XZQORMQJAFYPRT-UHFFFAOYSA-N 0.000 description 2
- GQMVLTNYCPDBLP-UHFFFAOYSA-N n-benzyl-2-[1-[(3,4-dimethoxyphenyl)methyl]-6-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C=1C=CC=CC=1CNC(=O)CN1CCC=2C=C(O)C(OC)=CC=2C1CC1=CC=C(OC)C(OC)=C1 GQMVLTNYCPDBLP-UHFFFAOYSA-N 0.000 description 2
- ZJLMETHEORLUCQ-UHFFFAOYSA-N n-benzyl-2-[1-[(3-hydroxy-4-methoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1=C(O)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NCC1=CC=CC=C1 ZJLMETHEORLUCQ-UHFFFAOYSA-N 0.000 description 2
- YNDQAFGFNLWXQB-UHFFFAOYSA-N n-benzyl-2-[1-[(4-hydroxy-3-methoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1=C(O)C(OC)=CC(CC2C3=CC(OC)=C(OC)C=C3CCN2CC(=O)NCC=2C=CC=CC=2)=C1 YNDQAFGFNLWXQB-UHFFFAOYSA-N 0.000 description 2
- NVSYANRBXPURRQ-UHFFFAOYSA-N naphthalen-1-ylmethanamine Chemical compound C1=CC=C2C(CN)=CC=CC2=C1 NVSYANRBXPURRQ-UHFFFAOYSA-N 0.000 description 2
- 201000003631 narcolepsy Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 208000015238 neurotic disease Diseases 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- 208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 201000002859 sleep apnea Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- CQXDYHPBXDZWBA-UHFFFAOYSA-N tert-butyl 2,2,2-trichloroethanimidate Chemical compound CC(C)(C)OC(=N)C(Cl)(Cl)Cl CQXDYHPBXDZWBA-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 1
- DOMQFIFVDIAOOT-ROUUACIJSA-N (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide Chemical compound COC1=C(C(=CC=C1)OC)N1C(=NN=C1C=1C=NC=C(C=1)C)NS(=O)(=O)[C@@H](C)[C@H](C)C1=NC=C(C=N1)C DOMQFIFVDIAOOT-ROUUACIJSA-N 0.000 description 1
- HMTSWYPNXFHGEP-UHFFFAOYSA-N (4-methylphenyl)methanamine Chemical compound CC1=CC=C(CN)C=C1 HMTSWYPNXFHGEP-UHFFFAOYSA-N 0.000 description 1
- MCCAWZYURZFQOX-UHFFFAOYSA-N (6-methoxynaphthalen-2-yl)methanamine Chemical compound C1=C(CN)C=CC2=CC(OC)=CC=C21 MCCAWZYURZFQOX-UHFFFAOYSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- MJUVRTYWUMPBTR-MRXNPFEDSA-N 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 MJUVRTYWUMPBTR-MRXNPFEDSA-N 0.000 description 1
- VMPLLPIDRGXFTQ-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound [Cl-].C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CC[NH2+]1 VMPLLPIDRGXFTQ-UHFFFAOYSA-N 0.000 description 1
- FWIDZCMQCGNXCP-UHFFFAOYSA-N 1-[(4-bromo-3-methoxyphenyl)methyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=C(Br)C(OC)=CC(CC2C3=CC(OC)=C(OC)C=C3CCN2)=C1 FWIDZCMQCGNXCP-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- VXRWKBITZHUSQW-UHFFFAOYSA-N 1-benzhydryl-5,8-dimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound N1CCC=2C(OC)=CC=C(OC)C=2C1C(C=1C=CC=CC=1)C1=CC=CC=C1 VXRWKBITZHUSQW-UHFFFAOYSA-N 0.000 description 1
- JXBGBNUEKURSRY-UHFFFAOYSA-N 1-benzyl-5,8-dimethoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound N1CCC=2C(OC)=CC=C(OC)C=2C1CC1=CC=CC=C1 JXBGBNUEKURSRY-UHFFFAOYSA-N 0.000 description 1
- VNHWPVLQRKKKRY-UHFFFAOYSA-N 1-bromo-3-fluoropropane Chemical compound FCCCBr VNHWPVLQRKKKRY-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- KEJFADGISRFLFO-UHFFFAOYSA-N 1H-indazol-6-amine Chemical compound NC1=CC=C2C=NNC2=C1 KEJFADGISRFLFO-UHFFFAOYSA-N 0.000 description 1
- MSYLETHDEIJMAF-UHFFFAOYSA-N 2,2-diphenylacetyl chloride Chemical compound C=1C=CC=CC=1C(C(=O)Cl)C1=CC=CC=C1 MSYLETHDEIJMAF-UHFFFAOYSA-N 0.000 description 1
- JUOJVMYJTALTKH-UHFFFAOYSA-N 2-(1-benzyl-3,4-dihydro-1h-isoquinolin-2-yl)-n-[(2-methylphenyl)methyl]acetamide Chemical compound CC1=CC=CC=C1CNC(=O)CN1C(CC=2C=CC=CC=2)C2=CC=CC=C2CC1 JUOJVMYJTALTKH-UHFFFAOYSA-N 0.000 description 1
- YSOLKWJQSARACF-UHFFFAOYSA-N 2-(1-benzyl-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-n-[(2-methylphenyl)methyl]acetamide Chemical compound C=1C=CC=CC=1CC1C=2C=C(OC)C(OC)=CC=2CCN1CC(=O)NCC1=CC=CC=C1C YSOLKWJQSARACF-UHFFFAOYSA-N 0.000 description 1
- RJUGHGUBIPEVPE-UHFFFAOYSA-N 2-(1-benzyl-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-n-[(4-fluorophenyl)methyl]acetamide Chemical compound C=1C=CC=CC=1CC1C=2C=C(OC)C(OC)=CC=2CCN1CC(=O)NCC1=CC=C(F)C=C1 RJUGHGUBIPEVPE-UHFFFAOYSA-N 0.000 description 1
- ZMWCKCLDAQWIDA-UHFFFAOYSA-N 2-(2,3,4-trimethoxyphenyl)acetic acid Chemical compound COC1=CC=C(CC(O)=O)C(OC)=C1OC ZMWCKCLDAQWIDA-UHFFFAOYSA-N 0.000 description 1
- LPXOPDKFARVIQB-UHFFFAOYSA-N 2-(2-methoxy-5-phenylmethoxyphenyl)ethanamine Chemical compound C1=C(CCN)C(OC)=CC=C1OCC1=CC=CC=C1 LPXOPDKFARVIQB-UHFFFAOYSA-N 0.000 description 1
- DDSJXCGGOXKGSJ-UHFFFAOYSA-N 2-(3,4,5-trimethoxyphenyl)acetic acid Chemical compound COC1=CC(CC(O)=O)=CC(OC)=C1OC DDSJXCGGOXKGSJ-UHFFFAOYSA-N 0.000 description 1
- YCAKYFIYUHHCKW-UHFFFAOYSA-N 2-(3,4-difluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C(F)=C1 YCAKYFIYUHHCKW-UHFFFAOYSA-N 0.000 description 1
- CFEHWNSMGUKJEU-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-2-methoxyethanamine Chemical compound COC(CN)C1=CC=C(OC)C(OC)=C1 CFEHWNSMGUKJEU-UHFFFAOYSA-N 0.000 description 1
- NFCIDYJGAZFATM-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-[2-(2,3,4-trimethoxyphenyl)ethyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC(=O)NCCC1=CC=C(OC)C(OC)=C1OC NFCIDYJGAZFATM-UHFFFAOYSA-N 0.000 description 1
- GYUWZWIKKACQSZ-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-[2-(2-methoxy-5-phenylmethoxyphenyl)ethyl]acetamide Chemical compound C1=C(CCNC(=O)CC=2C=C(OC)C(OC)=CC=2)C(OC)=CC=C1OCC1=CC=CC=C1 GYUWZWIKKACQSZ-UHFFFAOYSA-N 0.000 description 1
- BXUQYJBJJMBZDJ-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-[2-(3,4,5-trimethoxyphenyl)ethyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC(=O)NCCC1=CC(OC)=C(OC)C(OC)=C1 BXUQYJBJJMBZDJ-UHFFFAOYSA-N 0.000 description 1
- KEOYZVLRUGFKRP-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-[2-(3,5-dimethoxyphenyl)ethyl]acetamide Chemical compound COC1=CC(OC)=CC(CCNC(=O)CC=2C=C(OC)C(OC)=CC=2)=C1 KEOYZVLRUGFKRP-UHFFFAOYSA-N 0.000 description 1
- DSWVDOQADLXFFE-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-[2-(3-methoxy-4-phenylmethoxyphenyl)ethyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC(=O)NCCC(C=C1OC)=CC=C1OCC1=CC=CC=C1 DSWVDOQADLXFFE-UHFFFAOYSA-N 0.000 description 1
- UXKKZRKCHFAQGX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-[2-(3-methoxy-4-propan-2-yloxyphenyl)ethyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC(=O)NCCC1=CC=C(OC(C)C)C(OC)=C1 UXKKZRKCHFAQGX-UHFFFAOYSA-N 0.000 description 1
- UFDMCHIAXSZQGN-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-[2-(4-methoxy-3-phenylmethoxyphenyl)ethyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC(=O)NCCC1=CC=C(OC)C(OCC=2C=CC=CC=2)=C1 UFDMCHIAXSZQGN-UHFFFAOYSA-N 0.000 description 1
- GLMWLELOJCRYRI-UHFFFAOYSA-N 2-(3-methoxy-4-phenylmethoxyphenyl)ethanamine Chemical compound COC1=CC(CCN)=CC=C1OCC1=CC=CC=C1 GLMWLELOJCRYRI-UHFFFAOYSA-N 0.000 description 1
- HJGNAXXDNNYRNN-UHFFFAOYSA-N 2-(3-methoxy-4-propan-2-yloxyphenyl)ethanamine Chemical compound COC1=CC(CCN)=CC=C1OC(C)C HJGNAXXDNNYRNN-UHFFFAOYSA-N 0.000 description 1
- UZUYKYNVSJTWEH-UHFFFAOYSA-N 2-(3-methoxyphenyl)acetyl chloride Chemical compound COC1=CC=CC(CC(Cl)=O)=C1 UZUYKYNVSJTWEH-UHFFFAOYSA-N 0.000 description 1
- WJBMRZAHTUFBGE-UHFFFAOYSA-N 2-(3-methoxyphenyl)ethanamine Chemical compound COC1=CC=CC(CCN)=C1 WJBMRZAHTUFBGE-UHFFFAOYSA-N 0.000 description 1
- UMQUIRYNOVNYPA-UHFFFAOYSA-N 2-(4-chlorophenyl)acetyl chloride Chemical compound ClC(=O)CC1=CC=C(Cl)C=C1 UMQUIRYNOVNYPA-UHFFFAOYSA-N 0.000 description 1
- MGKPFALCNDRSQD-UHFFFAOYSA-N 2-(4-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1 MGKPFALCNDRSQD-UHFFFAOYSA-N 0.000 description 1
- WXWWJUKMWNYILA-UHFFFAOYSA-N 2-(4-methoxy-3-phenylmethoxyphenyl)acetic acid Chemical compound COC1=CC=C(CC(O)=O)C=C1OCC1=CC=CC=C1 WXWWJUKMWNYILA-UHFFFAOYSA-N 0.000 description 1
- HGPYIHOTQGSJAJ-UHFFFAOYSA-N 2-(4-methoxy-3-phenylmethoxyphenyl)ethanamine Chemical compound COC1=CC=C(CCN)C=C1OCC1=CC=CC=C1 HGPYIHOTQGSJAJ-UHFFFAOYSA-N 0.000 description 1
- CXJOONIFSVSFAD-UHFFFAOYSA-N 2-(4-methoxyphenyl)acetyl chloride Chemical compound COC1=CC=C(CC(Cl)=O)C=C1 CXJOONIFSVSFAD-UHFFFAOYSA-N 0.000 description 1
- UPPFDZBHJOPNAI-UHFFFAOYSA-N 2-(5-methoxy-2-phenylmethoxyphenyl)ethanamine Chemical compound NCCC1=CC(OC)=CC=C1OCC1=CC=CC=C1 UPPFDZBHJOPNAI-UHFFFAOYSA-N 0.000 description 1
- YVHFWLYZVUCPFZ-VWLOTQADSA-N 2-[(1s)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(2-phenylethyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1C[C@H]1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NCCC1=CC=CC=C1 YVHFWLYZVUCPFZ-VWLOTQADSA-N 0.000 description 1
- BFYOCLKGJYHCMY-NDEPHWFRSA-N 2-[(1s)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(naphthalen-1-ylmethyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1C[C@H]1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NCC1=CC=CC2=CC=CC=C12 BFYOCLKGJYHCMY-NDEPHWFRSA-N 0.000 description 1
- KEWALFLCFJBWCO-QHCPKHFHSA-N 2-[(1s)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-2-ylmethyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1C[C@H]1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NCC1=CC=CC=N1 KEWALFLCFJBWCO-QHCPKHFHSA-N 0.000 description 1
- NNLPZVSBJHQYHC-UHFFFAOYSA-N 2-[1-(1,3-benzodioxol-5-ylmethyl)-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-[(2-ethoxyphenyl)methyl]acetamide Chemical compound CCOC1=CC=CC=C1CNC(=O)CN1C(CC=2C=C3OCOC3=CC=2)C2=CC(OC)=C(OC)C=C2CC1 NNLPZVSBJHQYHC-UHFFFAOYSA-N 0.000 description 1
- NXBHJXJJEGBLBZ-UHFFFAOYSA-N 2-[1-[(2,5-dimethoxyphenyl)methyl]-5,8-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-[(2-ethoxyphenyl)methyl]acetamide Chemical compound CCOC1=CC=CC=C1CNC(=O)CN1C(CC=2C(=CC=C(OC)C=2)OC)C2=C(OC)C=CC(OC)=C2CC1 NXBHJXJJEGBLBZ-UHFFFAOYSA-N 0.000 description 1
- NMIADDOCHFQYMI-UHFFFAOYSA-N 2-[1-[(3,4-diethylphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-2-ylmethyl)acetamide Chemical compound C1=C(CC)C(CC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NCC1=CC=CC=N1 NMIADDOCHFQYMI-UHFFFAOYSA-N 0.000 description 1
- YHOZFZRJFBWWMD-UHFFFAOYSA-N 2-[1-[(3,4-diethylphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-4-ylmethyl)acetamide Chemical compound C1=C(CC)C(CC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NCC1=CC=NC=C1 YHOZFZRJFBWWMD-UHFFFAOYSA-N 0.000 description 1
- GCQCVZZGKIKVTL-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-5,8-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-2-ylmethyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=C(OC)C=CC(OC)=C2CCN1CC(=O)NCC1=CC=CC=N1 GCQCVZZGKIKVTL-UHFFFAOYSA-N 0.000 description 1
- UAXSWNJARCKBRP-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-5,8-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-[(2-methoxyphenyl)methyl]acetamide Chemical compound COC1=CC=CC=C1CNC(=O)CN1C(CC=2C=C(OC)C(OC)=CC=2)C2=C(OC)C=CC(OC)=C2CC1 UAXSWNJARCKBRP-UHFFFAOYSA-N 0.000 description 1
- MSTFIEWGGMZKOZ-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-5-methoxy-8-phenylmethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-2-ylmethyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=C(OCC=3C=CC=CC=3)C=CC(OC)=C2CCN1CC(=O)NCC1=CC=CC=N1 MSTFIEWGGMZKOZ-UHFFFAOYSA-N 0.000 description 1
- ZPAUIZYCDVBPDX-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6,7,8-trimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(2-phenylethyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=C(OC)C(OC)=C(OC)C=C2CCN1CC(=O)NCCC1=CC=CC=C1 ZPAUIZYCDVBPDX-UHFFFAOYSA-N 0.000 description 1
- BVIGMQYJRVBMEM-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6,7,8-trimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-2-ylmethyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=C(OC)C(OC)=C(OC)C=C2CCN1CC(=O)NCC1=CC=CC=N1 BVIGMQYJRVBMEM-UHFFFAOYSA-N 0.000 description 1
- BPPYYMZLRANARW-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(1-phenylethyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NC(C)C1=CC=CC=C1 BPPYYMZLRANARW-UHFFFAOYSA-N 0.000 description 1
- WIERBVPMWIMPQC-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-[(2-fluorophenyl)methyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NCC1=CC=CC=C1F WIERBVPMWIMPQC-UHFFFAOYSA-N 0.000 description 1
- LHFABXXKENNWII-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-[(2-methoxyphenyl)methyl]acetamide Chemical compound COC1=CC=CC=C1CNC(=O)CN1C(CC=2C=C(OC)C(OC)=CC=2)C2=CC(OC)=C(OC)C=C2CC1 LHFABXXKENNWII-UHFFFAOYSA-N 0.000 description 1
- ZQXGAZFIRYBSJF-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-[(4-methoxyphenyl)methyl]acetamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)CN1C(CC=2C=C(OC)C(OC)=CC=2)C2=CC(OC)=C(OC)C=C2CC1 ZQXGAZFIRYBSJF-UHFFFAOYSA-N 0.000 description 1
- NPBJMBYFVMURHZ-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-[(4-methylphenyl)methyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NCC1=CC=C(C)C=C1 NPBJMBYFVMURHZ-UHFFFAOYSA-N 0.000 description 1
- VOOAWEFAVCKUTD-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-[(6-methoxynaphthalen-2-yl)methyl]acetamide Chemical compound C1=CC2=CC(OC)=CC=C2C=C1CNC(=O)CN1CCC2=CC(OC)=C(OC)C=C2C1CC1=CC=C(OC)C(OC)=C1 VOOAWEFAVCKUTD-UHFFFAOYSA-N 0.000 description 1
- RLFWDBHTXGQMCU-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-phenylacetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NC1=CC=CC=C1 RLFWDBHTXGQMCU-UHFFFAOYSA-N 0.000 description 1
- QBEYTWHWIXHQJE-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6,8-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-[(2-ethoxyphenyl)methyl]acetamide Chemical compound CCOC1=CC=CC=C1CNC(=O)CN1C(CC=2C=C(OC)C(OC)=CC=2)C2=C(OC)C=C(OC)C=C2CC1 QBEYTWHWIXHQJE-UHFFFAOYSA-N 0.000 description 1
- CVNYSFJBKISKQS-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6,8-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-[(2-methoxyphenyl)methyl]acetamide Chemical compound C=1C=C(OC)C(OC)=CC=1CC1C=2C(OC)=CC(OC)=CC=2CCN1CC(=O)NCC1=CC=CC=C1OC CVNYSFJBKISKQS-UHFFFAOYSA-N 0.000 description 1
- MJCLZUWOLGLTJO-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-4-ylmethyl)acetamide Chemical compound C=1C=NC=CC=1CNC(=O)CN1CCC2=CC(OC)=CC=C2C1CC1=CC=C(OC)C(OC)=C1 MJCLZUWOLGLTJO-UHFFFAOYSA-N 0.000 description 1
- KEGPKYXRXFQHPW-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-[(2-methoxyphenyl)methyl]acetamide Chemical compound C=1C=CC=C(OC)C=1CNC(=O)CN1CCC2=CC(OC)=CC=C2C1CC1=CC=C(OC)C(OC)=C1 KEGPKYXRXFQHPW-UHFFFAOYSA-N 0.000 description 1
- IQTLSYMDRYQNTO-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-[(3-methylphenyl)methyl]acetamide Chemical compound C=1C=CC(C)=CC=1CNC(=O)CN1CCC2=CC(OC)=CC=C2C1CC1=CC=C(OC)C(OC)=C1 IQTLSYMDRYQNTO-UHFFFAOYSA-N 0.000 description 1
- HXNZSKZUCVPTLT-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6-methoxy-7-propan-2-yloxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-[(2-ethoxyphenyl)methyl]acetamide Chemical compound CCOC1=CC=CC=C1CNC(=O)CN1C(CC=2C=C(OC)C(OC)=CC=2)C2=CC(OC(C)C)=C(OC)C=C2CC1 HXNZSKZUCVPTLT-UHFFFAOYSA-N 0.000 description 1
- YHQXJDDOBCLKSE-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-6-methoxy-7-propan-2-yloxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-[(2-methoxyphenyl)methyl]acetamide Chemical compound COC1=CC=CC=C1CNC(=O)CN1C(CC=2C=C(OC)C(OC)=CC=2)C2=CC(OC(C)C)=C(OC)C=C2CC1 YHQXJDDOBCLKSE-UHFFFAOYSA-N 0.000 description 1
- MOHOMFSWMZYMPG-UHFFFAOYSA-N 2-[1-[(3,4-dimethoxyphenyl)methyl]-8-hydroxy-5-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-2-ylmethyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=C(O)C=CC(OC)=C2CCN1CC(=O)NCC1=CC=CC=N1 MOHOMFSWMZYMPG-UHFFFAOYSA-N 0.000 description 1
- IGIXENPZYHUOEF-UHFFFAOYSA-N 2-[1-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-yl]cyclohexa-2,4-dien-1-yl]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCC1C1(CC(O)=O)C=CC=CC1 IGIXENPZYHUOEF-UHFFFAOYSA-N 0.000 description 1
- HMTMDNMTEIWDEK-UHFFFAOYSA-N 2-[1-[[4-(dimethylamino)phenyl]methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-[(2-methoxyphenyl)methyl]acetamide Chemical compound COC1=CC=CC=C1CNC(=O)CN1C(CC=2C=CC(=CC=2)N(C)C)C2=CC(OC)=C(OC)C=C2CC1 HMTMDNMTEIWDEK-UHFFFAOYSA-N 0.000 description 1
- KQGHTOZUPICELS-UHFFFAOYSA-N 2-[4-(dimethylamino)phenyl]acetic acid Chemical compound CN(C)C1=CC=C(CC(O)=O)C=C1 KQGHTOZUPICELS-UHFFFAOYSA-N 0.000 description 1
- YKYNGHKFRYUMJA-UHFFFAOYSA-N 2-[5-butoxy-1-[(3,4-dimethoxyphenyl)methyl]-8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-2-ylmethyl)acetamide Chemical compound C=1C=CC=NC=1CNC(=O)CN1CCC=2C(OCCCC)=CC=C(OC)C=2C1CC1=CC=C(OC)C(OC)=C1 YKYNGHKFRYUMJA-UHFFFAOYSA-N 0.000 description 1
- XZZHDKSKEYPZIG-UHFFFAOYSA-N 2-[6,7-dimethoxy-1-(1-phenylpropyl)-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-2-ylmethyl)acetamide Chemical compound C=1C=CC=CC=1C(CC)C(C1=CC(OC)=C(OC)C=C1CC1)N1CC(=O)NCC1=CC=CC=N1 XZZHDKSKEYPZIG-UHFFFAOYSA-N 0.000 description 1
- MZLWVWSSAXTNOG-UHFFFAOYSA-N 2-[6,7-dimethoxy-1-[(2,3,4-trimethoxyphenyl)methyl]-3,4-dihydro-1h-isoquinolin-2-yl]-n-(2-phenylethyl)acetamide Chemical compound C=1C=C(OC)C(OC)=C(OC)C=1CC1C=2C=C(OC)C(OC)=CC=2CCN1CC(=O)NCCC1=CC=CC=C1 MZLWVWSSAXTNOG-UHFFFAOYSA-N 0.000 description 1
- LRRYWDRLFAGGED-UHFFFAOYSA-N 2-[6,7-dimethoxy-1-[(2,3,4-trimethoxyphenyl)methyl]-3,4-dihydro-1h-isoquinolin-2-yl]-n-[(2-ethoxyphenyl)methyl]acetamide Chemical compound CCOC1=CC=CC=C1CNC(=O)CN1C(CC=2C(=C(OC)C(OC)=CC=2)OC)C2=CC(OC)=C(OC)C=C2CC1 LRRYWDRLFAGGED-UHFFFAOYSA-N 0.000 description 1
- YOFNGHNWEITSRA-UHFFFAOYSA-N 2-[6,7-dimethoxy-1-[(3-methoxyphenyl)methyl]-3,4-dihydro-1h-isoquinolin-2-yl]-n-(pyridin-3-ylmethyl)acetamide Chemical compound COC1=CC=CC(CC2C3=CC(OC)=C(OC)C=C3CCN2CC(=O)NCC=2C=NC=CC=2)=C1 YOFNGHNWEITSRA-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- VIBOGIYPPWLDTI-UHFFFAOYSA-N 2-naphthylacetic acid Chemical compound C1=CC=CC2=CC(CC(=O)O)=CC=C21 VIBOGIYPPWLDTI-UHFFFAOYSA-N 0.000 description 1
- QGXMHCMPIAYMGT-UHFFFAOYSA-N 2-phenylbutanoyl chloride Chemical compound CCC(C(Cl)=O)C1=CC=CC=C1 QGXMHCMPIAYMGT-UHFFFAOYSA-N 0.000 description 1
- QISAUDWTBBNJIR-UHFFFAOYSA-N 2-phenylmethoxyacetyl chloride Chemical compound ClC(=O)COCC1=CC=CC=C1 QISAUDWTBBNJIR-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- MFEILWXBDBCWKF-UHFFFAOYSA-N 3-phenylpropanoyl chloride Chemical compound ClC(=O)CCC1=CC=CC=C1 MFEILWXBDBCWKF-UHFFFAOYSA-N 0.000 description 1
- AHZYDHMFNHSEHU-UHFFFAOYSA-N 3-pyridin-3-ylpropanamide Chemical compound NC(=O)CCC1=CC=CN=C1 AHZYDHMFNHSEHU-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- LTPVSOCPYWDIFU-UHFFFAOYSA-N 4-methoxyphenylethylamine Chemical compound COC1=CC=C(CCN)C=C1 LTPVSOCPYWDIFU-UHFFFAOYSA-N 0.000 description 1
- YQTZICLOPZEECN-UHFFFAOYSA-N 6,7-dimethoxy-1-(phenylmethoxymethyl)-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=2C=C(OC)C(OC)=CC=2CCNC1COCC1=CC=CC=C1 YQTZICLOPZEECN-UHFFFAOYSA-N 0.000 description 1
- IYDXQGNUXUOZOC-UHFFFAOYSA-N 6,7-dimethoxy-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=2C=C(OC)C(OC)=CC=2CCNC1CC1=CC(OC)=C(OC)C(OC)=C1 IYDXQGNUXUOZOC-UHFFFAOYSA-N 0.000 description 1
- OIMFNCWZUMIHMJ-UHFFFAOYSA-N 6,7-dimethoxy-1-[(4-methoxy-3-phenylmethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline Chemical compound COC1=CC=C(CC2C3=CC(OC)=C(OC)C=C3CCN2)C=C1OCC1=CC=CC=C1 OIMFNCWZUMIHMJ-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- UNQYAAAWKOOBFQ-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-8-[4-chloro-3-(trifluoromethoxy)phenoxy]-1-(3-hydroxypropyl)-3-methylpurine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCCO)C(=O)N(C)C=2N=C1OC1=CC=C(Cl)C(OC(F)(F)F)=C1 UNQYAAAWKOOBFQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 201000009586 Basophil Adenoma Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 238000006407 Bischler-Napieralski reaction Methods 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 208000027691 Conduct disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 201000001498 Froelich syndrome Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000004230 Gender Dysphoria Diseases 0.000 description 1
- 206010018265 Gigantism Diseases 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010056438 Growth hormone deficiency Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 101500025902 Homo sapiens Orexin-A Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 206010050515 Hyposmia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- 201000007493 Kallmann syndrome Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- FULZLIGZKMKICU-UHFFFAOYSA-N N-phenylthiourea Chemical class NC(=S)NC1=CC=CC=C1 FULZLIGZKMKICU-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010053142 Olfacto genital dysplasia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 208000014993 Pituitary disease Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 208000036623 Severe mental retardation Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010041738 Sports injury Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- PNJSUNGZWIXPBG-UHFFFAOYSA-N [4-[[2-[2-(benzylamino)-2-oxoethyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-1-yl]methyl]-2-methoxyphenyl] n,n-dimethylcarbamate Chemical compound C=1C=C(OC(=O)N(C)C)C(OC)=CC=1CC1C=2C=C(OC)C(OC)=CC=2CCN1CC(=O)NCC1=CC=CC=C1 PNJSUNGZWIXPBG-UHFFFAOYSA-N 0.000 description 1
- SUPZGQZIGFKYJW-UHFFFAOYSA-N [chloro(phenyl)methyl] acetate Chemical compound CC(=O)OC(Cl)C1=CC=CC=C1 SUPZGQZIGFKYJW-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- AMJRSUWJSRKGNO-UHFFFAOYSA-N acetyloxymethyl 2-[n-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-5-(2,7-dichloro-3-hydroxy-6-oxoxanthen-9-yl)phenoxy]ethoxy]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O AMJRSUWJSRKGNO-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 235000019558 anosmia Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- AQNQQHJNRPDOQV-UHFFFAOYSA-N bromocyclohexane Chemical compound BrC1CCCCC1 AQNQQHJNRPDOQV-UHFFFAOYSA-N 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- TYHRJHFMHFZOPQ-UHFFFAOYSA-N ethyl 2-[4-[[2-[2-(benzylamino)-2-oxoethyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-1-yl]methyl]-2-methoxyphenoxy]acetate Chemical compound C1=C(OC)C(OCC(=O)OCC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NCC1=CC=CC=C1 TYHRJHFMHFZOPQ-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 235000019559 hyposmia Nutrition 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- NHFBYYMNJUMVOT-UHFFFAOYSA-N methyl 2-bromo-2-phenylacetate Chemical compound COC(=O)C(Br)C1=CC=CC=C1 NHFBYYMNJUMVOT-UHFFFAOYSA-N 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- XMWFMEYDRNJSOO-UHFFFAOYSA-N morpholine-4-carbonyl chloride Chemical compound ClC(=O)N1CCOCC1 XMWFMEYDRNJSOO-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- FMASTMURQSHELY-UHFFFAOYSA-N n-(4-fluoro-2-methylphenyl)-3-methyl-n-[(2-methyl-1h-indol-4-yl)methyl]pyridine-4-carboxamide Chemical compound C1=CC=C2NC(C)=CC2=C1CN(C=1C(=CC(F)=CC=1)C)C(=O)C1=CC=NC=C1C FMASTMURQSHELY-UHFFFAOYSA-N 0.000 description 1
- SODGOGUDPVAERC-UHFFFAOYSA-N n-[(2-chlorophenyl)methyl]-2-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NCC1=CC=CC=C1Cl SODGOGUDPVAERC-UHFFFAOYSA-N 0.000 description 1
- TZBRNIWZOAPBHV-UHFFFAOYSA-N n-[(2-chlorophenyl)methyl]acetamide Chemical compound CC(=O)NCC1=CC=CC=C1Cl TZBRNIWZOAPBHV-UHFFFAOYSA-N 0.000 description 1
- DYSXPJXIDRWVOA-UHFFFAOYSA-N n-[(2-ethoxyphenyl)methyl]-2-[1-[(4-fluorophenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound CCOC1=CC=CC=C1CNC(=O)CN1C(CC=2C=CC(F)=CC=2)C2=CC(OC)=C(OC)C=C2CC1 DYSXPJXIDRWVOA-UHFFFAOYSA-N 0.000 description 1
- ZOUCHBXJUPPSRN-UHFFFAOYSA-N n-[(2-fluorophenyl)methyl]acetamide Chemical compound CC(=O)NCC1=CC=CC=C1F ZOUCHBXJUPPSRN-UHFFFAOYSA-N 0.000 description 1
- HRQJIGPCAHFWBT-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-2-(3,4-dimethylphenyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)CC1=CC=C(C)C(C)=C1 HRQJIGPCAHFWBT-UHFFFAOYSA-N 0.000 description 1
- DWKCRQVVSFBILN-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-2-[4-(dimethylamino)phenyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)CC1=CC=C(N(C)C)C=C1 DWKCRQVVSFBILN-UHFFFAOYSA-N 0.000 description 1
- OQSLRUAUSVKVBL-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-2-naphthalen-2-ylacetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)CC1=CC=C(C=CC=C2)C2=C1 OQSLRUAUSVKVBL-UHFFFAOYSA-N 0.000 description 1
- WYRVNRWVHSLADF-VWLOTQADSA-N n-benzyl-2-[(1s)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-methylacetamide Chemical compound C1=C(OC)C(OC)=CC=C1C[C@H]1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)N(C)CC1=CC=CC=C1 WYRVNRWVHSLADF-VWLOTQADSA-N 0.000 description 1
- FYSUZYYFUUADES-DEOSSOPVSA-N n-benzyl-2-[(1s)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1C[C@H]1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NCC1=CC=CC=C1 FYSUZYYFUUADES-DEOSSOPVSA-N 0.000 description 1
- IJHZXBWMUGHAPB-UHFFFAOYSA-N n-benzyl-2-[1-[(2,5-dimethoxyphenyl)methyl]-5,8-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound COC1=CC=C(OC)C(CC2C3=C(OC)C=CC(OC)=C3CCN2CC(=O)NCC=2C=CC=CC=2)=C1 IJHZXBWMUGHAPB-UHFFFAOYSA-N 0.000 description 1
- GXEWUQQANRBOSY-UHFFFAOYSA-N n-benzyl-2-[1-[(3,4-dimethoxyphenyl)methyl]-5,6,7-trimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-methylacetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C(C=C(OC)C(OC)=C2OC)=C2CCN1CC(=O)N(C)CC1=CC=CC=C1 GXEWUQQANRBOSY-UHFFFAOYSA-N 0.000 description 1
- RIFKIUVCVLNLNX-UHFFFAOYSA-N n-benzyl-2-[1-[(3,4-dimethoxyphenyl)methyl]-6,8-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C=1C=C(OC)C(OC)=CC=1CC1C=2C(OC)=CC(OC)=CC=2CCN1CC(=O)NCC1=CC=CC=C1 RIFKIUVCVLNLNX-UHFFFAOYSA-N 0.000 description 1
- UWLWEDNGFORSNG-UHFFFAOYSA-N n-benzyl-2-[1-[(3,4-dimethoxyphenyl)methyl]-6-ethoxy-7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C=1C=C(OC)C(OC)=CC=1CC1C=2C=C(OC)C(OCC)=CC=2CCN1CC(=O)NCC1=CC=CC=C1 UWLWEDNGFORSNG-UHFFFAOYSA-N 0.000 description 1
- FTSPPCVUJGHARL-UHFFFAOYSA-N n-benzyl-2-[1-[(3,4-dimethoxyphenyl)methyl]-6-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C=1C=CC=CC=1CNC(=O)CN1CCC2=CC(OC)=CC=C2C1CC1=CC=C(OC)C(OC)=C1 FTSPPCVUJGHARL-UHFFFAOYSA-N 0.000 description 1
- HFXHCZBJZUJSCZ-UHFFFAOYSA-N n-benzyl-2-[1-[(3,4-dimethoxyphenyl)methyl]-6-methoxy-7-phenylmethoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OCC=3C=CC=CC=3)=C(OC)C=C2CCN1CC(=O)NCC1=CC=CC=C1 HFXHCZBJZUJSCZ-UHFFFAOYSA-N 0.000 description 1
- QDVAKWOYMQNGGI-UHFFFAOYSA-N n-benzyl-2-[1-[(3,4-dimethoxyphenyl)methyl]-6-methoxy-7-propan-2-yloxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-methylacetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC(C)C)=C(OC)C=C2CCN1CC(=O)N(C)CC1=CC=CC=C1 QDVAKWOYMQNGGI-UHFFFAOYSA-N 0.000 description 1
- DLZVDBYNJQVSNK-UHFFFAOYSA-N n-benzyl-2-[1-[(3,4-dimethoxyphenyl)methyl]-6-methoxy-7-propan-2-yloxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC(C)C)=C(OC)C=C2CCN1CC(=O)NCC1=CC=CC=C1 DLZVDBYNJQVSNK-UHFFFAOYSA-N 0.000 description 1
- HSGSJIIJCGUGLY-UHFFFAOYSA-N n-benzyl-2-[1-[(3,4-dimethoxyphenyl)methyl]-7-hydroxy-6-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C=1C=C(OC)C(OC)=CC=1CC1C=2C=C(O)C(OC)=CC=2CCN1CC(=O)NCC1=CC=CC=C1 HSGSJIIJCGUGLY-UHFFFAOYSA-N 0.000 description 1
- JCMWNICXFYUVHB-UHFFFAOYSA-N n-benzyl-2-[1-[(3,4-dimethoxyphenyl)methyl]-7-methoxy-6-phenylmethoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OCC=3C=CC=CC=3)C=C2CCN1CC(=O)NCC1=CC=CC=C1 JCMWNICXFYUVHB-UHFFFAOYSA-N 0.000 description 1
- YJNWEXBIPHHTSL-UHFFFAOYSA-N n-benzyl-2-[1-[(3-bromo-4-methoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1=C(Br)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NCC1=CC=CC=C1 YJNWEXBIPHHTSL-UHFFFAOYSA-N 0.000 description 1
- KUUWMXNYUJXCJE-UHFFFAOYSA-N n-benzyl-2-[1-[(3-butoxy-4-methoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1=C(OC)C(OCCCC)=CC(CC2C3=CC(OC)=C(OC)C=C3CCN2CC(=O)NCC=2C=CC=CC=2)=C1 KUUWMXNYUJXCJE-UHFFFAOYSA-N 0.000 description 1
- XYHISTDQFPBNAJ-UHFFFAOYSA-N n-benzyl-2-[1-[(3-ethoxy-4-methoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1=C(OC)C(OCC)=CC(CC2C3=CC(OC)=C(OC)C=C3CCN2CC(=O)NCC=2C=CC=CC=2)=C1 XYHISTDQFPBNAJ-UHFFFAOYSA-N 0.000 description 1
- MQFIVYZEVJOKJT-UHFFFAOYSA-N n-benzyl-2-[1-[(4-ethoxy-3-methoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1=C(OC)C(OCC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CC(=O)NCC1=CC=CC=C1 MQFIVYZEVJOKJT-UHFFFAOYSA-N 0.000 description 1
- CSASHICNZSIRNV-UHFFFAOYSA-N n-benzyl-2-[1-[[3-(cyclopropylmethoxy)-4-methoxyphenyl]methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1=C(OCC2CC2)C(OC)=CC=C1CC(C1=CC(OC)=C(OC)C=C1CC1)N1CC(=O)NCC1=CC=CC=C1 CSASHICNZSIRNV-UHFFFAOYSA-N 0.000 description 1
- ZWPWVNIEQXBUHH-UHFFFAOYSA-N n-benzyl-2-[1-[[4-(cyclopropylmethoxy)-3-methoxyphenyl]methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C=1C=C(OCC2CC2)C(OC)=CC=1CC(C1=CC(OC)=C(OC)C=C1CC1)N1CC(=O)NCC1=CC=CC=C1 ZWPWVNIEQXBUHH-UHFFFAOYSA-N 0.000 description 1
- LEMFUGXOSANTBO-UHFFFAOYSA-N n-benzyl-2-[6,7-dimethoxy-1-[(3-methoxy-4-propan-2-yloxyphenyl)methyl]-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C=1C=C(OC(C)C)C(OC)=CC=1CC1C=2C=C(OC)C(OC)=CC=2CCN1CC(=O)NCC1=CC=CC=C1 LEMFUGXOSANTBO-UHFFFAOYSA-N 0.000 description 1
- RRBYCHHICVPEJB-UHFFFAOYSA-N n-benzyl-2-[6,7-dimethoxy-1-[(3-methoxy-4-pyrimidin-2-yloxyphenyl)methyl]-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C=1C=C(OC=2N=CC=CN=2)C(OC)=CC=1CC1C=2C=C(OC)C(OC)=CC=2CCN1CC(=O)NCC1=CC=CC=C1 RRBYCHHICVPEJB-UHFFFAOYSA-N 0.000 description 1
- RSIFYMWHCQCEJN-UHFFFAOYSA-N n-benzyl-2-[6,7-dimethoxy-1-[(4-methoxy-3-propoxyphenyl)methyl]-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1=C(OC)C(OCCC)=CC(CC2C3=CC(OC)=C(OC)C=C3CCN2CC(=O)NCC=2C=CC=CC=2)=C1 RSIFYMWHCQCEJN-UHFFFAOYSA-N 0.000 description 1
- CEUYUUKQQOETJF-UHFFFAOYSA-N n-benzyl-2-[6,7-dimethoxy-1-[(4-methoxy-3-pyrimidin-2-yloxyphenyl)methyl]-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1=C(OC=2N=CC=CN=2)C(OC)=CC=C1CC(C1=CC(OC)=C(OC)C=C1CC1)N1CC(=O)NCC1=CC=CC=C1 CEUYUUKQQOETJF-UHFFFAOYSA-N 0.000 description 1
- QFHFJDFMLQDNNR-UHFFFAOYSA-N n-benzyl-2-[6,7-dimethoxy-1-[[3-methoxy-4-(2-methylpropoxy)phenyl]methyl]-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1=C(OCC(C)C)C(OC)=CC(CC2C3=CC(OC)=C(OC)C=C3CCN2CC(=O)NCC=2C=CC=CC=2)=C1 QFHFJDFMLQDNNR-UHFFFAOYSA-N 0.000 description 1
- NQXVNLHPEJBZAT-UHFFFAOYSA-N n-benzyl-n-methylacetamide Chemical compound CC(=O)N(C)CC1=CC=CC=C1 NQXVNLHPEJBZAT-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000006259 organic additive Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000030062 persistent idiopathic facial pain Diseases 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 150000007925 phenylethylamine derivatives Chemical class 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 208000020351 pituitary gland basophil adenoma Diseases 0.000 description 1
- 208000017402 pituitary gland disease Diseases 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 208000026961 psychosexual disease Diseases 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- TXQWFIVRZNOPCK-UHFFFAOYSA-N pyridin-4-ylmethanamine Chemical compound NCC1=CC=NC=C1 TXQWFIVRZNOPCK-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- BHRZNVHARXXAHW-UHFFFAOYSA-N sec-butylamine Chemical compound CCC(C)N BHRZNVHARXXAHW-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Description
Foreliggende oppfinnelse angår nye 1,2,3,4-tetrahydroisokinolinderivater med den generelle formel I og anvendelse av dem som farmasøytiske midler. Oppfinnelsen angår også beslektede aspekter omfattende prosesser for fremstilling av forbindelsene, farmasøytiske preparater inneholdende én eller flere forbindelser med formel I og spesielt anvendelse av dem ved fremstilling av medikamenter som er orexin-reseptorantagonister.
Orexinene (hypocretiner) omfatter to neuropeptider produsert i hypothalamus: orexin A (OX-A) (et 33 aminosyrepeptid) og orexin B (OX-B) (et 28 aminosyrepeptid) (Sakurai T. et al, Cell, 1998,92, 573-585). Orexiner er funnet å stimulere matinntak hos rotter, hvilket indikerer en fysiologisk rolle for disse peptider som mediatorer i den sentrale feedback-mekanisme som regulerer foringsadferd (Sakurai T. et al, Cell, 1998,92,573-585). På den annen side ble det også foreslått at orexiner regulerer søvn- og våkentilstander som åpner for potensielt nye terapeutiske behandlinger av narkoleptiske pasienter (Chemelli R.M. et al, Cell, 1999,98,437-451). To orexin-reseptorer er klonet og karakterisert hos pattedyr som tilhører den G-proteinkoblete reseptorsuperfamilie (Sakurai T. et al, Cell, 1998,92,573-585), orexin-1-reseptoren (OXi) som er selektiv for OX-A og orexin-2 reseptoren (OX2) som er i stand til å binde OX-A så vel som OX-B.
Orexin-reseptorer er funnet hos pattedyreverter og kan være ansvarlig for mange biologiske funksjoner så som patologier omfattende, men ikke begrenset til, depresjon; angst; avhengighet; tvangsnevroser; følelsesnevrose; depressiv nevrose; angstnevrose; dysthymisk forstyrrelse; adferdsforstyrrelse; humørforstyrrelse; seksuell dysfunksjon; psykoseksuell dysfunksjon; kjønnsforstyrrelse; schizofreni; manisk depresjon; delerium; demens; alvorlig mental retardasjon og dyskinesier så som Huntington's sykdom og Tourette syndrom; spiseforstyrrelser så som anoreksi, bulimi, kakeksi og fedme; diabetes; appetitt/smaks-forstyrrelser; oppkast/kvalme; astma; kreft; Parkinson's sykdom; Cushing's syndrom/sykdom; basofil adenoma; prolactinoma; hyperprolactinemia; hypopituitarisme; hypophysis tumor/adenoma; hypothalamiske sykdommer; inflammatorisk tarmsykdom; gastrisk diskinesia; gastrisk ulcus; Froehlich's syndrom; adrenohypofysesykdom; hypofysesykdom; hypofyse-veksthormon; adrenohypofysehypofunksjon; adrenohypofysehyperfunksjon; hypothalamisk hypogonadisme; Kallman's syndrom (anosmia, hyposmia); funksjonell eller psykogen amenorrhea; hypopituitarisme; hypothalamisk hypothyroidisme; hypothalamisk-adrenal dysfunksjon; idiopatisk hyperprolactinemia; hypothalamiske forstyrrelser ved veksthormonmangel; idiopatisk vekstmangel; dvergsykdom; gigantisme; akromegali; forstyrrete biologiske og cirkadiske rytmer; søvnforstyrrelser forbundet med sykdommer så som nevrologiske forstyrrelser, nevropatisk smerte og urolig leggsyndrom; varme- og lungesykdommer, akutt og kongestiv hjertesvikt; hypotensjon; hypertensjon; urinretention; osteoporose; angina pectoris; myokardinalt infarkt; ischemisk eller blødningsslag; subaraknoidal blødning; ulcere; allergier; godartet prostatisk hypertrofi; kronisk nyresvikt; nyresykdom; svekket glukosetoleranse; migrene; hyperalgesi; smerte; øket eller overdrevet sensitivitet for smerte så som hyperalgesi, kausalgi og allodyni; akutt smerte; brannsmerte; atypisk facial smerte; nevropatisk smerte; ryggsmerte; komplekst regionalt smertesyndrom I og II; artrittisk smerte; sportsskadesmerte; smerte relatert til infeksjon f.eks. HIV, post-kjemoterapismerte; post-slagsmerte; post-operativ smerte; nevralgi; forstyrrelser forbundet med visceral smerte så som irritert tarmsyndrom, migrene og angina; urinblære- inkontinens f.eks. tvangsinkontinens; toleranse for narkotika eller opphør av narkotika; søvnforstyrrelser; søvnapné; narkolepsi; søvnløshet; parasomnia; jet-lag-syndrom; og neurodegerative forstyrrelser omfattende nosologisk entitier så som disinhibisjon-demens-parkinsonisme-amyotrofikompleks; pallido-ponto-nigral degenerasjonsepilepsi; slag- forstyrrelser og andre sykdommer relatert til med orexin.
Foreliggende oppfinnelse tilveiebringer 1,2,3,4-tetrahydroisokinolinderivater ved fremstilling av medikamenter som er ikke-peptidantagonister for humane orexin-reseptorer, spesielt OX preseptorer. Spesielt er disse forbindelser av potensiell anvendelse ved fremstilling av medikamenter ved behandling av fedme og/eller søvnforstyrrelser.
Hittil er ikke meget kjent om forbindelser med lav molekylvekt som har et potensiale for antagonise, enten spesifikt OXi eller OX2 eller begge reseptorer samtidig. Nylig er WO 9909024 publisert hvor fenylurea- og fenyltioureaderivater som OX|-antagonister er beskrevet. Også er helt nylig WO 9958533 publisert som beskriver samme type av forbindelser som igjen er angitt fortrinnsvis å være OXi.reseptorantagonister. De nye forbindelsene ifølge foreliggende oppfinnelse tilhører en fullstendig forskjellig klasse av forbindelser med lav molekylvekt sammenlignet med alle tidligere kjente orexin-reseptorantagonister som hittil er publisert.
Foreliggende oppfinnelse angår nye 1,2,3,4-tetrahydroisokinolinderivater med den generelle formel (I).
hvor:
R<1>, R<2>, R<3>, R<4> uavhengig representerer cyano, nitro, halogen, hydrogen, hydroksy, lavere-alkyl, lavere-alkenyl, lavere-alkoksy, lavere-alkenyloksy, trifluormetyl, trifluormetoksy, cykloalkyloksy, aryloksy, aralkyloksy, heterocyklyloksy, heterocyklylalkyloksy, R11 CO-, NR<12>R,<3>CO-, R<12>R1<3N->, R<n>OOC-, R<n>S02NH- eller R<14->CO-NH- eller R2 og R<3> sammen så vel som R og R sammen og R og R sammen kan med fenylringen danne en fem-, seks- eller syv-leddet ring inneholdende ett eller to oksygenatomer;
R<5> reprensenterer aryl, aralkyl, lavere-alkenyl, trifluormetyl, cykloalkyl, heterocyklyl eller heterocyklyl-lavere-alkyl;
R<6> representerer hydrogen, aryl, aralkyl, lavere-alkyl, lavere-alkenyl, trifluormetyl, cykloalkyl, heterocyklyl eller heterocyklyl-lavere-alkyl;
R 7 og R 8uavhengig representerer hydrogen, aryl, aralkyl, lavere-alkyl, lavere-alkenyl, cykloalkyl, heterocyklyl eller heterocyklyl-lavere-alkyl;
R<9> representerer, aryl, aralkyl, lavere-alkyl, lavere-alkenyl, trifluormetyl, cykloalkyl, heterocyklyl eller heterocyklyl-lavere-alkyl;
R<10> representerer hydrogen, aryl, aralkyl, lavere-alkyl, lavere-alkenyl, trifluormetyl, cykloalkyl, heterocyklyl eller heterocyklyl-lavere-alkyl;
R<11> representerer lavere-alkyl, aryl, aralkyl, heterocyklyl eller heterocyklyl-lavere-alkyl;
R<1>2 og R1<3> uavhengig representerer hydrogen, alkyl, cykloalkyl, aryl, aralkyl,
heterocyklyl eller heterocyklyl-lavere-alkyl;
R1<4> representerer alkyl, aryl, cykloalkyl, heterocyklyl, R<12>R13N-eller R<n>O-
hvor betegnelsen "lavere-alkyl", alene eller i kombinasjon, betyr en rettkjedet eller forgrenet alkylgruppe med 1 til 8 karbonatomer, betegnelsen "lavere-alkenyl", alene eller i kombinasjon, betyr en rettkjedet eller forgrenet alkenylgruppe med 2 til 5 karbonatomer, betegnelsen "cykloalkyl", alene eller i kombinasjon, betyr en cykloalkylring med 3 til 8 karbonatomer; betegnelsen "aryl", alene eller i kombinasjon, betyr en fenyl- eller naftylgruppe som eventuelt bærer én eller flere substituenter; og betegnelsen "heterocyklyl", allene eller i kombinasjon, betyr en 5- til 10-leddet monocyklisk eller bicyklisk ring, som kan være mettet, delvis umettet eller aromatisk og inneholdende 1, 2 eller 3 heteroatomer valgt fra oksygen, nitrogen og svovel som kan være like eller forskjellige og som eventuelt kan ha optil 5 substituenter; og optisk rene enantiomerer, blandinger av enantiomerer, racemater, optisk rene diastereoisomerer, blandinger av diastereoisomerer, diastereoisomere racemater, blanding av diastereoisomere racemater eller mesoformer og farmasøytisk akseptable salter derav. Forbindelsene med formel I kan inneholde ett eller flere asymmetriske sentere og kan foreligge i form av optisk rene enantiomerer, blandinger av enantiomerer så som, for eksempel, racemater, optisk rene diastereoisomerer, blandinger av diastereoisomerer, diastereoisomere racemater, blanding av diastereoisomere racemater eller mesoformer og farmasøytisk akseptable salter derav.
Om ikke spesifikt angitt i kravene gjelder følgende definisjoner:
Betegnelsen "lavere-alkyl", alene eller i kombinasjon, betyr en rettkjedet eller forgrenet alkylgruppe med 1 til 8 karbonatomer, fortrinnsvis en lineær eller forgrenet alkyl gruppe med 1-5 karbonatomer. Eksempler på rettkjedete og forgrenete Ci-Cs alkylgrupper er metyl, etyl, propyl, isopropyl, butyl, pentyl, heksyl, heptyl, oktyl, isobutyl, tert-butyl, de isomere pentyler, de isomere heksyler, de isomere heptyler og de isomere oktyler, fortrinnsvis metyl, etyl, propyl, isopropyl, butyl, 2-butyl, tert-butyl og pentyl.
Betegnelsen "lavere-alkenyl", alene eller i kombinasjon, betyr en rettkjedet eller forgrenet alkenylgruppe med 2 til 5 karbonatomer, fortrinnsvis allyl og vinyl.
Betegnelsen "lavere-alkoksy", alene eller i kombinasjon, betyr en gruppe med
formel alkyl-O- hvor betegnelsen "alkyl" har den tidligere angitte betydning, slik som metoksy, etoksy, n-propoksy, isopropoksy, n-butoksy, isobutoksy, sek-butoksy og tert-butoksy, fortrinnsvis metoksy og etoksy.
Lavere-alkenyloksygrupper er fortrinnsvis vinyloksy og allyloksy.
Betegnelsen "cykloalkyl", alene eller i kombinasjon, betyr en cykloalkylring med
3 til 8 karbonatomer og fortrinnsvis en cykloalkylring med 3 til 6 karbonatomer.
Eksempler på C3-C8 cykloalkyl er cyklopropyl, cyklobutyl, cyklopentyl, cykloheksyl, cykloheptyl og cyklooktyl, fortrinnsvis cyklopropyl, cykloheksyl og spesielt cykloheksyl eller lavere-alkyl substituert cykloalkyl som fortrinnsvis kan være substituert med lavere-alkyl så som metyl-cyklopropyl, dimetyl-cyklopropyl, metyl-cyklobutyl, metyl-cyklopentyl, metyl-cykloheksyl, dimetyl-cykloheksyl.
Betegnelsen "aryl", alene eller i kombinasjon, betyr en fenyl- eller naftylgruppe
som eventuelt bærer én eller flere substituenter, fortrinnsvis én eller to substituenter,
hver uavhengig valgt fra cyano, halogen, hydroksy, lavere-alkyl, lavere-alkenyl, lavere-alkoksy, lavere-alkenyloksy, nitro, trifluormetyl, trifluormetoksy, amino,
karboksy og lignende, så som fenyl, p-tolyl, 4-metoksyfenyl, 4-tert-butoksyfenyl, 4-fluorfenyl, 2-klorfenyl, 4-hydroksyfenyl, 1-naftyl og 2-naftyl. Foretrukket er karboksyfenyl, lavere-alkoksy-fenyl, hydroksyfenyl og spesielt fenyl.
Betegnelsen "aralkyl", alene eller i kombinasjon, betyr en alkyl eller cykloalkyl gruppe som tidligere definert hvor et hydrogenatom er erstattet av en arylgruppe som tidligere er definert. Foretrukket er benzyl og benzyl substituert i fenylringen med hydroksy, lavere-alkyl, lavere-alkoksy eller halogen, fortrinnsvis klor. Spesielt foretrukket er benzyl.
For betegnelsen "heterocyklyl" og "heterocyklyl-lavere-alkyl", er heterocyklylgruppen fortrinnsvis en 5- til 10-leddet monocyklisk eller bicyklisk ring, som kan være mettet, delvis umettet eller aromatisk inneholdende for eksempel 1,2 eller 3 heteroatomer valgt fra oksygen, nitrogen og svovel som kan være like eller forskjellige. Eksempler på slike heterocyklylgrupper er pyrrolidinyl, piperidinyl, piperazinyl, morfolinyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, kinolyl, isokinolyl, tienyl, tiazolyl, isotiazolyl, furyl, imidazoyl, pyrazolyl, pyrrolyl, indazolyl, indolyl, isoindolyl, isoksazolyl, oksazolyl, kinoksalinyl, ftalazinyl, cinnolinyl, dihydropyrrolyl, pyrrolidinyl, isobenzofuranyl, tetrahydrofuranyl, dihydropyranyl. Heterocyklylgruppen kan ha opptil 5, fortrinnsvis 1,2 eller 3 eventuelle substituenter. Eksempler på egnede substituenter omfatter halogen, lavere-alkyl, amino, nitro, cyano, hydroksy, lavere-alkoksy, karboksy og lavere-alkyloksy-karbonyler.
Betegnelsen "halogen" betyr fluor, klor, brom eller jod og fortrinnsvis
klor og brom og spesielt klor.
Betegnelsen "karboksy", alene eller i kombinasjon, betyr en -COOH gruppe.
En gruppe foretrukne forbindelser ifølge foreliggende oppfinnelse er forbindelser med formel (I) hvor R<2>, R<3>, R<6>, R<7>, R<8> og R<9> er hydrogen. Eksempler på foretrukne forbindelser er: 2-[l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-JV-(pyridin-2-yl-metyl)-acetamid: 2-[l-(3,4-dimetoksy-benzyl)-8-etoksy-5-metoksy-3,4-dihydro^ (pyridin-2-yl-metyl)-acetamid: 2-[l-(3,4-dimetoksy-benzyl)-8-propoksy-5-metoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-(pyridin-2-yl-metyl)-acetamid: 2-[ 1 -(3,4-dimetoksy-benzyl)-8-allyloksy-5-metoksy-3,4-dihydro- l//-isokinolin-2-yl]-iV-(pyridin-2-yl-metyl)-acetamid: 2-[l-(3,4-dimetoksy-benzyl)-8-isopropoksy-5-metoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-(pyridin-2-yl-metyl)-acetamid: 2-[l-(3,4-dimetoksy-benzyl)-5-propoksy-8-metoksy-3,4-dihydro-li/-isokinolin-2-yl]-A^-(pyridin-2-yl-rnetyl)-acetamid: En annen gruppe med foretrukne forbindelser ifølge foreliggende oppfinnelse er forbindelser med formel (II)
hvor:
R'1 and R'2 uavhengig representerer hydrogen, hydroksy, metoksy eller halogen eller kan
med fenylringen danne en fem-, seks- eller syvleddet ring inneholdende ett eller to oksygenatomer,
R'3 representerer aryl, aralkyl, lavere-alkenyl, cykloalkyl, heterocyklyl eller heterocyklyl-lavere-alkyl;
R'<4> representerer hydrogen, aryl, aralkyl, lavere-alkyl, lavere-alkenyl, cykloalkyl, heterocyklyl eller heterocyklyl-lavere-alkyl;
R'<5> representerer aryl, aralkyl, lavere-alkyl, lavere-alkenyl, cykloalkyl, heterocyklyl eller heterocyklyl-lavere-alkyl;
og optisk rene enantiomerer, blandinger av enantiomerer, racemater, optisk rene diastereoisomerer, blandinger av diastereoisomerer, diastereoisomere racemater, blanding av diastereoisomere racemater eller mesoformer og farmasøytisk akseptable salter derav.
Eksempler på foretrukne forbindelser med formel (II) er: 2- [ 1 -(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-1 #-isokinolin-2-yl] - N-benzyl-acetamid
2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-A?-naftalen-1 -ylmetyl-acetamid
2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-(2-metoksy-benzyl)-acetamid
2-[ 1 -(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro- l//-isokinolin-2-yl]-Af-(4-fluor-benzyl)-acetamid
2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-(6-metoksy-naftalen-2-ylmetyl)-acetamid
2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l/f-isokinolin-2-yl]-A^-(4-metoksy-naftalen-2-ylmetyl)-acetamid
2-[ 1 -(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro- lH-isokinolin-2-yl] - N-(3,6)-difluor-benzyl)-acetamid
2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-AT-(1 -fenyl-etyl)-acetamid
2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-AT-(pyridin-3-ylmetyl)-acetamid
2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l/f-isokinolin-2-yl]-iV-(2-metyl-benzyl)-acetamid
2-[ 1 -(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro- lH-isokinolin-2-yl] - N-(3-metyl-benzyl)-acetamid
2-{l-[4-(pyrimidin-2-yloksy)-3-metoksy-benzyl]-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl} -Af-benzyl-acetamid
2-[ l-(3,4-dimetoksy-benzyl)-7-( ^ ^ 2-yl]-A^-benzyl-acetamid
2-[ 1 -(3,4-dimetoksy-benzyl)-6-metoksy-7-isopropoksy-3,4-dihydro- 1 Jf-isokinolin-2-yl]-iV-benzyl-acetamid
2-[l-(3,4-dimetoksy-benzyl)-7-etoksy-6-metoksy-3,4-dihydro-l/f-isokinolin-2-yl]-A^-benzyl-acetamid
2-[l-(3,4-dimetoksy-benzyl)-7-propoksy-6-metoksy-3,4-dihydro-l//-isokinolin-2-yl]-iV'-benzyl-acetamid
2-[l-(3,4-dimetoksy-benzyl)-7-allyloksy-6-metoksy-3,4-dihydro-l//-isokinolin-2-yl]-N-benzyl-acetamid
A^-benzyl-2-[l-(3,4-dimetyl-benzyl)-6J-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-acetam A^-benzyl-2-[l-(3,4-dietyl-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-acetarru^
2-[ 1 -(3,4-dietyl-benzyl)-6,7-dimetoksy-3,4-dihydro- lH-isokinolin-2-yl]-A^-(pyridin-2-yl-metyl)-acetamid
2-[l-(3,4-dietyl-benzyl)-6J-dimetoks<y>-3,4-dihydro-l^-isokinolin-2-yl]-A^-(pyridin-3-yl-metyl)-acetamid
2-[l-(3,4-dietyl-benzyl)-6J-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-(pyridin-4-yl-metyl)-acetamid
2-[l-(3,4-diklor-benzyl)-6J-dimetoksy-3,4-dihydro-l//-i^^ metyl)-acetamid
Eksempler på spesielt foretrukne forbindelser med formel (II) er: 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-A^-benzyl-acetamid
2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-
naftalen-1 -ylmetyl-acetamid
2-[ 1 -(3,4-dimetoksy-benzyl)-7-( 1 -metyl-prop-2-oksy)-6-metoksy-3,4-dihydro-1//-isokinolin-2-yl]-iV-benzyl-acetamid
2-[l-(3,4-dirnetoksy-benzyl)-6-metoksy-7-isopropoksy-3,4-dihydro-l//-isokinolin-2-yl]-Ar-benzyl-acetamid
2-[ 1 -(3,4-dimetoksy-benzyl)-7-etoksy-6-metoksy-3,4-dihydro- l/f-isokinolin-2-yl]-iV-benzyl-acetamid
2-[l-(3,4-dimetoksy-benzyl)-7-propoksy-6-metoksy-3,4-dihydro-l//-isokinolin-2-yl]-Ar<->benzyl-acetamid
2-[l-(3,4-dimetoksy-benzyl)-7-allyloksy-6-metoksy-3,4-dihydro-l//-isokinolin-2-yl]-^V-benzyl-acetamid
Af-benzyl-2-[ 1 -(3,4-dimetyl-benzyl)-6,7-dimetoksy-3,4-dihydro- l/f-isokinolin-2-yl]-acetamid AT-benzyl-2-[ 1 -(3,4-dietyl-benzyl)-6,7-dimetoksy-3,4-dihydro- 1//-i sokinolin-2-yl]-acetamid
2-[l-(3,4-dietyl-benzyl)-6,7-dimetoksy-3,4-dihydro-l/f-isokinolin-2-yl]-N-(pyridin-2-yl-metyl)-acetamid
2-[l-(3,4-dietyl-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-iV-(pyridin-3-yl-metyl)-acetamid
2-[l-(3,4-dietyl-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-A^-(pyridin-4-yl-metyl)-acetamid
2-[l-(3,4-diklor-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-(pyridin-3-yl-metyl)-acetamid
Eksempler på fysiologisk anvendelige eller farmasøytisk akseptable salter av forbindelsene med formel (I) er salter med fysiologisk kompatible mineralsyrer slik
som saltsyre, svovelsyre eller fosforsyre; eller med organiske syrer så som metansulfonsyre, eddiksyre, trifluoreddiksyre, sitronsyre, fumarsyre, maleinsyre
syre, vinsyre, ravsyre eller salisylsyre. Forbindelsene med formel (I) med frie karboksygrupper kan også danne salter med fysiologisk kompatible baser.
Eksempler på slike salter er alkalimetall-, jordalkalimetall-, ammonium- og alkylammoniumsalter så som Na, K, Ca eller tetraalkylammoniumsalt. Forbindelsene med formel (I) kan også foreligge i form av et zwitterion.
Forbindelsene med formel (I) kan inneholde mange asymmetriske sentere og kan foreligge i form av optisk rene enantiomerer, blandinger av enantiomerer så som,
for eksempel racemater, optisk rene diastereoisomerer, blandinger av diastereoisomerer, diasteroisomere racemater eller blandinger av diastereoisomere racemater og meso-
formene.
Foretrukne forbindelser som beskrevet ovenfor har ICso-verdier under 1000 nM; spesielt foretrukne forbindelser har ICso-verdier under 100 nM som bestemmes ved FLIPR (Fluormetric Imaging Plate Reader) metoden beskrevet på begynnelsen av den eksperimentelle del.
Forbindelsene med den generelle formel (I) og deres farmasøytisk anvendelige
salter kan anvendes for fremstilling av medikamenter for behandling av sykdommer eller forstyrrelser hvor en antagonist for en human orexin-reseptor er nødvendig så som fedme, diabetes, prolactinoma, narkolepsi, søvnløshet, søvnapné, parasomnia, depresjon, angst, avhengigheter, schizofreni og demens.
Forbindelsene med formel (I) og deres farmasøytisk anvendelige salter er spesielt anvendelige for fremstilling av medikamenter for behandling av fedme og søvnforstyrrelser.
Forbindelsene med formel (I) og deres farmasøytisk anvendelige salter kan anvendes som medikament (f.eks. i form av farmasøytiske preparater). De farmasøytiske preparater kan administreres internt, så som oralt (f.eks. i form av tabletter, belagte tabletter, drasjeer, harde og myke gelatinkapsler, løsninger, emulsjoner eller suspensjoner), nasalt (f.eks. i form av nesespray-preparater) eller rektalt (f.eks. i form av suppositorier). Imidlertid kan administreringen også utføres parentalt, så som intramuskulært eller intravenøst (f.eks. i form av injeksj onsløsninger).
Forbindelsene med formel (I) og deres farmasøytisk anvendelige salter kan behandles med farmasøytisk inerte, uorganiske eller organiske tilsetningsmidler for produksjon av
tabletter, belagte tabletter, drasjéer og harde gelatinkapsler. Laktose, maisstivelse eller derivater derav, talkum, stearinsyre eller dens salter etc. kan anvendes, for eksempel, som sådanne tilsetningsmidler for tabletter, drasjéer og harde gelatinkapsler.
Egnede tilsetningsmidler for myke gelatinkapsler, er for eksempel vegetabilske oljer, vokser, fett, halvfaste substanser og flytende polyoler, etc.
Egnede tilsetningsmidler for fremstilling av løsninger og siruper er for eksempel
vann, polyoler, sakkarose, invertsukker, glukose, etc.
Egnede tilsetningsmidler for injeksjonsløsninger er for eksempel vann, alkoholer, polyoler, glycerol, vegetabilske oljer, etc.
Egnede tilsetningsmidler for suppositorier er for eksempel naturlige eller herdede oljer, vokser, fett, halvfast eller flytende polyoler, etc.
Videre kan farmasøytiske preparater inneholde konserveringsmidler, solubiliserings-midler, viskositetsøkende substanser, stabiliseringsmidler, fuktemidler, emulgeringsmidler, søtningsmidler, fargemidler, smaksmidler, salter for å variere det osmotiske trykket, buffere, maskeringsmidler eller antioksydasjonsmidler. De kan også inneholde enda andre terapeutisk verdifulle substanser. Oppfinnelsen angår også fremgangsmåter for fremstilling av forbindelser med formel I.
Forbindelsene med den generelle formel (I) ifølge foreliggende oppfinnelse blir fremstilt i henhold til den generelle sekvens av reaksjoner beskrevet i skjemaene nedenfor, hvor R<1>, R<2>, R<3>, R<4>, R<5>, R<6>, R7, R8, R1<0> er som definert i formel (I) ovenfor. Avhengig av forbindelsen som blir oppnådd med ett eller flere optisk aktive karbonatomer kan den oppløses i rene enantiomerer eller diastereomerene, blandinger av enantiomerer eller diastereomerene, diastereomere racemater og meso-formene på en i og for seg kjent måte.
Forbindelsene som oppnås kan også omdannes til et farmasøytisk akseptabelt salt derav på en i seg selv kjent måte.
Forbindelsene med formel (I) kan fremstilles som enkeltforbindelser eller som biblioteker av forbindelser omfattende minst 2, f.eks. 5 til 1000 forbindelser med formel (I).
Forbindelsesbiblioteker kan fremstilles ved en kombinatorisk metode eller ved multippel parallelsyntese ved anvendelse av løsningsfasekjemi. For den kombinatoriske metode blir forbindelsene med den generelle formel (I) hvor R<6>, R<7>, R<9> er hydrogen, fremstilt ved anvendelse av en Ugi-tre-komponent-kondenseringsreaksjon (Ugi-3-CC) som involverer én-satsreaksjon mellom et 1,2,3,4-tetrahydroisokinolinderivat, et aldehyd og et isocyanid ( Skjema 1).
Isocyanider som ikke er kommersielt tilgjengelig kan fremstilles fra de tilsvarende aminer ved N-formylering fulgt av behandling med POCI3 (se f.eks. J. March, fjerde utgave, Wiley-Interscience publikasjon, s. 1042).
Forbindelsene med den generelle formel (I) hvor R<6> og R<7> er hydrogen, kan
også fremstilles ved forskjellige prosedyrer. Synteseveien avhenger av siste kjemiske transformasjon som må utføres.
I alle tilfeller hvor koblingen av tetrahydroisokinolinet med amidsidekjeden er det siste trinn ble standardprosedyren vist i ( Skjema2) fulgt. Tetrahydroisokinolinene så vel som aminene (R<9>R,<0>NH) kan være enten kommersielt tilgjengelig eller syntetiseres.
Tetrahydroisokinoliner som ikke er kommersielt tilgjengelige kan fremstilles fra de tilsvarende fenyletylaminer ved kobling med den ønskede karboksylsyre fulgt av behandling med POCI3 og til slutt NaBH4 (se eksperimentell del). Forbindelser med den generelle formel (I) hvor én substituent i 1 -benzyl-tetrahydro-isokinolinstrukturen er en karbamoyloksy-, heteroaryloksy- eller alkoksy-rest (ikke metoksy) blir syntetisert i henhold til ( Skjema 3). De benzyl-beskyttete fenoler blir fremstilt ved metoden vist i ( Skjema 2).
I tilfellet R<5> (generelle formel I) er en heterocyklyl-metylsubstituent er det siste trinn substitusjon av en mesylatgruppe med den tilsvarende nitrogenholdige nukleofil i henhold til ( Skjema 4). Det nødvendige utgangsmateriale ble syntetisert ved samme prosedyre som beskrevet tidligere ( Skjema 2).
Stereokjemisk rene forbindelser med den generelle formel I blir oppnådd ved kinetisk spaltning av tetrahydroisokinolinet (Corrodi H., Hardegger E., Heiv. Chim. Acta, 1956, 39, 889-897) og kobling av den rene enantiomer med amidbindinger i henhold til Skjema 2.
Eksperimentell del
I. Biologi
Bestemmelse av OXi reseptorantagonistaktivitet
OXi reseptorantagonistaktiviteten til forbindelsene med formel (I) ble
bestemt i henhold til den følgende eksperimentelle metode.
Eksperimentell metode:
Intracellulære kalsiummålinger
Kinesisk hamstereggstokk(CHO)celler som uttrykker henholdsvis den humane orexin-1 reseptor og den humane orexin-2 reseptor, ble dyrket i dyrkningsmedium (Ham F-12 med L-Glutamin) inneholdende 300 |ig/ml G418, 100 U/ml penicillin, 100 (lg/ml streptomycin og 10 % inaktivert føtalt kalveserum (FCS).
Cellene ble podet ved 80 000 celler / brønn into 96-brønners sorte klarbunnete sterile plater (Costar) som hadde blitt forut belagt med 1% gelatin i Hanks' Balanced saltløsning (HBSS). Alle reagenser var fra Gibco BRL.
De podete plater ble inkubert natten over ved 37°C i 5% CO2.
Human orexin-A som en agonist ble fremstilt som 1 mM stamløsning i metanohvann (1:1), fortynnet i HBSS inneholdende 0,1 % bovint serumalbumin (BSA) og 2 mM HEPES for anvendelse i forsøket i en sluttkonsentrasjon på 10 nM.
Antagonister ble fremstilt som 10 mM lagerløsning i DMSO, deretter fortynnet i 96-brønners plater, først i DMSO, deretter i HBSS inneholdende 0,1 % bovint serumalbumin (BSA) og 2
mM HEPES.
På målingsdagen ble 100 |il tilført medium (HBSS inneholdende 1% FCS, 2 mM HEPES, 5 mM probenecid (Sigma) og 3 (iM av den fluorescerende kalsiumindikator fluo-3 AM (1 mM stamløsning i DMSO med 10% pluronsyre) (Molecular Probes) satt til hver brønn.
96-brønnersplatene ble inkubert i 60 min ved 37° C i 5% CO2. Den tilførte løsning ble deretter avdampet og cellene ble vasket 3 ganger med 200 til HBSS inneholdende 2,5 mM probenecid, 0,1% BSA, 2 mM HEPES. 100 ul av den samme buffer var tilbake i hver brønn.
I Fluorescerent Imaging Plate Reader (FLTPR, Molecular Devices), sattes antagonister til platen i et volum på 50 ble inkubert i 20 min og til slutt ble 100 |il agonist tilsatt. Fluorescens ble målt for hver brønn med 1 sekunds intervaller og høyden av hver fluorescenstopp ble sammenlignet med høyden til fluorescenstoppen fremkalt med 10 nM orexin-A med buffer istedenfor antagonist. For hver antagonist ble IC50-verdien (konsentrasjonen av forbindelse som er nødvendig for å å hemme 50 % av de agonistiske respons) bestemt.
II. Kiemi
De følgende eksempler illustrerer fremstilling av farmakologisk aktive forbindelser ifølge foreliggende oppfinnelse. Alle temperaturer er angitt i °C.
Alle hydrokloridsalter ble fremstilt ved oppløsning av den fri-base i diklormetan
og behandling med et overskudd av HC1 i eter (2M).
Generelle fremgangsmåter:
A. Generell fremgangsmåte A: l-[(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-eddiksyre-benzylester
Til en hvit suspensjon av l-(4,5-dimetoksybenzyl)-6,7-dimetoksy-1,2,3,4-tetrahydroisokinolin-hydroklorid (lg, 2,632 mmol) i en blanding av toluen/ DMF
(9/1) (10 ml), sattes trietylamin (1,1 ml, 7,896 mmol) og klorbenzylacetat (440 ul, 2,895 mmol). Reaksjonsblandingen ble rørt ved tilbakeløp under argon i 20 timer. Etter avkjøling ble blandingen fortynnet i CH2CI2 og vasket med vann.
Den vandige fasen ble ekstrahert to ganger med CH2CI2, de samlede organiske faser ble tørket over vannfritt MgSO-t, filtrert og inndampet, hvilket ga en rå brunoransje olje. Flashkromatografi (AcOEt/ heksan 1/1) ga 1,15 g (89%) av tittelproduktet som en brunoransje olje.
TLC (AcOEt/ heksan: 1/1): Rf = 0,55.
LC-MS (MeCN/ H20: 1/1): R, = 4,16 min. m/ z = 492 (M + 1).
1- (3,4-dimetoksybenzyl)-6,7-dimetoksy-(3,4-dihydro-lH-isokinolin-2-yl)-eddiksyre.
Til en løsning av l-[(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-eddiksyre benzylester (1,15 g, 2,34 mmol) i tørr AcOEt (20 ml) sattes i én porsjon Pd-C 10%
(250 mg). Den resulterende sorte suspensjon ble hydrogenert ved normaltrykk og romtemperatur i 20 timer. Blandingen ble deretter filtrert over celite og inndampet i vakuum, hvilket ga brune krystaller.
LC-MS (MeCN/ H20: 1/1): R, = 3,34 min. m/ z = 402 (M + 1).
Eksempel 1
2- [l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-benzyl-acetamid
Til en løsning av l-(4,5-dimetoksybenzyl)-6,7-dimetoksy-(3,4-dihydro-lH-isokinolin-2-yl)-eddiksyre (100 mg, 0,249 mmol) i 4 ml tørt DMF sattes
129,6 mg (0,249 mmol) PyBOP, 29,9 jxl (0,226 mmol) benzylamin og dråpevis 110 (il (0,521 mmol) diisopropyletylamin (Hiinig's base). Reaksjonsblandingen ble rørt ved RT under argon i 20 timer. Blandingen ble deretter oppløst i CH2CI2 og vasket med vann. Den vandige fasen ble ekstrahert to ganger med CH2CI2, de samlede organiske ekstrakter ble tørket over MgS04, filtrert og inndampet, hvilket ga en rå brun rest. Flash- kromatografi (AcOEt/ heksan 8/2) ga 126 mg (94%) av tittelforbindelsen som en brun viskøs olje.
TLC (AcOEt/ heksan: 8/2): Rf = 0,65.
LC-MS (MeCN/ H20: 1/1): Rt= 4,83 min. m/ z = 491 (M + 1).
Eksempel 2
2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-Ar-naftalen-l-ylmetyl-acetamid
Analogt med Eksempel 1, men for det siste trinn, omsetning av l-(4,5-dimetoksybenzyl)-6,7-dimetoksy-(3,4-dihydro-lH-isokinolin-2-yl)-eddiksyre med 1-naftlalenmetylamin, hvilket ga tittelforbindelsen som den fri base (brun viskøs olje) og hydrokloridsaltet (brune krystaller)
-TLC (AcOEt): Rf = 0,55.
-LC-MS (MeCN/H20: 1/1): R, = 5,97 min. m/ z = 541(M + 1).
Eksempel 3
2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-iV-(6-metoksy-naftalen-2-ylmetyl)-acetamid
Analogt med Eksempel 1, men for det siste trinn, omsetning av l-(4,5-dimetoksybenzyl)-6,7-dimetoksy-(3,4-dihydro- lH-isokinolin-2-yl)-eddiksyre med 6-metoksynaftalen-2-metylamin, hvilket ga tittelforbindelsen som den fri base (brun olje). -TLC (AcOEt): Rf = 0,40 -LC-MS (MeCN/H20: 1/1): Rt = 4,68 min. m/ z = 571(M + 1).
2-(3-brom-4-metoksy-fenyl)-iV-[2-(3,4-dimetoksy)-etyl]-acetamid LC-MS (MeCN/ H20: 1/1): R, 4,28 min, 409 (M+l, ES+).
A^-[2-(3,4-dimetoksy-fenyl)-etyl]-2-(3,4-dimetyl-fenyl)-acetamid
LC-MS (MeCN/ H20: 1/1): R,4,36 min, 328 (M+l, ES+).
2-(3,4-dietyl-fenyl)-iV-[2-(3,4-dimetoksy)-etyl]-acetamid
LC-MS (MeCN/ H20: 1/1): Rt 4,18 min, 356 (M+l, ES+).
2-(3,4-diklor-fenyl)-A^-[2-(3,4-dimetoksy)-etyl]-acetamid
LC-MS (MeCN/ H20: 1/1): R, 4,12 min, 369 (M+l, ES+). l-(4-brom-3-metoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydro-isokinolin LC-MS (MeCN/ H20: 1/1): Rt 2,96 min, 393 (M+l, ES+). l-(3,4-dimetyl-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydro-isokinolin LC-MS (MeCN/ H20: 1/1): R, 3,19 min, 312 (M+l, ES+). l-(3,4-dietyl-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydro-isokinolin LC-MS (MeCN/ H20: 1/1): Rt 2,25 min, 340 (M+l, ES+). l-(3,4-diklor-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydro-isokinolin LC-MS (MeCN/ H20: 1/1): R, 3,20 min, 353 (M+l, ES+). l-[(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydro-naftalen-2-yl]-fenyl-eddiksyre-metylester
Til en hvit suspensjon av l-(4,5-dimetoksybenzyl)-6,7-dirnetoksy-l,2,3,4-tetrahydroisokinolin-hydroklorid (5 g, 0,013 mol) i tørt toluen (50 ml) sattes trietylamin (5,5 ml, 0,039 mol) og brom-fenyl-eddiksyre-metylester (2,07 ml, 0,013 mol). Reaksjonsblandingen ble rørt ved tilbakeløp under argon i 20 timer. Etter avkjøling ble blandingen fortynnet i CH2C12 og vasket med vann. Den vandige fasen ble ekstrahert to ganger med CH2C12, de samlede organiske faser ble tørket over vannfritt MgS04, filtrert og inndampet, hvilket ga en rå brunoransje olje. Flashkromatografi (AcOEt/ heksan 1/1) ga 5,85 g (90%) av tittelproduktet som en brunoransje olje.
TLC (AcOEt/ heksan: 1/1): Rf = 0,55.
LC-MS (MeCN/ H20: 1/1): Rt 4,00 min og Rt 4,36 min, 492 (M+l, ES+).
l-[(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydro-naftalen-2-yl]-fenyl-eddiksyre
Til en løsning av l-[(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydro-naftalen-2-yl]-fenyl- eddiksyre-metylester (5,85 g, 0,011 mmol) i en blanding av dioksan/ MeOH (4/3) (160 ml) sattes dråpevis 2M NaOH(Vandig) (81 ml). Den resulterende blanding ble rørt ved RT i 20 timer under nitrogen. Blandingen ble deretter inndampet i vakuum, kombinert med vann og AcOEt. Den vandige fasen ble surgjort inntil pH 1 med 2N HC1, ekstrahert tre ganger med med CH2C12, de samlede organiske faser ble tørket over vannfritt MgS04, filtrert og inndampet, hvilket ga tittelproduktet (5,55 g, 97%) som gulgrønne krystaller.
LC-MS (MeCN/ H20: 1/1): R, 3,62 min og Rt 3,65 min, 478 (M+l, ES+).
Eksempel 7
iV-benzyl-2-[l-(3,4-dimetyl-benzyl)-6,7-dimetoksy-3,4-dihydro-l£f-isokinolin-2-yl]-acetamid: fremstilt ved omsetning av l-(3,4-dimetyl-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin.
LC-MS (MeCN/ H20: 1/1): Rt = 4,35 min, 459 (M+l, ES+).
Eksempel 9
2-[l-(3,4-dimetyl-benzyl)-6,7-dimetoksy-3,4-dihydro-lff-isokinolin-2-yl]-A^-pyridin-2-yl-acetamid: fremstilt ved omsetning av l-(3,4-dimetyl-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-pikolylamin.
LC-MS (MeCN/ H20: 1/1): R, = 2,99 min, 460 (M+l, ES+).
Eksempel 10
2-[l-(3,4-dimetyl-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-A^-pyridin-3-yl-acetamid: fremstilt ved omsetning av l-(3,4-dimetyl-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 3-pikolylamin.
LC-MS (MeCN/H20: 1/1): Rt= 2,61 min, 460 (M+l, ES+).
Eksempel 11
iV-benzyl-2-[l-(3,4-dietyl-benzyl)-6,7-dimetoksy-3,4-dihydro-lff-isokinolin-2-yl]-acetamid: fremstilt ved omsetning av l-(3,4-dietyl-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin.
LC-MS (MeCN/ H20: 1/1): Rt= 4,35 min, 459 (M+l, ES+).
Eksempel 12
2-[l-(3,4-dietyl-benzyl)-6,7-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-AT-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dietyl-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisoldnolin og 2-bromacetylbromid med 2-pikolylamin.
LC-MS (MeCN/ H20: 1/1): Rt = 2,87 min, 488 (M+l, ES+).
Eksempel 13
2-[l-(3,4-dietyl-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(pyirdin-3-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dietyl-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 3-pikolylamin.
LC-MS (MeCN/ H20: 1/1): R, = 2,85 min, 488 (M+l, ES+).
Eksempel 14
2-[l-(3,4-dietyl-benzyl)-6,7-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-iV-(pyirdin-4-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dietyl-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 4-pikolylamin.
LC-MS (MeCN/ H20: 1/1): Rt = 2,71 min, 488 (M+l, ES+).
Eksempel 15
2-[l-(3,4-diklor-benzyl)-6,7-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-N-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-diklor-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-pikolylamin.
LC-MS (MeCN/ H20: 1/1): Rt = 3,72 min, 501 (M+l, ES+).
Eksempel 16
2-[l-(3,4-diklor-benzyl)-6,7-dimetoksy-3,4-dihydro-li<y->isokinoIin-2-yl]-A^-(pyridin-3-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-diklor-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 3-pikolylamin.
LC-MS (MeCN/ H20: 1/1): Rt = 3,29 min, 501 (M+l, ES+).
B Kobling av 1,2,3,4-tetrahydroisokinoliner med 2-bromacetamider
B,l Utgangsmaterialer: Syntese av 1,2,3,4-tetrahydroisokinolinderivater:
B,l,l Syntese av fenyletylamidene:
Fremgangsmåte I:
En løsning av det respektive fenyletylamin (80 mmol) og av trietylamin (90 mmol) i THF (120 ml) ble avkjølt til 0°C og behandlet porsjonsvis med det respektive acetylklorid (80 mmol). Etter røring i 10 min ved 0°C og i 14 timer ved romtemperatur ble en mettet vandig NaHCC>3 løsning tilsatt, fasene ble separert, og den vandige fasen ble ekstrahert tre ganger med etylacetat (150 ml). Løsningsmidlet ble fjernet i vakuum og residuet ble enten omkrystallisert fra toluen eller renset ved flashkromatografi,
hvilket ga de følgende amider:
N-[2-(3-metoksy-fenyl)-etyl]-3,4-dimetoksyfenyl-acetamid:
fremstilt ved omsetning av 3-metoksyfenyletylamin med 3,4-dimetoksyfenyl acetylklorid.
LC-MS: rt = 4,1 min, 330 (M+l, ES+).
N-[2-(3,4-dimetoksy-fenyl)-etyl]-fenyI-acetamid:
fremstilt ved omsetning av 3,4-dimetoksyfenyletylamin med fenyl acetylklorid.
N-[2-(3,4-dimetoksy-fenyl)-etyl]-3-metoksyfenyl-acetamid:
fremstilt ved omsetning av 3,4-dimetoksyfenyletylamin med 3-metoksyfenyl acetylklorid.
LC-MS: rt = 4,0 min, 330 (M+l, ES+).
N-[2-(3,4-dimetoksy-fenyl)-etyl]-4-metoksyfenyl-acetamid:
fremstilt ved omsetning av 3,4-dimetoksyfenyletylamin med 4-metoksyfenyl acetylklorid.
LC-MS: rt = 4,0 min, 330 (M+l, ES+).
N-[2-(3,4-dimetoksy-fenyl)-etyl]-2,5-dimetoksyfenyl-acetamid:
fremstilt ved omsetning av 3,4-dimetoksyfenyletylamin med 2,5-dimetoksyfenyl acetylklorid.
LC-MS: rt = 4,1 min, 360 (M+l, ES+).
N-[2-(2,5-dimetoksy-fenyl)-etyl]-3,4-dimetoksyfenyl-acetamid:
fremstilt ved omsetning av 2,5-dimetoksyfenyletylamin med 3,4-dimetoksyfenyl acetylklorid.
LC-MS: rt = 4,2 min, 360 (M+l, ES+).
N-[2-(3,4-dimetoksy-fenyl)-etyl]-3-fenyl-propionamid:
fremstilt ved omsetning av 3,4-dimetoksyfenyletylamin med 3-fenyl propionylklorid. LC-MS: rt = 4,2 min, 314 (M+l, ES+).
N-[2-(3,4-dimetoksy-fenyl)-etyl]-2-fenyl-butyramid:
fremstilt ved omsetning av 3,4-dimetoksyfenyletylamin med 2-fenylbutyrylklorid.
Rf = 0,21 (etylacetat/heptan 1/1)
N-[2-(2,5-dimetoksy-fenyl)-etyl]-difenyl-acetamid:
fremstilt ved omsetning av 2,5-dimetoksyfenyletylamin med difenylacetylklorid. LC-MS: rt = 5,3 min, 376 (M+l, ES+).
N-[2-(2,5-dimetoksy-fenyl)-etyl]-2,5-dimetoksyfenyl-acetamid:
fremstilt ved omsetning av 2,5-dimetoksyfenyletylamin med 2,5-dimetoksyfenyl acetylklorid.
LC-MS: rt = 4,6 min, 360 (M+l, ES+).
N-[2-(3,4-dimetoksy-fenyl)-etyl]-4-klorfenyl-acetamid:
fremstilt ved omsetning av 3,4-dimetoksyfenyletylamin med 4-klorfenyl acetylklorid. LC-MS: rt = 4,4 min, 334 (M+l, ES+).
N-[2-(2,5-dimetoksy-fenyl)-etyl]-fenyl-acetamid:
fremstilt ved omsetning av 2,5-dimetoksyfenyletylamin med fenylacetylklorid. LC-MS: rt = 4,5 min, 300 (M+l, ES+).
N-[2-(3-metoksy4-isopropoksy-fenyl)^tyl]-3,4-dimetoksyfenyl-acetamid:
fremstilt ved omsetning av 3-metoksy-4-isopropoksyfenyletylamin med 3,4-dimetoksyfenyl acetylklorid.
LC-MS: rt = 4,2 min, 388 (M+l, ES+).
N-[2-(3,4£-trimetoksy -fenyl)-etyl]-3,4-dimetoksyfenyl-acetamid:
fremstilt ved omsetning av 3,4,5-trimetoksyfenyletylamin med 3,4-dimetoksyfenyl acetylklorid.
LC-MS: rt = 3,8 min, 390 (M+l, ES+).
N-[2-(2^,4-trimetoksy-fenyl)^tyl]-3,4-dimetoksyfenyl-acetamid:
fremstilt ved omsetning av 2,3,4-trimetoksyfenyletylamin med 3,4-dimetoksyfenyl acetylklorid.
LC-MS: rt = 4,1 min, 390 (M+l, ES+).
N-[2-(3^^1irnetoksy-fenyl)^tyl]-3,4-dimetoksyfenyl-acetamid:
fremstilt ved omsetning av 3,5-trimetoksyfenyletylamin med 3,4-dimetoksyfenyl acetylklorid.
LC-MS: rt = 4,2 min, 360 (M+l, ES+).
N-[2-(3-benzyloksy4-metoksy^^
fremstilt ved omsetning av 3-benzyloksy-4-metoksyfenyletylamin med 3,4-dimetoksyfenyl acetylklorid.
LC-MS: rt = 4,7 min, 436 (M+l, ES+), 434 (M-l, ES-).
N-[2-(4-benzyloksy-3-metoksy-fenyl)-et^^^
fremstilt ved omsetning av 4-benzyloksy-3-metoksyfenyletylamin med 3,4-dimetoksyfenyl acetylklorid.
LC-MS: rt = 4,8 min, 436 (M+l, ES+).
N-[2-(2-benzyloksy-5-metoksy-fenyl)-etyl]-3,4-dimetoksyfenyl-acetamid:
fremstilt ved omsetning av 2-benzyloksy-5-metoksyfenyletylamin med 3,4-dimetoksyfenyl acetylklorid.
LC-MS: rt = 4,8 min, 436 (M+l, ES+).
N-[2-(5-benzyloksy-2-metoksy-fenyl)^tyl]-3,4^imetoksyfenyl-acetamid:
fremstilt ved omsetning av 5-benzyloksy-2-metoksyfenyletylamin med 3,4-dimetoksyfenyl acetylklorid.
LC-MS: rt = 4,9 min, 436 (M+l, ES+).
N-[2-(3,4-dimetoksy-fenyl)-etyl]-benzyloksy-acetamid:
fremstilt ved omsetning av 3,4-dimetoksyfenyletylamin med benzyloksy acetylklorid. LC-MS: rt = 4,2 min, 330 (M+l, ES+).
Fremgangsmåte II:
En løsning av det respektive fenyletylamin (25,0 mmol) og den respektive fenyleddiksyre (25,0 mmol) i 100 ml toluen ble tilbakeløpskokt i 24 timer i nærvær av en Dean-Stark. Løsningsmidlet ble fjernet i vakuum og residuet ble enten omkrystallisert fra toluen eller renset ved flashkromatografi, hvilket ga de følgende amider:
N-[2-(3,4-dimetoksy-fenyl)-etyl]-3,4-metylendioksyfenyl-acetamid:
fremstilt ved omsetning av 3,4-dimetoksyfenyletylamin og 3,4-metylendioksyfenyleddiksyre.
LC-MS: rt = 4,1 min, 344 (M+l, ES+).
N-[2-(3,4-dimetoksy-fenyl)-etyl]-4-dimetylaminofenyl-acetamid:
fremstilt ved omsetning av 3,4-dimetoksyfenyletylamin og 4-dimetyl-aminofenyleddiksyre.
LC-MS: rt = 3,1 min, 343 (M+l, ES+).
N-[2-(3,4-dimetoksy-fenyl)-etyl]-4-fluorfenyl-acetamid:
fremstilt ved omsetning av 3,4-dimetoksyfenyletylamin og 4-fluorfenyl-eddiksyre. LC-MS: rt = 4,1 min, 318 (M+l, ES+).
N-[2-(3,4-dimetoksy-fenyl)-etyl]-3,4-difluorfenyl-acetamid:
fremstilt ved omsetning av 3,4-dimetoksyfenyletylamin og 3,4-difluorfenyleddiksyre. LC-MS: rt = 4,2 min, 336 (M+l, ES+).
N-[2-(3,4-dimetoksy-fenyl)-etyl]-3,4,5-trimetoksyfenyl-acetamid:
fremstilt ved omsetning av 3,4-dimetoksyfenyletylamin og 3,4,5-trimetoksyfenyleddiksyre.
LC-MS: rt = 3,8 min, 390 (M+l, ES+).
N-[2-(3,4-dimetoksy-fenyl)-etyl]-2,3,4-trimetoksyfenyl-acetamid:
fremstilt ved omsetning av 3,4-dimetoksyfenyletylamin og 2,3,4-trimetoksyfenyleddiksyre.
LC-MS: rt = 4,1 min, 390 (M+l, ES+).
N-[2-(3,4-dimetoksy-fenyl)-etyl]-naftalen-2-yl-acetamid:
fremstilt ved omsetning av 3,4-dimetoksyfenyletylamin og 2-naftyleddiksyre. LC-MS: rt = 4,9 min, 350 (M+l, ES+).
N-[2-(2,5-dimetoksy-fenyl)-etyl]-3,4-metylendioksyfenyl-acetamid:
fremstilt ved omsetning av 2,5-dimetoksyfenyletylamin og 3,4-metylen-dioksyfenyleddiksyre.
LC-MS: rt = 4,3 min, 344 (M+l, ES+).
N-[2-(3,4-dimetoksy-fenyl)-etyI]-4-hydroksy-3-metoksy-fenyl-acetamid:
fremstilt ved omsetning av 3,4-dimetoksyfenyletylamin og 4-hydroksy-3-metoksy-fenyleddiksyre.
LC-MS: rt = 3,6 min, 346 (M+l, ES+), 344 (M-l, ES-).
N-[2-(3,4-dimetoksy-fenyI)-etyl]-3-benzyloksy-4-metoksy-fenyl-acetamid:
fremstilt ved omsetning av 3,4-dimetoksyfenyletylamin og 3-benzyloksy-4-metoksy-fenyleddiksyre.
LC-MS: rt = 4,6 min, 436 (M+l, ES+), 434 (M-l, ES-).
B.1.2. Syntese av 1,2,3,4-tetrahydroisokinoliner gjennom Bischler-Napieralski-reaksjon (generell fremgangsmåte): Til en suspensjon av det respektive acetamid (60 mmol) i acetonitril (100 ml) sattes fosforoksyklorid (16,2 ml, 177 mmol). Blandingen ble oppvarmet til tilbakeløp i 6 timer og løsningsmidlet ble fjernet i vakuum. Den resulterende olje ble tatt opp i MeOH (70 ml), inndampet til tørrhet, oppløst i MeOH (130 ml) og avkjølt til 0°C. NaBH4 ble tilsatt i små (!) porsjoner og reaksjonsblandingen ble rørt i 14 timer. Løsningsmidlet ble fjernet i vakuum, diklormetan (150 ml) og vann (100 ml) ble tilsatt, fasene ble separert, og den vandige fasen ble ekstrahert tre ganger med diklormetan (100 ml). De samlede organiske faser ble inndampet i vakuum, hvilket ga de følgende tetrahydroisokinoliner, som ble renset enten ved flashkromatografi eller ved krystallisering som hydrokloridsalt:
l-(3,4-dimetoksy-benzyl)-6-metoksy-l,2,3,4-tetrahydroisokinolin:
fremstilt ved cyklisering av N-[2-(3-metoksy-fenyl)-etyl]-3,4-dimetoksyfenyl-acetamid.
LC-MS: rt = 3,1 min, 314 (M+l, ES+).
l-benzyl-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin:
fremstilt ved cyklisering av N-[2-(3,4-dimetoksy-fenyl)-etyl]-fenyl-acetamid.
Rf (diklormetan/metanol 5/1) = 0,51.
LC-MS: rt = 3,1 min, 284 (M+l, ES+).
l-(3-metoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin:
fremstilt ved cyklisering av N-[2-(3,4-dimetoksy-fenyl)-etyl]-3-metoksyfenyl-acetamid.
LC-MS: rt = 3,0 min, 314 (M+l, ES+).
l-(4-metoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin:
fremstilt ved cyklisering av N-[2-(3,4-dimetoksy-fenyl)-etyl]-4-metoksyfenyl-acetamid.
LC-MS: rt = 3,0 min, 314 (M+l, ES+). l-(2,5-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin: fremstilt ved cyklisering av N-[2-(3,4-dimetoksy-fenyl)-etyl]-2,5-dimetoksy-fenyl-acetamid.
LC-MS: rt = 3,2 min, 344 (M+l, ES+). l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-l,2,3,4-tetrahydroisokinolin: fremstilt ved cyklisering av N-[2-(2,5-dimetoksy-fenyl)-etyl]-3,4-dimetoksy-fenyl-acetamid.
LC-MS: rt = 3,3 min, 344 (M+l, ES+).
l-(2-fenyl-etyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin:
fremstilt ved cyklisering av N-[2-(3,4-dimetoksy-fenyl)-etyl]-3-fenyl-propionamid. LC-MS: rt = 3,2 min, 298 (M+l, ES+).
l-(l-fenyl-propyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin:
fremstilt ved cyklisering av N-[2-(3,4-dimetoksy-fenyl)-etyl]-2-fenyl-butyramid.
LC-MS: rt = 3,3 min, 312 (M+l, ES+).
l-(difenylmetyI)-5,8-dimetoksy-l,2,3,4-tetrahydroisokinolin:
fremstilt ved cyklisering av N-[2-(2,5-dimetoksy-fenyl)-etyl]-difenyl-acetamid. LC-MS: rt = 3,7 min, 360 (M+l, ES+).
l-(2,5-dimetoksy-benzyl)-5,8-dimetoksy-l,2,3,4-tetrahydroisokinolin:
fremstilt ved cyklisering av N-[2-(2,5-dimetoksy-fenyl)-etyl]-2,5-dimetoksy-fenyl-acetamid.
LC-MS: rt = 3,6 min, 344 (M+l, ES+).
l-(4-klor-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin:
fremstilt ved cyklisering av N-[2-(3,4-dimetoksy-fenyl)-etyl]-4-klor-fenyl-acetamid. LC-MS: rt = 3,2 min, 318 (M+l, ES+).
l-benzyl-5,8-dimetoksy-l,2,3,4-tetrahydroisokinolin:
fremstilt ved cyklisering av N-[2-(2,5-dimetoksy-fenyl)-etyl]-fenyl-acetamid. LC-MS: rt = 3,4 min, 284 (M+l, ES+). l-(3,4-dimetoksy-benzyl)-6-metoksy-7-isopropoksy-l,2,3,4-tetrahydro-isokinolin: fremstilt ved cyklisering av N-[2-(3-metoksy-4-isopropoksy-fenyl)-etyl]-3,4-dimetoksy-fenyl-acetamid.
LC-MS: rt = 3,32 min, 372 (M+l, ES+). l-(3,4-metylendioksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydro-isokinolin: fremstilt ved cyklisering av N-[2-(3,4-dimetoksy-fenyl)-etyl]-3,4-metylendioksy-fenyl-acetamid.
LC-MS: rt = 3,0 min, 328 (M+l, ES+). l-(4-dimetylamino-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydro-isokinolin: fremstilt ved cyklisering av N-[2-(3,4-dimetoksy-fenyl)-etyl]-4-dimetyl-amino-fenyl-acetamid.
LC-MS: rt = 2,6 min, 327 (M+l, ES+).
l-(4-fluor-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin:
fremstilt ved cyklisering av N-[2-(3,4-dimetoksy-fenyl)-etyl]-4-fluor-fenyl-acetamid. LC-MS: rt = 3,1 min, 302 (M+l, ES+).
l-(3,4-difluor-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin:
fremstilt ved cyklisering av N-[2-(3,4-dimetoksy-fenyl)-etyl]-3,4-difluor-fenyl-acetamid.
LC-MS: rt = 3,1 min, 320 (M+l, ES+). l-(3,4,5-trimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydro-isokinolin: fremstilt ved cyklisering av N-[2-(3,4-dimetoksy-fenyl)-etyl]-3,4,5-trimetoksy-fenyl-acetamid.
LC-MS: rt = 3,0 min, 374 (M+l, ES+).
l-(3,4-dimetoksy-benzyl)-6,7,8-trimetoksy-l,2,3,4-tetrahydro-
isokinolin:
fremstilt ved cyklisering av N-[2-(3,4,5-trimetoksy-fenyl)-etyl]-3,4-dimetoksy-fenyl-acetamid.
LC-MS: rt = 3,2 min, 374 (M+l, ES+).
l-(3,4-dimetoksy-benzyl)-5,6,7-trimetoksy-l,2,3,4-tetrahydro-
isokinolin:
fremstilt ved cyklisering av N-[2-(2,3,4-trimetoksy-fenyl)-etyl]-3,4-dimetoksy-fenyl-acetamid.
LC-MS: rt = 3,2 min, 374 (M+l, ES+).
l-(3,4-dimetoksy-benzyl)-6,8-dimetoksy-l,2,3,4-tetrahydro-
isokinolin:
fremstilt ved cyklisering av N-[2-(3,5-dimetoksy-fenyl)-etyl]-3,4-dimetoksy-fenyl-acetamid.
LC-MS: rt = 3,5 min, 344 (M+l, ES+).
l-(2,3,4-trimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydro-
isokinolin:
fremstilt ved cyklisering av N-[2-(3,4-dimetoksy-fenyl)-etyl]-2,3,4-trimetoksy-fenyl-acetamid.
LC-MS: rt = 3,2 min, 374 (M+l, ES+).
l-(naftalen-2-yl-metyl)-6,7-dimetoksy-l,2,3,4-tetrahydro-
isokinolin:
fremstilt ved cyklisering av N-[2-(3,4-dimetoksy-fenyl)-etyl]-naftalen-2-yl acetamid. LC-MS: rt = 3,6 min, 334 (M+l, ES+).
l-(3,4-metylendioksy-benzyl)-5,8-dimetoksy-l,2,3,4-tetrahydro-
isokinolin:
fremstilt ved cyklisering av N-[2-(2,5-dimetoksy-fenyl)-etyl]-3,4-metylendioksy-fenyl-acetamid.
LC-MS: rt = 3,2 min, 328 (M+l, ES+). l-(3,4-dimetoksy-benzyl)-6-benzyloksy-7-metoksy-l,2,3,4-tetrahydroisokinolin: fremstilt ved cyklisering av N-[2-(3-benzyloksy-4-metoksy-fenyl)-etyl]-3,4-dimetoksy-fenyl-acetamid.
LC-MS: rt = 3,7 min, 420 (M+l, ES+). l-(3,4-dimetoksy-benzyl)-7-benzyloksy-6-metoksy-l,2,3,4-tetrahydroisokinolin: fremstilt ved cyklisering av N-[2-(4-benzyloksy-3-metoksy-fenyl)-etyl]-3,4-dimetoksy-fenyl-acetamid.
LC-MS: rt = 3,6 min, 420 (M+l, ES+).
l-(3,4-dimetoksy-benzyl)-5-benzyloksy-8-metoksy-l,2,3,4-tetrahydroisokinolin: fremstilt ved cyklisering av N-[2-(2-benzyloksy-5-metoksy-fenyl)-etyl]-3,4-dimetoksy-fenyl-acetamid.
LC-MS: rt = 4,1 min, 420 (M+l, ES+). l-(3,4-dimetoksy-benzyl)-8-benzyloksy-5-metoksy-l,2,3,4-tetrahydroisokinolin: fremstilt ved cyklisering av N-[2-(5-benzyloksy-2-metoksy-fenyl)-etyl]-3,4-dimetoksy-fenyl-acetamid.
LC-MS: rt = 3,9 min, 420 (M+l, ES+). l-(4-hydroksy-3-metoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin: fremstilt ved cyklisering av N-[2-(3,4-dimetoksy-fenyl)-etyl]-4-hydroksy-3-metoksy-fenyl-acetamid.
LC-MS: rt = 2,8 min, 330 (M+l, ES+). l-(3-benzyIoksy-4-metoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin: fremstilt ved cyklisering av N-[2-(3,4-dimetoksy-fenyl)-etyl]-3-benzyloksy-4-metoksy-fenyl-acetamid.
LC-MS: rt = 3,6 min, 420 (M+l, ES+). l-benzyloksymetyl-6,7-dimetoksy-l,2,3,4-tetrahydro-isokinolin: fremstilt ved cyklisering av N-[2-(3,4-dimetoksy-fenyl)-etyl]-benzyloksy-acetamid.
B.2. Alkylering av 1,2,3,4-tetrahydroisokinoliner med 2-brom-acetamider
(generell fremgansmåte)
Ved -15°C ble en løsning av de respektive amin i THF (250 |il, 0,40 M) satt til en løsning av 2-bromacetylbromid i THF (500 0,20 M). Reaksjonsblandingen ble behandlet med en løsning av diisopropyletylamin i THF (250 uj, 2,0 M), fikk oppvarmes opp til romtemperatur og ble rørt i 30 min. En løsning av det respektive tetrahydroisokinolin i DMSO (500 |il, 0,20 M) ble tilsatt og blandingen ble oppvarmet til 75°C i 18 timer. Etter avkjøling til romtemperatur ble vann (2,0 ml) og etylacetat (2,0 ml) tilsatt, fasene ble separert, og den vandige fasen ble ekstrahert to ganger med etylacetat. De samlede organiske faser ble inndampet i vakuum, hvilket ga de følgende tetrahydroisokinolinderivater: Eksempel 17
2-(l-benzyl-3,4-dihydro-lH-isokinolin-2-yl)-iV-(2-metyl-benzyl)-acetamid: fremstilt ved omsetning av l-benzyl-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-metylbenzylamin
LC-MS: rt = 4,6 min, 385 (M+l, ES+).
Eksempel 18
2-(l-benzyl-3,4-dihydro-lff-isokinolin-2-yl)-<y>V-(2-klor-benzyl)-acetamid: fremstilt ved omsetning av l-benzyl-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-klorbenzylamin
LC-MS: rt = 4,7 min, 405 (M+l, ES+).
Eksempel 19
2-(l-benzyl-3,4-dihydro-l^-isokinolin-2-yl)-iV-(l-naftalen-l-yl-etyl)-acetamid: fremstilt ved omsetning av l-benzyl-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 1-naftaleneetylamin
LC-MS: rt = 4,7 og 4,8 min, 435 (M+l, ES+).
Eksempel 20
2-(l-benzyl-3,4-dihydro-l£f-isokinolin-2-yl)-iV-benzyl-iV-metyl-acetamid: fremstilt ved omsetning av 1-benzyl-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med N-benzylmetylamin
LC-MS: rt = 3,9 min, 385 (M+l, ES+).
Eksempel 21
2-[l-(3,4-dimetoksy-benzyl)-6-metoksy-3,4-dihydro-lH-isokinolin-2-yl]-A^-(2-metoksy-benzyl)-acetamid:
fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6-metoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-metoksybenzylamin LC-MS: rt = 4,0 min, 491 (M+l, ES+). Eksempel 22 2-[l-(3,4-dimetoksy-benzyl)-6-metoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-benzyl-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6-metoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin LC-MS: rt = 3,9 min, 461 (M+l, ES+). Eksempel 23 2-[l-(3,4-dimetoksy-benzyl)-6-metoksy-3,4-dihydro-l£T-isokinolin-2-yl]-iV-(4-metoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6-metoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 4-metoksybenzylamin LC-MS: rt = 3,9 min, 491 (M+l, ES+). Eksempel 24 2-[l-(3,4-dimetoksy-benzyl)-6-metoksy-3,4-dihydro-m-isokinolin-2-yl]-A^-(naftalen-l-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6-metoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 1-naftalenmetylamin LC-MS: rt = 4,3 min, 511 (M+l, ES+). Eksempel 25 2-[l-(3,4-dimetoksy-benzyl)-6-metoksy-3,4-dihydro-lH-isokinolin-2-yl]-A^-(3-metyl-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6-metoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 3-metylbenzylamin LC-MS: rt = 4,1 min, 475 (M+l, ES+).
Eksempel 28
2-[l-(3,4-dimetoksy-benzyl)-6-metoksy-3,4-dihydro-m-isokinolin-2-yl]-Ar<->
(pyridin-3-yl-metyl)-acetamid:
fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6-metoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 3-pikonylamin LC-MS: rt = 3,1 min, 462 (M+l, ES+). Eksempel 29 2-[l-(3,4-dimetoksy-benzyl)-6-metoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(pyridin-4-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6-metoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 4-pikonylamin LC-MS: rt = 3,1 min, 462 (M+l, ES+). Eksempel 30 2-[l-(3,4-dimetoksy-benzyl)-6-metoksy-3,4-dihydro-l^-isokinolin-2-yl]-Ar-(2-fluor-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6-metoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-fluorbenzylamin LC-MS: rt = 4,0 min, 479 (M+l, ES+).
Eksempel 31
2-(l-benzyl-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl)-<y>V-benzyl-acetamid: fremstilt ved omsetning av l-benzyl-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin
LC-MS: rt = 3,9 min, 431 (M+l, ES+).
Eksempel 34
2-(l-benzyl-6,7-dimetoksy-3,4-dihydro-l£f-isokinolin-2-yl)-iV-(pyridin-3-yl-metyl)-acetamid: fremstilt ved omsetning av l-benzyl-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 3-pikonylamin
LC-MS: rt = 3,0 min, 432 (M+l, ES+).
Eksempel 35
2-(l-benzyl-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl)-N-(2-metyl-benzyl)-acetamid: fremstilt ved omsetning av l-benzyl-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-metylbenzylamin
LC-MS: rt = 4,1 min, 445 (M+l, ES+).
Eksempel 36
2-(l-benzyl-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl)-/V-(2,5-difluor-benzyl)-acetamid: fremstilt ved omsetning av l-benzyl-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2,5-difluorbenzylamin
LC-MS: rt = 4,1 min, 467 (M+l, ES+).
Eksempel 37
2-(l-benzyl-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl)-iV-(4-fluor-benzyl)-acetamid: fremstilt ved omsetning av l-benzyl-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 4-fluorbenzylamin
LC-MS: rt = 4,0 min, 449 (M+l, ES+).
Eksempel 38
2-(l-benzyl-6,7-dimetoksy-3,4-dihydro-lff-isokinolin-2-yl)-iV-(2-klor-benzyl)-acetamid: fremstilt ved omsetning av l-benzyl-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-klorbenzylamin
LC-MS: rt = 4,2 min, 465 (M+l, ES+).
Eksempel 39
2-(l-benzyl-6,7-dimetoksy-3,4-dihydro-l£f-isokinolin-2-yl)-A^-(l-naftalen-l-yl-etyl)-acetamid: fremstilt ved omsetning av l-benzyl-6,7-dimetoksy-l,2,3,4-tetrahydro-isokinolin og 2-bromacetylbromid med 1-naftaleneetylamin
LC-MS: rt = 4,3 og 4,4 min, 495 (M+l, ES+).
Eksempel 40
2-(l-benzyl-6,7-dimetoksy-3,4-dihydro-lff-isokinolin-2-yl)-iV-benzyl-iV-metyl-acetamid: fremstilt ved omsetning av l-benzyl-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med N-benzylmetylamin
LC-MS: rt = 3,8 min, 445 (M+l, ES+).
Eksempel 41
2-[l-(3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-A^-(2-metoksy-benzyl)-acetamid:
fremstilt ved omsetning av l-(3-metoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-metoksybenzylamin LC-MS: rt = 4,0 min, 491 (M+l, ES+). Eksempel 42 2-[l-(3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-A^-benzyl-acetamid: fremstilt ved omsetning av l-(3-metoksy-benzyl)-6,7-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin
LC-MS: rt = 3,9 min, 461 (M+l, ES+).
Eksempel 43
2-[l-(3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-iV-(naftalen-l-yl-metyl)-acetamid:
fremstilt ved omsetning av l-(3-metoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med naftalen-1-yl-metylamin LC-MS: rt = 4,3 min, 511 (M+l, ES+). Eksempel 44 2-[l-(3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(3-metyl-benzyO-acetamid: fremstilt ved omsetning av l-(3-metoksy-benzyl)-6,7-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 3-metyl-benzylamin LC-MS: rt = 4,1 min, 475 (M+l, ES+). Eksempel 47 2-[l-(3-metoksy-benzyI)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(pyridin-3-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3-metoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 3-aminometyl-pyridin LC-MS: rt = 3,1 min, 462 (M+l, ES+). Eksempel 48 2-[l-(3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]W-(2-fluor-benzyl)-acetamid: fremstilt ved omsetning av l-(3-metoksy-benzyl)-6,7-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-fluor-benzylamin
LC-MS: rt = 4,0 min, 479 (M+l, ES+).
Eksempel 49
2-[l-(4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-llf<r->isokinolin-2-yl]-A^-benzyl-acetamid: fremstilt ved omsetning av l-(4-metoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin
LC-MS: rt = 3,9 min, 461 (M+l, ES+).
Eksempel 50
2-[l-(4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-17/-isokinolin-2-yl]-A?<->
(naftalen-1 -yl-metyl)-acetamid:
fremstilt ved omsetning av l-(4-metoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med naftalen-1-yl-metylamin LC-MS: rt = 4,2 min, 511 (M+l, ES+). Eksempel 53 2-[l-(4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-Ar<->(2-fluor-benzyl)-acetamid: fremstilt ved omsetning av l-(4-metoksy-benzyl)-6,7-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-fluor-benzylamin
LC-MS: rt = 3,9 min, 479 (M+l, ES+).
Eksempel 54
2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-A^-(2-metoksy-benzyl)-acetamid:
fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-metoksybenzylamin LC-MS: rt = 3,7 min, 521 (M+l, ES+). Eksempel 55 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(4-metoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 4-metoksybenzylamin LC-MS: rt = 3,7 min, 521 (M+l, ES+). Eksempel 56 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(3-metyl-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 3-metylbenzylamin LC-MS: rt = 3,8 min, 505 (M+l, ES+). Eksempel 58 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-N-(4-metyl-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 4-metylbenzylamin LC-MS: rt = 3,8 min, 505 (M+l, ES+). Eksempel 60 241-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lff-isokinolin-2-yl]-A^-(pyridin-3-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 3-pikonylamin LC-MS: rt = 2,9 min, 492 (M+l, ES+). Eksempel 61 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lff-isokinolin-2-yl]-iV-(pyridin-4-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 4-pikonylamin LC-MS: rt = 2,9 min, 492 (M+l, ES+). Eksempel 62 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-fenyl-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med anilin
LC-MS: rt = 3,7 min, 477 (M+l, ES+).
Eksempel 63
2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-A^-(2-fluor-benzyl)-acetamid:
fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-fluorbenzylamin LC-MS: rt = 3,7 min, 509 (M+l, ES+). Eksempel 64 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-A^-[2-(4-metoksy-fenyl)-etyl] -acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 4-metoksyfenyletyl-amin LC-MS: rt = 3,8 min, 535 (M+l, ES+). Eksempel 65 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-^-(2-metyl-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-metylbenzylamin LC-MS: rt = 3,9 min, 505 (M+l, ES+). Eksempel 66 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-N-(2-trifluormetyl-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-trifluorbenzylamin LC-MS: rt = 4,0 min, 559 (M+l, ES+). Eksempel 67 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-7V-(2,5-difluor-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2,5-difluorbenzylamin LC-MS: rt = 3,8 min, 527 (M+l, ES+). Eksempel 68 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(4-fluor-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 4-fluorbenzylamin LC-MS: rt = 3,8 min, 509 (M+l, ES+). Eksempel 69 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinoIin-2-yl]-iV-(2-klor-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-klorbenzylamin LC-MS: rt = 3,9 min, 525 (M+l, ES+). Eksempel 70 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lff-isokinolin-2-yl]-A^-(2,4-dimetoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2,4-dimetoksybenzylamin LC-MS: rt = 3,8 min, 551 (M+l, ES+). Eksempel 71 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-iV-(l-fenyl-etyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 1-fenyletylamin LC-MS: rt = 3,7 min, 505 (M+l, ES+). Eksempel 72 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-A^-(l-naftalen-l-yl-etyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 1-naftaleneetylamin LC-MS: rt = 4,0 min, 555 (M+l, ES+). Eksempel 73 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-A^-benzyl-<y>V-metyl-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med N-benzylmetylamin LC-MS: rt = 3,6 min, 505 (M+l, ES+). Eksempel 74 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-17/-isokinolin-2-yl]-jV-furan-2-yl-metyl-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 1-aminometylfuran LC-MS: rt = 3,5 min, 481 (M+l, ES+). Eksempel 75 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-AT-but-2-yl-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-butylamin LC-MS: rt = 0,57 min, 457 (M+l, ES+). Eksempel 76 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-m-isokinoIin-2-yl]-N-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-pikolylamin LC-MS: rt = 0,46 min, 492 (M+l, ES+). Eksempel 89 2-[(lS)-l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-benzyl-acetamid: fremstilt ved omsetning av (lS)-l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin LC-MS: rt = 3,7 min, 491 (M+l, ES+). Eksempel 90 2-[(lS)-l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(naftalen-l-yl-metyl)-acetamid: fremstilt ved omsetning av (lS)-l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med naftalen-1-yl-metylamin LC-MS: rt = 4,0 min, 541 (M+l, ES+). Eksempel 91 2-[(lS)-l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(2-metoksy-benzyl)-acetamid: fremstilt ved omsetning av (lS)-l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-metoksy-benzylamin LC-MS: rt = 3,7 min, 521 (M+l, ES+). Eksempel 92 2-[(lS)-l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(2-etoksy-benzyl)-acetamid: fremstilt ved omsetning av (lS)-l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-etoksy-benzylamin LC-MS: rt = 4,0 min, 535 (M+l, ES+). Eksempel 93 2-[(lS)-l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-benzyl-iV-metyl-acetamid: fremstilt ved omsetning av (lS)-l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med iV-benzyl-iV-metylamin LC-MS: rt = 3,7 min, 505 (M+l, ES+). Eksempel 96 2-[(lS)-l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av (lS)-l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-pikolylamin LC-MS: rt = 3,1 min, 492 (M+l, ES+). Eksempel 97 2-[(lS)-l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-A^-(2-fenyl-etyl)-acetamid: fremstilt ved omsetning av (lS)-l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-fenyl-etylamin LC-MS: rt = 3,8 min, 505 (M+l, ES+). Eksempel 99 2-[l-(2,5-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l»-isokinolin-2-yl]-A^-(4-metoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(2,5-dimetoksy-benzyl)-6,7-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 4-metoksybenzylamin LC-MS: rt = 3,9 min, 521 (M+l, ES+). Eksempel 100 2-[l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(2-metoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-metoksybenzylamin LC-MS: rt = 4,3 min, 521 (M+l, ES+). Eksempel 101 2-[l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-7V-benzyl-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin LC-MS: rt = 4,3 min, 491 (M+l, ES+). Eksempel 102 2-[l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-iV-[2-(3,4-dimetoksy-fenyl)-etyl] -acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 3,4-dimetoksyfenyl-etylamin LC-MS: rt = 4,3 min, 565 (M+l, ES+). Eksempel 104 2-[l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-3,4-dihydro-l£f-isokinolin-2-yl]-iV-(pyridin-3-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 3-pikolylamin LC-MS: rt = 3,4 min, 492 (M+l, ES+). Eksempel 105 2-[l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-butyl-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med n-butylamin LC-MS: rt = 4,2 min, 457 (M+l, ES+). Eksempel 106 2-[l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-^-(2-fluor-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-fluorbenzylamin LC-MS: rt = 4,4 min, 509 (M+l, ES+). Eksempel 107 2-[l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-iV-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-pikolylamin LC-MS: rt = 3,7 min, 492 (M+l, ES+). Eksempel 108 2-[l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-^V-[l,3,4]tiadiazol-2-yl-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-amino-l,3,4-tiadiazol LC-MS: rt = 3,8 min, 485 (M+l, ES+). Eksempel 109 2-[l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-Ar-(l/7-benzoimidazol-2yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-(aminometyl)-benzimidazol LC-MS: rt = 3,4 min, 531 (M+l, ES+). Eksempel 110 2-[l-(2-fenyl-etyl)-6,7-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-A^-(pyridin-3-yl-metyl)-acetamid: fremstilt ved omsetning av l-(2-fenyl-etyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 3-pikolylamin
LC-MS: rt = 2,7 min, 446 (M+l, ES+).
Eksempel 111
2-[l-(2-fenyl-etyl)-6,7-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-AT-(2-fluor-benzyl)-acetamid: fremstilt ved omsetning av l-(2-fenyl-etyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-fluorbenzylamin
LC-MS: rt = 4,0 min, 463 (M+l, ES+).
Eksempel 112
2-[l-(2-fenyl-etyl)-6,7-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-^-cykloheksyl-acetamid: fremstilt ved omsetning av l-(2-fenyl-etyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med cykloheksylamin
LC-MS: rt = 4,0 min, 437 (M+l, ES+).
Eksempel 113
2-[l-(l-fenyl-propyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-A^-benzyl-acetamid:
fremstilt ved omsetning av l-(l-fenyl-propyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin LC-MS: rt = 4,4 min, 459 (M+l, ES+). Eksempel 114 2-[l-(l-fenyl-propyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av l-(l-fenyl-propyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-pikolylamin LC-MS: rt = 3,7 min, 460 (M+l, ES+). Eksempel 118 2-[l-(2,5-dimetoksy-benzyl)-5,8-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-benzyl-acetamid: fremstilt ved omsetning av l-(2,5-dimetoksy-benzyl)-5,8-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin LC-MS: rt = 4,4 min, 491 (M+l, ES+). Eksempel 119 2-[l-(2,5-dimetoksy-benzyl)-5,8-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-iV-(2-metoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(2,5-dimetoksy-benzyl)-5,8-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-metoksy-benzyl-amin
LC-MS: rt = 4,5 min, 521 (M+l, ES+).
Eksempel 120
2-[l-(2,5-dimetoksy-benzyl)-5,8-dimetoksy-3,4-dihydro-l//-isokinolin-2-yI]-A^-(2-etoksy-benzyl)-acetamid:
fremstilt ved omsetning av l-(2,5-dimetoksy-benzyl)-5,8-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-etoksy-benzyl-amin LC-MS: rt = 4,6 min, 535 (M+l, ES+). Eksempel 123 2-[l-(2,5-dimetoksy-benzyl)-5,8-dimetoksy-3,4-dihydro-lff-isokinolin-2-yl]-A^-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av l-(2,5-dimetoksy-benzyl)-5,8-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-pikolylamin LC-MS: rt = 3,8 min, 492 (M+l, ES+). Eksempel 126 2-[l-(4-klor-benzyl)-6,7-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-Ar<->benzyl-acetamid: fremstilt ved omsetning av l-(4-klor-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin
LC-MS: rt = 4,4 min, 465 (M+l, ES+).
Eksempel 127
2-[l-(4-klor-benzyl)-6,7-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-A^-(2-etoksy-benzyl)-acetamid:
fremstilt ved omsetning av l-(4-klor-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-etoksy-benzylamin LC-MS: rt = 4,7 min, 509 (M+l, ES+). Eksempel 129 2-[l-(4-klor-benzyl)-6,7-dimetoksy-3,4-dihydro-l£f-isokinolin-2-yl]-iV-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av l-(4-klor-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-pikolylamin
LC-MS: rt = 3,6 min, 466 (M+l, ES+).
Eksempel 134
2-[l-(3,4-dimetoksy-benzyl)-6-metoksy-7-isopropoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-benzyl-acetamid:
fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6-metoksy-7-isopropoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin LC-MS: rt = 3,9 min, 519 (M+l, ES+). Eksempel 135 2-[l-(3,4-dimetoksy-benzyl)-6-metoksy-7-isopropoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(naftalen-l-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6-metoksy-7-isopropoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med naftalen-1-yl-metylamin LC-MS: rt = 4,3 min, 569 (M+l, ES+). Eksempel 136 2-[l-(3,4-dimetoksy-benzyl)-6-metoksy-7-isopropoksy-3,4-dihydro-lH-isokinoIin-2-yl]-iV-(2-metoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dirnetoksy-benzyl)-6-metoksy-7-isopropoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-metoksy-benzylamin LC-MS: rt = 4,0 min, 549 (M+l, ES+). Eksempel 137 2-[l-(3,4-dimetoksy-benzyl)-6-metoksy-7-isopropoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(2-etoksy-benzyI)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6-metoksy-7-isopropoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-etoksy-benzylamin LC-MS: rt = 4,2 min, 563 (M+l, ES+). Eksempel 139 2-[l-(3,4-dimetoksy-benzyl)-6-metoksy-7-isopropoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-benzyl-iV-metyl-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6-metoksy-7-isopropoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med N-benzyl-A^-metyl-amin LC-MS: rt = 3,9 min, 533 (M+l, ES+). Eksempel 141 2-[l-(3,4-dimetoksy-benzyl)-6-metoksy-7-isopropoksy-3,4-dihydro-li<y->isokinolin-2-yl]-ZV-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6-metoksy-7-isopropoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-pikolylamin LC-MS: rt = 3,4 min, 520 (M+l, ES+). Eksempel 143 2-[l-(3,4-dimetoksy-benzyl)-6-metoksy-7-isopropoksy-3,4-dihydro-l^-isokinolin-2-yl]-iV-(2-fenyl-etyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6-metoksy-7-isopropoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-fenyl-etylamin LC-MS: rt = 4,0 min, 533 (M+l, ES+). Eksempel 160 2-[l-(3,4-metylendioksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-iV-benzyl-acetamid: fremstilt ved omsetning av l-(3,4-metylendioksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin LC-MS: rt = 4,0 min, 475 (M+l, ES+). Eksempel 161 2-[l-(3,4-metylendioksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(2-etoksy-benzy l)-acetamid: fremstilt ved omsetning av l-(3,4-metylendioksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-etoksy-benzylamin LC-MS: rt = 4,2 min, 519 (M+l, ES+). Eksempel 166 2-[l-(4-dimetylamino-benzyl)-6,7-dimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-N-benzyl-acetamid: fremstilt ved omsetning av l-(4-dimetylamino-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin LC-MS: rt = 3,5 min, 474 (M+l, ES+). Eksempel 167 2-[l-(4-dimetylamino-benzyl)-6,7-dimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-iV-(naftalen-1 -yl-metyl)-acetamid: fremstilt ved omsetning av l-(4-dimetylamino-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med naftalen-1-yl-metylamin LC-MS: rt = 4,0 min, 524 (M+l, ES+). Eksempel 168 2-[l-(4-dimetylamino-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(2-metoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(4-dimetylamino-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-metoksy-benzylamin LC-MS: rt = 3,6 min, 504 (M+l, ES+). Eksempel 169 2-[l-(4-dimetylamino-benzyl)-6,7-dimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-N-(2-etoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(4-dimetylamino-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-etoksy-benzylamin LC-MS: rt = 3,8 min, 518 (M+l, ES+). Eksempel 171 2-[l-(4-dimetylamino-benzyl)-6,7-dimetoksy-3,4-dihydro-l£T-isokinolin-2-yl]-A^-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av l-(4-dimetylamino-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-pikolylamin LC-MS: rt = 2,9 min, 475 (M+l, ES+). Eksempel 174 2-[l-(4-fluor-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-A^-(2-etoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(4-fluor-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-etoksy-benzylamin LC-MS: rt = 4,3 min, 493 (M+l, ES+). Eksempel 175 2-[l-(4-fluor-benzyl)-6,7-dimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-A^-benzyl-A^-metyl-acetamid: fremstilt ved omsetning av l-(4-fluor-benzyl)-6,7-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med A^-benzyl-A^-metylamin LC-MS: rt = 3,8 min, 463 (M+l, ES+). Eksempel 176 2-[l-(3,4-difluor-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-<y>V-benzyl-iV-metyl-acetamid: fremstilt ved omsetning av l-(3,4-difluor-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med AT-benzyl-iV-metylamin
LC-MS: rt = 3,9 min, 481 (M+l, ES+).
Eksempel 180
2-[l-(3,4-dimetoksy-benzyl)-6,7,8-trimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-A^-benzyl-acetamid:
fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7,8-trimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin LC-MS: rt = 4,4 min, 521 (M+l, ES+). Eksempel 181 2-[l-(3,4-dimetoksy-benzyl)-6,7,8-trimetoksy-3,4-dihydro-l£f-isokinolin-2-yl]-A^-(naftalen-l-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7,8-trimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med naftalen-1-yl-metylamin LC-MS: rt = 4,8 min, 571 (M+l, ES+). Eksempel 182 2-[l-(3,4-dimetoksy-benzyl)-6,7,8-trimetoksy-3,4-dihydro-ljff-isokinolin-2-yl]-A^-(2-metoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7,8-trimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-metoksy-benzyl-amin LC-MS: rt = 4,4 min, 551 (M+l, ES+). Eksempel 183 2-[l-(3,4-dimetoksy-benzyl)-6,7,8-trimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-iV-(2-etoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7,8-trimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-etoksy-benzyl-amin LC-MS: rt = 4,6 min, 565 (M+l, ES+). Eksempel 184 2-[l-(3,4-dimetoksy-benzyl)-6J,84rimetoksy-3,4-dihydro-m-isokinolin-2-yl]-N-benzyl-iV-metyl-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7,8-trimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med iV-benzyl-iV-metylamin LC-MS: rt = 4,0 min, 535 (M+l, ES+). Eksempel 187 2-[l-(3,4-dimetoksy-benzyl)-6,7,8-trimetoksy-3,4-dihydro-lf/-isokinolin-2-yl]-N-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7,8-trimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-pikolylamin LC-MS: rt = 3,7 min, 522 (M+l, ES+). Eksempel 188 2-[l-(3,4-dimetoksy-benzyl)-6,7,8-trimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(2-fenyl-etyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,7,8-trimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-fenyl-etylamin LC-MS: rt = 4,5 min, 535 (M+l, ES+). Eksempel 192 2-[l-(3,4-dimetoksy-benzyl)-5,6,7-t^imetoksy-3,4-dihyd^o-lH-isokinolin-2-yl]-A',-benzyl-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-5,6,7-trimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin LC-MS: rt = 4,1 min, 521 (M+l, ES+). Eksempel 193 2-[l-(3,4-dimetoksy-benzyl)-5,6,7-trimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-A^-(naftalen-l-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-5,6,7-trimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med naftalen- 1-yl-metylamin LC-MS: rt = 4,5 min, 571 (M+l, ES+). Eksempel 194 2-[l-(3,4-dimetoksy-benzyl)-5,6,7-trimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-iV-(2-metoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-5,6,7-trimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-metoksy-benzyl-amin LC-MS: rt = 4,2 min, 551 (M+l, ES+). Eksempel 195 2-[l-(3,4-dimetoksy-benzyl)-5,6,7-trimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-A^-(2-etoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-5,6,7-trimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-etoksy-benzyl-amin LC-MS: rt = 4,3 min, 565 (M+l, ES+). Eksempel 196 2-[l-(3,4-dimetoksy-benzyl)-5,6,7-trimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-benzyl-iV-metyl-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-5,6,7-tximetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med Af-benzyl-iV-metyl-amin LC-MS: rt = 3,9 min, 535 (M+l, ES+). Eksempel 199 2-[l-(3,4-dimetoksy-benzyl)-5,6,7-trimetoksy-3,4-dihydro-lÆT-isokinolin-2-yl]-iV-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-5,6,7-trimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-pikolylamin LC-MS: rt = 3,4 min, 522 (M+l, ES+). Eksempel 200 2-[l-(3,4-dimetoksy-benzyl)-5,6,7-trimetoksy-3,4-dihydro-m-isokinolin-2-yl]-iV-(2-fenyl-etyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-5,6,7-trimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-fenyl-etylamin LC-MS: rt = 4,2 min, 535 (M+l, ES+). Eksempel 206 2-[l-(3,4-dimetoksy-benzyl)-6,8-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-benzyl-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,8-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin LC-MS: rt = 4,2 min, 491 (M+l, ES+). Eksempel 207 2-[l-(3,4-dimetoksy-benzyl)-6,8-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(naftalen-l-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,8-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med naftalen-1-yl-metylamin LC-MS: rt = 4,5 min, 541 (M+l, ES+). Eksempel 208 2-[l-(3,4-dimetoksy-benzyl)-6,8-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-jV-(2-metoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,8-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-metoksy-benzyl-amin LC-MS: rt = 4,2 min, 521 (M+l, ES+). Eksempel 209 2-[l-(3,4-dimetoksy-benzyl)-6,8-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-(2-etoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,8-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-etoksy-benzyl-amin LC-MS: rt = 4,4 min, 535 (M+l, ES+). Eksempel 210 2-[l-(3,4-dimetoksy-benzyl)-6,8-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-A^-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6,8-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-pikolylamin LC-MS: rt = 4,2 min, 492 (M+l, ES+). Eksempel 215 2-[l-(2,3,4-trimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-A^-benzyl-acetamid: fremstilt ved omsetning av l-(2,3,4-trimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin LC-MS: rt = 3,9 min, 521 (M+l, ES+). Eksempel 216 2-[l-(2,3,4-trimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(naftalen-1 -yl-metyl)-acetamid: fremstilt ved omsetning av l-(2,3,4-trimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med naftalen-1-yl-metylamin LC-MS: rt = 4,3 min, 571 (M+l, ES+). Eksempel 217 2-[l-(2,3,4-trimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lfl<r->isokinolin-2-yl]-A^-(2-metoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(2,3,4-trimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-metoksy-benzyl-amin LC-MS: rt = 4,0 min, 551 (M+l, ES+). Eksempel 218 2-[l-(2,3,4-trimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-N-(2-etoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(2,3,4-trimetoksy-benzyl)-6,7-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-etoksy-benzyl-amin LC-MS: rt = 4,1 min, 565 (M+l, ES+). Eksempel 220 2-[l-(2,3,4-trimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-(2-fenyl-etyl)-acetamid: fremstilt ved omsetning av l-(2,3,4-trimetoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-fenyl-etylamin LC-MS: rt = 4,0 min, 535 (M+l, ES+). Eksempel 224 2-[l-(Naftalen-2-yl-metyl)-6,7-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-iV-benzyl-acetamid: fremstilt ved omsetning av l-(Naftalen-2-yl-metyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin LC-MS: rt = 4,5 min, 481 (M+l, ES+). Eksempel 225 2-[l-(Naftalen-2-yl-metyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-iV-(naftalen-1 -yl-metyl)-acetamid: fremstilt ved omsetning av l-(Naftalen-2-yl-metyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med naftalen-1-yl-metylamin LC-MS: rt = 4,8 min, 531 (M+l, ES+). Eksempel 226 2-[l-(Naftalen-2-yl-metyl)-6,7-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-iV-(2-metoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(Naftalen-2-yl-metyl)-6,7-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-metoksy-benzyl-amin LC-MS: rt = 4,5 min, 511 (M+l, ES+). Eksempel 227 2-[l-(Naftalen-2-yl-metyl)-6,7-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-iV-(2-etoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(Naftalen-2-yl-metyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-etoksy-benzyl-amin LC-MS: rt = 4,7 min, 525 (M+l, ES+). Eksempel 228 2-[l-(Naftalen-2-yI-metyl)-6,7-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-^-benzyl-iV-metyl-acetamid: fremstilt ved omsetning av l-(Naftalen-2-yl-metyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med iV-benzyl-iV-metyl-amin LC-MS: rt = 4,2 min, 495 (M+l, ES+). Eksempel 230 2-[l-(Naftalen-2-yl-metyl)-6,7-dimetoksy-3,4-dihydro-m-isokinolin-2-yl]-^V-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av l-(Naftalen-2-yl-metyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-pikolylamin LC-MS: rt = 4,4 min, 482 (M+l, ES+). Eksempel 236 2-[l-(3-brom-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-benzyl-acetamid: fremstilt ved omsetning av l-(3-brom-4-metoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin LC-MS: rt = 4,3 min, 539 (M+l, ES+). Eksempel 237 2-[l-(3-brom-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-iV-(naftalen-l-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3-brom-4-metoksy-benzyl)-6,7-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med naftalen-1-yl-metylamin LC-MS: rt = 4,7 min, 589 (M+l, ES+). Eksempel 238 2-[l-(3-brom-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l£f-isokinolin-2-yl]-iV-(2-etoksy-benzyl)-acetamid: fremstilt ved omsetning av l-(3-brom-4-metoksy-benzyl)-6,7-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-etoksy-benzylamin LC-MS: rt = 4,6 min, 583 (M+l, ES+). Eksempel 239 2-[l-(3-brom-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3-brom-4-metoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-pikolylamin LC-MS: rt = 3,6 min, 541 (M+l, ES+). Eksempel 241 2-[l-(3,4-metylendioksy-benzyl)-5,8-dimetoksy-3,4-dihydro-llf<r->isokinolin-2-yl]-iV-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-metylendioksy-benzyl)-5,8-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-pikolylamin LC-MS: rt = 3,8 min, 476 (M+l, ES+). Eksempel 242 2-[l-(3,4-metylendioksy-benzyl)-5,8-dimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-iV-(2-metoksy-benzyl)-acetamid: fremstilt ved omsetning av 1-(3,4-metylendioksy-benzyl)-5,8-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-metoksy-benzylamin
LC-MS: rt = 4,6 min, 505 (M+l, ES+).
Eksempel 243
2-[l-(3,4-metylendioksy-benzyl)-5,8-dimetoksy-3,4-dihydro-lff-isokinolin-2-yl]-iV-[l,3,4]tiadiazol-2-yl-acetamid:
fremstilt ved omsetning av l-(3,4-metylendioksy-benzyl)-5,8-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-amino-l,3,4-tiadiazol LC-MS: rt = 4,4 min, 469 (M+l, ES+). Eksempel 244 2-[l-(3,4-metylendioksy-benzyl)-5,8-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-N-(lJJ-benzoimidazol-2-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-metylendioksy-benzyl)-5,8-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-(aminometyl)-benzimidazol LC-MS: rt = 3,8 min, 515 (M+l, ES+). Eksempel 245 2-[l-(3,4-metylendioksy-benzyl)-5,8-dimetoksy-3,4-dihydro-l^-isokinoIin-2-yI]-iV-(iZ<y->indazol-6-yl)-acetamid: fremstilt ved omsetning av l-(3,4-metylendioksy-benzyl)-5,8-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 6-aminoindazol LC-MS: rt = 4,4 min, 501 (M+l, ES+).
Analogt med ovennevnte fremgangsmåte, men i større skala, ble de følgende tetrahydroisokinolinderivater syntetisert:
Eksempel 246 2-[l-(3,4-dimetoksy-benzyl)-6-benzyloksy-7-metoksy-3,4-dihydro-l£f-isokinolin-2-yl]-iV-benzyI-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-6-benzyloksy-7-metoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin LC-MS: rt = 4,5 min, 567 (M+l, ES+). Eksempel 247 2-[l-(3,4-dimetoksy-benzyl)-7-benzyloksy-6-metoksy-3,4-dihydro-l^-isokinolin-2-yl] -iV-benzyl-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-7-benzyloksy-6-metoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin LC-MS: rt = 4,4 min, 567 (M+l, ES+). Eksempel 248 2-[l-(3,4-dimetoksy-benzyl)-5-benzyloksy-8-metoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-5-benzyloksy-8-metoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-pikolylamin LC-MS: rt = 4,4 min, 568 (M+l, ES+). 2-[l-(3,4-dimetoksy-benzyl)-8-benzyloksy-5-metoksy-3,4-dihydro-lH-isokinolin-2-yl]-A^-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av l-(3,4-dimetoksy-benzyl)-8-benzyloksy-5-metoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med 2-pikolylamin
LC-MS: rt = 4,4 min, 568 (M+l, ES+).
Eksempel 249
2-[l-(4-hydroksy-3-metoksy-benzyI)-6,7-dimetoksy-3,4-dihydro-lJ7-isokinolin-2-yl]-iV-benzyl-acetamid:
fremstilt ved omsetning av l-(4-hydroksy-3-metoksy-benzyl)-6,7-dimetoksy-l,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin LC-MS: rt = 3,4 min, 477 (M+l, ES+). 2-[l-(3-benzyloksy-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-AM>enzyl-acetamid: fremstilt ved omsetning av l-(3-benzyloksy-4-metoksy-benzyl)-6,7-dimetoksy-1,2,3,4-tetrahydroisokinolin og 2-bromacetylbromid med benzylamin LC-MS: rt = 4,4 min, 567 (M+l, ES+).
C Kobling av fenoler med alkylbromider, heteroarylklorider, heteroaryl-metylsulfoner og karbamoylklorider
Cl Utgangsmaterialer: Avbeskyttelse av benzyliske etere:
Til en blanding av MeOH (60 ml) og maursyre (11,0 ml) sattes palladium (10% Pd/C, våt, 274 mg). Den respektive benzyleter (4,0 mmol) ble tilsatt porsjonsvis og blandingen ble rørt i 40 timer. I løpet av dette tidsrom ble ytterligere porsjoner av Pd/C ble tilsatt inntil utgangsmaterialet var oppbrukt. Blandingen ble filtrert, løsningsmidlet ble fjernet i vakuum og residuet ble renset ved flashkromatografi, hvilket ga de følgende fenoler: Eksempel 250 2-[l-(3,4-dimetoksy-benzyl)-6-hydroksy-7-metoksy-3,4-dihydro-lH-isokinolin-2-yl] -N-benzyl-acetamid: fremstilt ved avbeskyttelse av 2-[l-(3,4-dimetoksy-benzyl)-6-benzyloksy-7-metoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-benzyl-acetamid
LC-MS: rt = 3,5 min, 477 (M+l, ES+).
Eksempel 251
2-[l-(3,4-dimetoksy-benzyl)-7-hydroksy-6-metoksy-3,4-dihydro-lff-isokinolin-2-yl]-iV-benzyl-acetamid: fremstilt ved avbeskyttelse av 2-[l-(3,4-dimetoksy-benzyl)-7-benzyloksy-6-metoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-benzyl-acetamid
LC-MS: rt = 3,5 min, 477 (M+l, ES+).
Eksempel 252
2-[l-(3,4-dimetoksy-benzyl)-5-hydroksy-8-metoksy-3,4-dihydro-l^-isokinolin-2-yl]-iV-(pyridin-2-yl-metyl)-acetamid:
fremstilt ved avbeskyttelse av 2-[l-(3,4-dimetoksy-benzyl)-5-benzyloksy-8-metoksy-3,4-dihydro-l/f-isokinolin-2-yl]-A^-(pyridin-2-yl-metyl)-acetamid LC-MS: rt = 3,2 min, 478 (M+l, ES+), 476 (M-l, ES-). 2-[l-(3,4-dimetoksy-benzyl)-8-hydroksy-5-metoksy-3,4-dihydro-l^-isokinolin-2-yl]-iV-(pyridin-2-yl-metyl)-acetamid: fremstilt ved avbeskyttelse av 2-[l-(3,4-dimetoksy-benzyl)-8-benzyloksy-5-metoksy-3,4-dihydro-l/f-isokinolin-2-yl]-N-(pyridin-2-yl-metyl)-acetamid LC-MS: rt = 3,3 min, 478 (M+l, ES+), 476 (M-l, ES-). Eksempel 253 2-[l-(3-hydroksy-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-y 1] -ZV-benzy 1-acetamid: fremstilt ved avbeskyttelse av 2-[l-(3-benzyloksy-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l#-isokinolin-2-yl]-AMjenzyl-acetamid:
LC-MS: rt = 3,5 min, 477 (M+l, ES+), 475 (M-l, ES-).
C.2 Alkylering av fenoler med alkylbromider (generell fremgangsmåte):
ved RT ble en løsning av de respektive fenol i DMF (250 ul, 0,40 M) satt til K2CO3 (70 mg). Reaksjonsblandingen ble behandlet med en løsning av det respektive alkylbromid i DMF (150 ul, 1,00 M), ristet ved 100°C i 90 min og avkjølt til romtemperatur. Etter tilsetning av en andre porsjon av alkylbromid (150 ul, 1,00 M), risting (100°C, 90 min) og avkjøling til romtemperatur ble en løsning av trietylamin i THF (250 ul, 2,0 M) tilsatt, og blandingen ble ristet i 14 timer. Vann (2,0 ml) og etylacetat (2,0 ml) ble tilsatt, fasene ble separert, og den vandige fasen ble ekstrahert to ganger med etylacetat. De samlede organiske faser ble inndampet i vakuum, hvilket ga de følgende tetrahydroisokinolinderivater: Eksempel 254 2-[l-(3,4-dimetoksy-benzyl)-6-etoksy-7-metoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-6-hydroksy-7-metoksy-3,4-dihydro-lH-isokinolin-2-yl]-N-benzyl-acetamid med etyljodid LC-MS: rt = 3,8 min, 505 (M+l, ES+). Eksempel 255 2-[l-(3,4-dimetoksy-benzyl)-6-propoksy-7-metoksy-3,4-dihydro-l^-isokinolin-2-y 1] -iV-benzy 1 -acetamid: fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-6-hydroksy-7-metoksy-3,4-dihydro-l//-isokinolin-2-yl]-AM>enzyl-acetamid med propylbromid LC-MS: rt = 4,1 min, 519 (M+l, ES+). Eksempel 256 2-[l-(3,4-dimetoksy-benzyl)-6-allyloksy-7-metoksy-3,4-dihydro-l£T-isokinolin-2-yl]-iV-benzyI-acetamid: fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-6-hydroksy-7-metoksy-3,4-dihydro-l/f-isokinolin-2-yl]-A^-benzyl-acetamid med allylbromid LC-MS: rt = 4,0 min, 517 (M+l, ES+). Eksempel 260 2-[l-(3,4-dimetoksy-benzyl)-7-etoksy-6-metoksy-3,4-dihydro-lff-isokinolin-2-yl]-iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-7-hydroksy-6-metoksy-3,4-dihydro-li/-isokinolin-2-<y>l]-N-benzyl-acetamid med etyljodid LC-MS: rt = 3,8 min, 505 (M+l, ES+). Eksempel 261 2-[l-(3,4-dimetoksy-benzyl)-7-propoksy-6-metoksy-3,4-dihydro-l^-isokinolin-2-yl]-iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-7-hydroksy-6-metoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-benzyl-acetamid med propylbromid LC-MS: rt = 4,0 min, 519 (M+l, ES+). Eksempel 262 2-[l-(3,4-dimetoksy-benzyl)-7-butoksy-6-metoksy-3,4-dihydro-lff-isokinolin-2-yl] -N-benzy 1-acetamid: fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-7-hydroksy-6-metoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-benzyl-acetamid med butylbromid LC-MS: rt = 4,2 min, 533 (M+l, ES+). Eksempel 263 2-[l-(3,4-dimetoksy-benzyl)-7-allyloksy-6-metoksy-3,4-dihydro-lH-isokinolin-2-yl]-N-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-7-hydroksy-6-metoksy-3,4-dihydro-lH-isokinolin-2-yl]-N-benzyl-acetamid med allylbromid LC-MS: rt = 3,9 min, 517 (M+l, ES+). Eksempel 279 2-[l-(3,4-dimetoksy-benzyl)-5-etoksy-8-metoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-5-hydroksy-8-metoksy-3,4-dihydro- l/f-isokinolin-2-yl]-A^-(pyridin-2-yl-metyl)-acetamid med etyljodid LC-MS: rt = 0,61 min, 506 (M+l, ES+). Eksempel 280 2-[l-(3,4-dimetoksy-benzyl)-5-propoksy-8-metoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-5-hydroksy-8-metoksy-3,4-dihydro- l//-isokinolin-2-yl]-iV-(pyridin-2-yl-metyl)-acetarnid med propylbromid LC-MS: rt = 0,66 min, 520 (M+l, ES+). Eksempel 281 2-[l-(3,4-dimetoksy-benzyl)-5-allyloksy-8-metoksy-3,4-dihydro-liy-isokinolin-2-yl]-iV-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-5-hydroksy-8-metoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-(pyridin-2-yl-metyl)-acetamid med allylbromid
LC-MS: rt = 0,63 min, 518 (M+l, ES+).
Eksempel 282
2-[l-(3,4-dimetoksy-benzyI)-5-isopropoksy-8-metoksy-3,4-dihydro-l^-isokinolin-2-yl]-N-(pyridin-2-yl-metyl)-acetamid:
fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-5-hydroksy-8-metoksy-3,4-dihydro- l//-isokinolin-2-yl]-AT-(pyridin-2-yl-metyl)-acetamid med isopropylbromid LC-MS: rt = 0,64 min, 520 (M+l, ES+). Eksempel 283 2-[l-(3,4-dimetoksy-benzyl)-5-butoksy-8-metoksy-3,4-dihydro-lH-isokinolin-2-yl] -iV-(py ridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-5-hydroksy-8-metoksy-3,4-dihydro- l//-isokinolin-2-yl]-A^-(pyridin-2-yl-metyl)-acetamid med butylbromid LC-MS: rt = 0,70 min, 534 (M+l, ES+). Eksempel 284 2-[l-(3,4-dimetoksy-benzyl)-5-isobutoksy-8-metoksy-3,4-dihydro-lff-isokinolin-2-yl] -iV-(py ridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-5-hydroksy-8-metoksy-3,4-dihydro- l//-isokinolin-2-yl]-A^-(pyridin-2-yl-metyl)-acetamid med l-brom-2-metyl-propan
LC-MS: rt = 0,70 min, 534 (M+l, ES+).
Eksempel 285
2-[l-(3,4-dimetoksy-benzyl)-5-(but-2-oksy)-8-metoksy-3,4-dihydro-l^-isokinolin-2-yl]-iV-(pyridin-2-yl-metyl)-acetamid:
fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-5-hydroksy-8-metoksy-3,4-dihydro-l//-isokinolin-2-yl]-N-(pyridin-2-yl-metyl)-acetamidmed2-brom-butan LC-MS: rt = 0,68 min, 534 (M+l, ES+). Eksempel 291 2-[l-(3,4-dimetoksy-benzyl)-8-etoksy-5-metoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-8-hydroksy-5-metoksy-3,4-dihydro- l//-isokinolin-2-yl]-A^-(pyridin-2-yl-metyl)-acetamid med etyljodid LC-MS: rt = 0,62 min, 506 (M+l, ES+). Eksempel 292 2-[l-(3,4-dimetoksy-benzyl)-8-propoksy-5-metoksy-3,4-dihydro-lff-isokinolin-2-yl]-iV-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-8-hydroksy-5-metoksy-3,4-dihydro- l//-isokinolin-2-yl]-A^-(pyridin-2-yl-metyl)-acetamid med propylbromid LC-MS: rt = 0,66 min, 520 (M+l, ES+). Eksempel 293 2-[l-(3,4-dimetoksy-benzyl)-8-allyloksy-5-metoksy-3,4-dihydro-lH-isokinolin-2-y 1] -N-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-8-hydroksy-5-metoksy-3,4-dihydro-lH-isokinolin-2-yl]-A^-(pyridin-2-yl-metyl)-acetamid med allyl- bromid LC-MS: rt = 0,63 min, 518 (M+l, ES+). Eksempel 294 2-[l-(3,4-dimetoksy-benzyl)-8-isopropoksy-5-metoksy-3,4-dihydro-lff-isokinoIin-2-yl]-iV-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-8-hydroksy-5-metoksy-3,4-dihydro- lH-isokinolin-2-yl]-Af-(pyridin-2-yl-metyl)-acetamid med isopropylbromid LC-MS: rt = 0,64 min, 520 (M+l, ES+). Eksempel 295 2-[l-(3,4-dimetoksy-benzyl)-8-butoksy-5-metoksy-3,4-dihydro-l^-isokinolin-2-yl]-AT-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-8-hydroksy-5-metoksy-3,4-dihydro- l//-isokinolin-2-yl]-A^-(pyridin-2-yl-metyl)-acetamid med butylbromid LC-MS: rt = 0,69 min, 534 (M+l, ES+). Eksempel 296 2-[l-(3,4-dimetoksy-benzyl)-8-isobutoksy-5-metoksy-3,4-dihydro-lH-isokinolin-2-yl]-N-(pyridin-2-yl-metyI)-acetamid: fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-8-hydroksy-5-metoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-(pyridin-2-yl-metyl)-acetamid med l-brom-2-metyl-propan
LC-MS: rt = 0,69 min, 534 (M+l, ES+).
Eksempel 297
2-[l-(3,4-dimetoksy-benzyl)-8-(but-2-oksy)-5-metoksy-3,4-dihydro-l^-isokinolin-2-yl]-ZV-(pyridin-2-yl-metyl)-acetamid:
fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-8-hydroksy-5-metoksy-3,4-dihydro- lH-isokinolin-2-yl]-A^-(pyridin-2-yl-metyl)-acetamid med 2-brom-butan LC-MS: rt = 0,68 min, 534 (M+l, ES+). Eksempel 299 2-[l-(3,4-dimetoksy-benzyl)-8-cykloheksyloksy-5-metoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-(pyridin-2-yl-metyl)-acetamid: fremstilt ved omsetning av 2-[l-(3,4-dimetoksy-benzyl)-8-hydroksy-5-metoksy-3,4-dihydro- l//-isokinolin-2-yl]-A^-(pyridin-2-yl-metyl)-acetamid med cykloheksyl-bromid
LC-MS: rt = 0,73 min, 560 (M+l, ES+).
Eksempel 303
2-[l-(4-etoksy-3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yI]-iV-benzyl-acetamid:
fremstilt ved omsetning av 2-[l-(4-hydroksy-3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-benzyl-acetamid med etyljodid LC-MS: rt = 3,9 min, 505 (M+l, ES+). Eksempel 304 2-[l-(4-propoksy-3-metoksy-benzyI)-6,7-dimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(4-hydroksy-3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lff-isokinolin-2-yl]-N-benzyl-acetamid med propylbromid LC-MS: rt = 4,2 min, 519 (M+l, ES+). Eksempel 305 2-[l-(4-butoksy-3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lfl<r->isokinolin-2-yl]-iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(4-hydroksy-3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-iV-benzyl-acetamid med butylbromid LC-MS: rt = 4,4 min, 533 (M+l, ES+). Eksempel 306 2-[l-(4-allyloksy-3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(4-hydroksy-3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-benzyl-acetamid med allylbromid LC-MS: rt = 4,0 min, 517 (M+l, ES+). Eksempel 307 2-[l-(4-isopropoksy-3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(4-hydroksy-3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-benzyl-acetamid med isopropylbromid LC-MS: rt = 4,0 min, 519 (M+l, ES+). Eksempel 308 2-[l-(4-isobutoksy-3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl] -iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(4-hydroksy-3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro- l//-isokinolin-2-yl]-A^-benzyl-acetamid med 1 -brom-2-metyl-propan LC-MS: rt = 4,5 min, 533 (M+l, ES+). Eksempel 309 2-[l-(4-(cyklopropyl-metoksy)-3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(4-hydroksy-3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro- l//-isokinolin-2-yl]-A^-benzyl-acetamid med cyklopropyl-metylbromid LC-MS: rt = 4,2 min, 531 (M+l, ES+). Eksempel 310 {4-[2-(Benzylkarbamoyl-metyl)-6,7-dimetoksy-l,2,3,4-tetrahydro-isokinolin-l-ylmetyl]-2-metoksy-fenoksy}-eddiksyre-etylester fremstilt ved omsetning av 2-[l-(4-hydroksy-3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-A^-benzyl-acetamid med etylbromacetat LC-MS: rt = 3,9 min, 563 (M+l, ES+). Eksempel 311 2-[l-(3-etoksy-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(3-hydroksy-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l#-isolrinolin-2-yl]-AM)enzyl-acetamid med etyljodid LC-MS: rt = 3,8 min, 505 (M+l, ES+). Eksempel 312 2-[l-(3-propoksy-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-y 1] -iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(3-hydroksy-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-A^-benzyl-acetamid med propylbromid LC-MS: rt = 4,1 min, 519 (M+l, ES+). Eksempel 313 2-[l-(3-allyloksy-4-metoksy-benzyI)-6,7-dimetoksy-3,4-dihydro-l£f-isokinolin-2-yl] -iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(3-hydroksy-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-17y<->isokinolin-2-yl]-A^-benzyl-acetamid med allylbromid LC-MS: rt = 4,0 min, 517 (M+l, ES+). Eksempel 314 2-[l-(3-isopropoksy-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lfl<r->isokinolin-2-yl] -iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(3-hydroksy-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-benzyl-acetamid med isopropylbromid LC-MS: rt = 4,0 min, 519 (M+l, ES+). Eksempel 315 2-[l-(3-butoksy-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-y I] -iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(3-hydroksy-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihyclro-l//-isokinolin-2-yl]-Af-benzyl-acetamid med butylbromid LC-MS: rt = 4,3 min, 533 (M+l, ES+). Eksempel 316 2-{l-[3-(but-2-oksy)-4-metoksy-benzyl]-6,7-dimetoksy-3,4-dihydro-l£f-isokinolin-2-yl}-N-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(3-hydroksy-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l#-isokinolin-2-yl]-iV-benzyl-acetamid med 2-brom-butan LC-MS: rt = 4,2 min, 533 (M+l, ES+). Eksempel 317 2-{l-[3-(cyklopropyl-metoksy)-4-metoksy-benzyl]-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl}-iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(3-hydroksy-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-1 //-isokinolin-2-yl] -iV-benzyl-acetamid med cyklopropyl-metylbromid LC-MS: rt = 4,0 min, 531 (M+l, ES+). Eksempel 318 2-{l-[3-(3-fluor-propoksy)-4-metoksy-benzyl]-6,7-dimetoksy-3,4-dihydro-lff-isokinolin-2-yl}-iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(3-hydroksy-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl]-N-benzyl-acetamid med l-brom-3-fluor-propan LC-MS: rt = 3,9 min, 537 (M+l, ES+). Eksempel 319 2-[l-(3,4-dimetoksy-benzyl)-7-(l-metyl-prop-2-oksy)-6-metoksy-3,4-dihydro-lH-isokinolin-2-y 1] -iV-benzy l-acetamid: Ved romtemperatur ble ter^-butyl-2,2,2-trikloracetimidat (437 mg, 0,36 ml, 2,0 mmol) satt til en løsning av 2-[l-(3,4-dimetoksy-benzyl)-7-hydroksy-6-metoksy-3,4-dihydro-l#-isokinolin-2-yl]-AM>enzyl-acetamid (95,3 mg, 0,2 mmol) i diklormetan (5,0 ml) og
cykloheksan (5,0 ml). Reaksjonsblandingen ble behandlet med en løsning av bortrifluorid-dietyleterat (50 ul, 0,4 mmol) i 10 ml diklormetan og rørt i 22 timer. En andre porsjon av ter?.-butyl-2,2,2-trikloracetimidat (244 mg, 0,20 ml, 1,1 mmol) ble tilsatt. Etter røring i tre dager ble en mettet løsning av NaHCC«3 (10 ml), vann (10 ml) og etylacetat (40 ml) tilsatt, fasene ble separert, og den vandige fasen ble ekstrahert tre ganger med etylacetat (30 ml). De samlede organiske faser ble inndampet i vakuum og renset ved flashkromatografi, hvilket ga tittelproduktet (80,4 mg, 75%) som blekgul olje.
LC-MS: rt = 4,2 min, 533 (M+l, ES+).
C.3 Reaktion av fenoler med heteroarylklorider eller heteroaryl-metylsulfoner (generell fremgangsmåte): En løsning av det respektive heteroarylklorid eller metyl-sulfon i DMF (1,0 ml, 0,20 M) ble satt til en blanding av det respektive fenol (0,15 mmol) og K2CO3 (75 mg). Reaksjonsblandingen ble rørt ved 100°C i 16 timer. Vann (2,0 ml) og etylacetat (2,0 ml) ble tilsatt, fasene ble separert og den vandige fasen ble ekstrahert to ganger med etylacetat. De samlede organiske faser ble inndampet i vakuum, hvilket ga de følgende tetrahydroisokinolinderivater: Eksempel 320 2-{l-[3-(pyrimidin-2-yloksy)-4-metoksy-benzyl]-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl}-iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(3-hydroksy-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-benzyl-acetamid med 2-klor-pyrimidin LC-MS: rt = 0,60 min, 555 (M+l, ES+). Eksempel 321 2-{l-[4-(pyrimidin-2-yloksy)-3-metoksy-benzyl]-6,7-dimetoksy-3,4-dihydro-lH-isokinolin-2-yl}-iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(4-hydroksy-3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^benzyl-acetamid med 2-klor-pyrimidin LC-MS: rt = 0,60 min, 555 (M+l, ES+). C.4 Reaksjon av fenoler med karbamoylklorider (generell fremgangsmåte): En løsning av den respektive fenol (0,20 mmol) og trietylamin (0,30 ml, 2,15 mmol) i THF (1,0 ml) ble behandlet med det respektive karbamoylklorid (2,2 mmol) og rørt ved tilbakeløp i 16 timer. Vann (2,0 ml) og etylacetat (2,0 ml) ble tilsatt, fasene ble separert, og den vandige fasen ble ekstrahert to ganger med etylacetat. De samlede organiske faser ble inndampet i vakuum, hvilket ga de følgende
tetrahydroisokinolinderivater:
Eksempel 337 2-{l-[4-metoksy-3-(A^iV-dimetylkarbamoyloksy)-benzyl]-6,7-dimetoksy-3,4-dihydro-lff-isokinolin-2-yl}-iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(3-hydroksy-4-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro- l/f-isokinolin-2-yl]-A^-benzyl-acetamid med N, Af-dimetyl-karbamoylklorid LC-MS: rt = 0,62 min, 548 (M+l, ES+). Eksempel 338 2-{l-[3-metoksy-4-(iV,iV-dimetylkarbamoyloksy)-benzyl]-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl}-iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(4-hydroksy-3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro- l//-isokinolin-2-yl]-A^benzyl-acetamid med N, iV-dimetyl-karbamoylklorid LC-MS: rt = 0,63 min, 548 (M+l, ES+). Eksempel 339 2-{l-[3-metoksy-4-(4-morfolin-karbonyloksy)-benzyl]-6,7-dimetoksy-3,4-dihydro-l/7-isokinolin-2-yl}-iV-benzyl-acetamid: fremstilt ved omsetning av 2-[l-(4-hydroksy-3-metoksy-benzyl)-6,7-dimetoksy-3,4-dihydro- l//-isokinolin-2-yl]-A^-benzyl-acetamid med 4-morfolin-karbonylklorid LC-MS: rt = 0,61 min, 590 (M+l, ES+).
E. Generell fremgangsmåte for fremstilling av isonitrilderivatene
Isonitriler (eller isocyanider) blir fremstilt ved omsetning av N-alkyl-formamidene (dannet ved omsetning av det tilsvarende amin med maursyre-etylester) med POCI3.
Forkortelser:
BSA Bovint serumalbumin
CHO Kinesisk hamstereggstokk
DMF Dimetylformamid
DMSO Dimetylsulfoksyd
ES Electronspray
FCS Føtalt kalveserum
FLIPR Fluorescerende imaging plate reader
HBSS Hank's balanserte saltløsning
HEPES 4-(2-hydroksyetyl)-piperazin-1 -etansulfonsyre
MeOH Metanol
MS Massespektroskopi
LC Væskekromatografi
PyBOP Benzotriazol-l-yl-oksy-tris-pyrrolidino-Fosfoniumheksafluorfosfat
Rf Retensjonsfront
Rt retensjonstid
RT Romtemperatur
THF Tetrahydrofuran
Claims (9)
1. Forbindelser med den generelle formel (I)
hvor: R<1>, R2, R<3>, R<4> uavhengig representerer cyano, nitro, halogen, hydrogen, hydroksy, lavere-alkyl, lavere-alkenyl, lavere-alkoksy, lavere-alkenyloksy, trifluormetyl, trifluormetoksy, cykloalkyloksy, aryloksy, aralkyloksy, heterocyklyloksy, heterocyklylalkyloksy, R11 CO-, NR<12>R,<3>CO-, R12R<13>N-, R<n>OOC-, R<u>S02NH- eller R1<4->CO-NH- eller R2 og R<3> sammen så vel som R<1> og R<2> sammen og R<3> og R<4> sammen kan med fenylringen danne en fem-, seks- eller syv-leddet ring inneholdende ett eller to oksygenatomer; R<5> reprensenterer aryl, aralkyl, lavere-alkenyl, trifluormetyl, cykloalkyl, heterocyklyl eller heterocyklyl-lavere-alkyl; R<6> representerer hydrogen, aryl, aralkyl, lavere-alkyl, lavere-alkenyl, trifluormetyl, cykloalkyl, heterocyklyl eller heterocyklyl-lavere-alkyl; R7 og R8 uavhengig representerer hydrogen, aryl, aralkyl, lavere-alkyl, lavere-alkenyl, cykloalkyl, heterocyklyl eller heterocyklyl-lavere-alkyl; R<9> representerer, aryl, aralkyl, lavere-alkyl, lavere-alkenyl, trifluormetyl, cykloalkyl, heterocyklyl eller heterocyklyl-lavere-alkyl; R<10> representerer hydrogen, aryl, aralkyl, lavere-alkyl, lavere-alkenyl, trifluormetyl, cykloalkyl, heterocyklyl eller heterocyklyl-lavere-alkyl; R<11> representerer lavere-alkyl, aryl, aralkyl, heterocyklyl eller heterocyklyl-lavere-alkyl; R og R uavhengig representerer hydrogen, alkyl, cykloalkyl, aryl, aralkyl, heterocyklyl eller heterocyklyl-lavere-alkyl;R1<4> representerer alkyl, aryl, cykloalkyl, heterocyklyl, R<12>R13N- eller R<ll>O-hvor betegnelsen "lavere-alkyl", alene eller i kombinasjon, betyr en rettkjedet eller forgrenet alkylgruppe med 1 til 8 karbonatomer, betegnelsen "lavere-alkenyl", alene eller i kombinasjon, betyr en rettkjedet eller forgrenet alkenylgruppe med 2 til 5 karbonatomer, betegnelsen "cykloalkyl", alene eller i kombinasjon, betyr en cykloalkylring med 3 til 8 karbonatomer; betegnelsen "aryl", alene eller i kombinasjon, betyr en fenyl- eller naftylgruppe som eventuelt bærer én eller flere substituenter; og betegnelsen "heterocyklyl", allene eller i kombinasjon, betyr en 5- til 10-leddet monocyklisk eller bicyklisk ring, som kan være mettet, delvis umettet eller aromatisk og inneholdende 1,2 eller 3 heteroatomer valgt fra oksygen, nitrogen og svovel som kan være like eller forskjellige og som eventuelt kan ha optil 5 substituenter; og optisk rene enantiomerer, blandinger av enantiomerer, racemater, optisk rene diastereoisomerer, blandinger av diastereoisomerer, diastereoisomere racemater, blanding av diastereoisomere racemater eller mesoformer og farmasøytisk akseptable salter derav.
2. Forbindelser med den generelle formel (II)
hvor: R' and R' uavhengig representerer hydrogen, hydroksy, metoksy eller halogen eller kan med fenylringen danne en fem-, seks- eller syvleddet ring inneholdende ett eller to oksygenatomer,
R'<3> representerer aryl, aralkyl, lavere-alkenyl, cykloalkyl, heterocyklyl eller heterocyklyl-lavere-alkyl;
R'<4> representerer hydrogen, aryl, aralkyl, lavere-alkyl, lavere-alkenyl, cykloalkyl, heterocyklyl eller heterocyklyl-lavere-alkyl;
R'<5> representerer aryl, aralkyl, lavere-alkyl, lavere-alkenyl, cykloalkyl, heterocyklyl eller heterocyklyl-lavere-alkyl;
og optisk rene enantiomerer, blandinger av enantiomerer, racemater, optisk rene diastereoisomerer, blandinger av diastereoisomerer, diastereoisomere racemater, blanding av diastereoisomere racemater eller mesoformer og farmasøytisk akseptable salter derav.
3. Forbindelse ifølge hvilket som helst av krav 1 til 2 valgt fra gruppen bestående av 2-[l-(3,4-dimetoksy-benzyl)-5,8-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-A'-(pyridin-2-yl-metyl)-acetamid: 2- [ 1 -(3,4-dimetoksy-benzyl)-8-(cyklopropyl-metoksy)-5 -metoksy-3,4-dihydro-1 if-isokinolin-2-yl] -Af-(pyridin-2-yl-mety l)-acetamid: 2-[l-(3,4-dimetoksy-benzyl)-8-(2-fluor-etoksy)-5-metoksy-3,4-dihydro-l//-isokinolin-2-yl]-7V-(pyridin-2-yl-metyl)-acetamid: 2-[ 1 -(3,4-dimetoksy-benzyl)-8-(2,2-difluor-etoksy)-5-metoksy-3,4-dihydro-1 fl-isokinolin-2-yl]-N-(pyridin-2-yl-metyl)-acetamid: 2-[l-(3,4-dimetoksy-benzyl)-8-etoksy-5-metoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-(pyridin-2-yl-metyl)-acetamid: 2- [ 1 -(3,4-dimetoksy-benzyl)-8-propoksy-5-metoksy-3,4-dihydro-17/-isokinolin-2-yl]-A/- (pyridin-2-yl-metyl)-acetamid: 2-[l-(3,4-dimetoksy-benzyl)-8-allyloksy-5-metoksy-3,4-dihydro-l//-isokinolin-2-yl]-A'-(pyridin-2-yl-metyl)-acetamid: 2-[l-(3,4-dimetoksy-benzyl)-8-isopropoksy-5-metoksy-3,4-dihydro-li/-isokinolin-2-yl]-AT-(pyridin-2-yl-metyl)-acetamid: 2-[l-(3,4-dimetoksy-benzyl)-5-propoksy-8-metoksy-3,4-dihydro-li/-isokinolin-2-yl]-iv'-(pyridin-2-yl-metyl)-acetamid: 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl]-A^-benzyl-acetamid 2-[l-(3,4-dimetoksy-benzyl)-6,7-dimetoksy-3,4-dihydro-l^-isokinolin-2-yl]-iV-naftalen-1 -ylmetyl-acetamid 2-{l-[4-(pyrimidin-2-yloksy)-3-metoksy-benzyl]-6,7-dimetoksy-3,4-dihydro-l//-isokinolin-2-yl} -7V-benzyl-acetamid 2- [ 1 -(3,4-dimetoksy-benzyl)-7-( 1 -metyl-prop-2-oksy)-6-metoksy-3,4-dihydro-1 //-isokinolin-2-yl] -Af-benzyl-acetamid 2- [ 1 -(3,4-dimetoksy-benzyl)-6-metoksy-7-isopropoksy-3,4-dihydro-1 i/-isokinolin-2-yl]-iV-benzyl-acetamid 2- [ 1 -(3,4-dimetoksy-benzyl)-7-etoksy-6-metoksy-3,4-dihydro-1 //-isokinolin-2-yl]-7/-benzyl-acetamid 2-[l-(3,4-dimetoksy-benzyl)-7-propoksy-6-metoksy-3,4-dihydro-l//-isokinolin-2-yl]-7V-benzyl-acetamid 2- [ 1 -(3,4-dimetoksy-benzyl)-7-aliyloksy-6-metoksy-3,4-dihydro-1 //-isokinolin-2-yl] - N-benzyl-acetamid iV-benzyl-2- [ 1 -(3,4-dimetyl-benzyl)-6,7-dimetoksy-3,4-dihydro-1 if-isokinolin-2-yl] -acetamid A^-benzyl-2-[l-(3,4-dietyl-benzyl)-6,7-dimetoksy-3,4-dihydro-l/f-isokinolin-2-yl]-acetamid 2- [ 1 -(3,4-dietyl-benzyl)-6,7-dimetoksy-3,4-dihydro-1 //-isokinolin-2-yl] -7V-(pyridin-2-yl-mety 1)-acetamid 2- [ 1 -(3,4-dietyl-benzy l)-6,7-dimetoksy-3,4-dihydro-1 J7-isokinolin-2-yl] -JV-(pyridin-3 -yl-metyl)-acetamid 2- [ 1 -(3,4-dietyl-benzy l)-6,7-dimetoksy-3,4-dihydro-1 i/-isokinolin-2-yl] -7V-(pyridin-4-yl-metyl)-acetamid 2- [ 1 -(3,4-diklor-benzyl)-6,7-dimetoksy-3,4-dihydro-1 i/-isokinolin-2-yl] -JV-(pyridin-3 -yl-metyl-acetamid
4. Fremgangsmåte for kombinatorisk fremstilling av forbindelser med den generelle formel I, hvor R<6>, R<7> og R<9> er hydrogen, ved anvendelse av en Ugi-tre-komponent-kondenseringsreaksjon, omfattende én-satsreaksjon av en forbindelse med formel III
hvor Ri, R2, R3, R4 og R5 har betydningen gitt i formel I ovenfor og R&representerer hydrogen,
med en forbindelse med formel IV
hvor R7 representerer hydrogen og R» har betydningen gitt i formel I ovenfor, og en forbindelse med formel V
hvor Rio har betydningen gitt i formel I ovenfor,
om ønsket, isolering av farmakologisk aktive forbindelser på en i og for seg kjent måte, hvis ønsket, oppløsning av et racemat oppnådd på en i og for seg kjent måte, og, om ønsket omdannelse av en oppnådd forbindelse eller forbindelser til et salt på en i og for seg kjent måte.
5. Fremgangsmåte for fremstilling av forbindelser med formel I ovenfor, omfattende omsetning av en forbindelse med formel III<1>,
hvor substituentene Ri til R$ har betydningen gitt i formel I ovenfor, med en forbindelse med formel VI
hvor R7 til Rio har betydningen gitt i formel I ovenfor.
6. Fremgangsmåte for fremstilling av forbindelser med formel I ovenfor, omfattende omsetning av en forbindelse med formel III',
hvor substituentene Ri til R6 har betydningen gitt i formel I ovenfor, med a) en forbindelse med formel IX
hvor R7, Rg og Ri i har betydningen gitt i formel I ovenfor, b) Spaltning av en ester oppnådd på en i og for seg kjent måte og omsetning av syren som blir dannet med c) en forbindelse med formel X
hvor substituentene R9 og Rio har betydningen gitt i formel I ovenfor,
om ønsket, oppløsning av et racemat oppnådd på en i og for seg kjent måte. og, om ønsket, omdannelse av en oppnådd forbindelse til et salt på en i og for seg kjent måte.
7. Farmasøytiske preparater for behandling av forstyrrelser som er assosiert med rollen til orexin, spesielt forstyrrelser så som fedme og søvnforstyrrelser, inneholdende en forbindelse ifølge hvert av kravene 1 til 3, eller et farmasøytisk akseptabelt salt derav og vanlige bærermaterialer og hjelpemidler.
8. Forbindelsene ifølge hvilket som helst én av kravene 1 til 3 eller et farmasøytisk akseptabelt salt derav for anvendelse som medikamenter for behandling av forstyrrelser som er forbundet med en rolle av orexin, spesielt fedme og søvnforstyrrelser.
9. Fremgangsmåte for fremstilling av farmasøytiske preparater for behandling av forstyrrelser forbundet med rollen til orexin, spesielt fedme og søvnforstyrrelser, inneholdende én eller flere forbindelser som krevet i hvilket som helst av kravene 1 til 3 eller et farmasøytisk akseptabelt salt eller salter derav, som aktive bestanddeler, hvilken fremgangsmåte omfatter blanding av én aktiv bestanddel eller flere aktive bestanddeler med farmasøytisk akseptable tilsetningsmidler og tilsetningsmidler på en i og for seg kjent måte.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP0002245 | 2000-03-14 | ||
PCT/EP2001/002733 WO2001068609A1 (en) | 2000-03-14 | 2001-03-12 | 1,2,3,4-tetrahydroisoquinoline derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20024339L NO20024339L (no) | 2002-09-11 |
NO20024339D0 NO20024339D0 (no) | 2002-09-11 |
NO324932B1 true NO324932B1 (no) | 2008-01-07 |
Family
ID=8163870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20024339A NO324932B1 (no) | 2000-03-14 | 2002-09-11 | 1,2,3,4-Tetrahydroisokinolin-derivater, fremgangsmate for fremstilling av slike, farmasoytiske preparater inneholdende slike samt slike forbindelser anvendt til fremstilling av medikament for behandling av sykdommer |
Country Status (18)
Country | Link |
---|---|
US (1) | US6703392B2 (no) |
JP (1) | JP4009460B2 (no) |
KR (2) | KR20070087103A (no) |
CN (1) | CN100393703C (no) |
AT (1) | ATE286500T1 (no) |
AU (2) | AU2001260113B2 (no) |
BR (1) | BRPI0109200B8 (no) |
CA (1) | CA2402431C (no) |
DE (1) | DE60108236T2 (no) |
ES (1) | ES2234840T3 (no) |
HU (1) | HU227811B1 (no) |
IL (2) | IL150986A0 (no) |
MX (1) | MXPA02008797A (no) |
NO (1) | NO324932B1 (no) |
NZ (1) | NZ520624A (no) |
PT (1) | PT1274687E (no) |
WO (1) | WO2001068609A1 (no) |
ZA (1) | ZA200206467B (no) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2234929T3 (es) | 2000-11-28 | 2005-07-01 | Smithkline Beecham Plc | Derivados de morfolina como antagonistas de los receptores de orexina. |
GB0126292D0 (en) * | 2001-11-01 | 2002-01-02 | Smithkline Beecham Plc | Compounds |
GB0130388D0 (en) * | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
WO2004033418A2 (en) | 2002-10-11 | 2004-04-22 | Actelion Pharmaceuticals Ltd. | Sulfonylamino-acetic derivatives and their use as orexin receptor antagonists |
GB0225884D0 (en) * | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2004076411A2 (en) * | 2003-02-24 | 2004-09-10 | Merck & Co., Inc. | Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity |
JP4637089B2 (ja) * | 2003-03-26 | 2011-02-23 | アクテリオン ファーマシューティカルズ リミテッド | アセトアミド誘導体 |
US7321065B2 (en) * | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
US7538109B2 (en) | 2003-04-28 | 2009-05-26 | Actelion Pharmaceuticals Ltd | Quinoxalin-3-one derivatives as orexin receptor antagonists |
WO2005028438A1 (ja) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
ATE493421T1 (de) * | 2004-01-23 | 2011-01-15 | Janssen Pharmaceutica Nv | Neue inhibitoren von chymase |
US20100048513A1 (en) | 2008-08-20 | 2010-02-25 | Hawkins Michael J | Novel inhibitors of chymase |
SI1751111T1 (sl) * | 2004-03-01 | 2015-04-30 | Actelion Pharmaceuticals Ltd. | Substituirani 1,2,3,4-tetrahidroizokinolinski derivati |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
EP1814590B2 (en) | 2004-11-01 | 2013-12-11 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
WO2006081522A2 (en) * | 2005-01-26 | 2006-08-03 | The Regents Of The Unversity Of California | Modulation of nmda receptor currents via orexin receptor and/or crf receptor |
US20090286723A1 (en) | 2005-02-11 | 2009-11-19 | Amylin Pharmaceuticals, Inc. | Hybrid Polypeptides with Selectable Properties |
US7501395B2 (en) | 2005-04-25 | 2009-03-10 | Eisai R & D Management Co., Ltd. | Method of screening for antianxiety drugs |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
ES2574014T3 (es) | 2005-05-30 | 2016-06-14 | Msd K.K. | Derivado de piperidina novedoso |
EP1916239A4 (en) | 2005-08-10 | 2009-10-21 | Banyu Pharma Co Ltd | PYRIDONE COMPOUND |
BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
EP1921065B1 (en) | 2005-08-24 | 2010-10-20 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
WO2007029847A1 (ja) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | 二環性芳香族置換ピリドン誘導体 |
EP1940842B1 (en) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
BRPI0617621A2 (pt) | 2005-10-21 | 2011-08-02 | Novartis Ag | combinação de compostos orgánicos |
AU2006307046A1 (en) | 2005-10-27 | 2007-05-03 | Msd K.K. | Novel benzoxathiin derivative |
MY146564A (en) | 2005-11-10 | 2012-08-30 | Msd Kk | Aza-substituted spiro derivatives |
CA2635126A1 (en) * | 2006-01-26 | 2007-08-02 | Actelion Pharmaceuticals Ltd | Tetrahydropyrane antibiotics |
MX2008011647A (es) * | 2006-03-15 | 2008-09-22 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroisoquinolina para mejorar la funcion de la memoria. |
MX2008013238A (es) * | 2006-04-12 | 2008-10-21 | Merck & Co Inc | Antagonistas de los canales de calcio de tipo t de piridil amida. |
WO2007122591A2 (en) * | 2006-04-26 | 2007-11-01 | Actelion Pharmaceuticals Ltd | Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists |
WO2008008517A2 (en) | 2006-07-14 | 2008-01-17 | Merck & Co., Inc. | Bridged diazepan orexin receptor antagonists |
ES2339822T3 (es) * | 2006-08-28 | 2010-05-25 | Actelion Pharmaceuticals Ltd. | Derivados de 1,4,5,6,7,8-hexahidro-1,2,5-triaza-azuleno como antagonistas del receptor de orexina. |
EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
WO2008038692A1 (fr) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | dÉrivÉ de diarylcÉtimine |
PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
EP2125823B1 (en) | 2006-12-22 | 2012-02-15 | Actelion Pharmaceuticals Ltd. | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives |
AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
WO2008122513A1 (en) * | 2007-04-04 | 2008-10-16 | F. Hoffmann-La Roche Ag | Heterocycles as orexin antagonists |
EP2150114A4 (en) | 2007-05-18 | 2012-01-18 | Merck Sharp & Dohme | OXO-BRIDGED DIAZEPANOREXINE RECEPTOR ANTAGONISTS |
WO2008150364A1 (en) | 2007-05-23 | 2008-12-11 | Merck & Co., Inc. | Cyclopropyl pyrrolidine orexin receptor antagonists |
RU2470021C2 (ru) | 2007-05-23 | 2012-12-20 | Мерк Шарп Энд Домэ Корп. | Пиридилпиперидиновые антагонисты рецептора орексинов |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
PE20091010A1 (es) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
US8637513B2 (en) * | 2007-10-24 | 2014-01-28 | Merck Sharp & Dohme Corp. | Heterocycle phenyl amide T-type calcium channel antagonists |
JP5829399B2 (ja) * | 2007-12-28 | 2015-12-09 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | 3置換3,4−ジヒドロ−1h−イソキノリン化合物、その製造方法及びその使用 |
CA2714617A1 (en) | 2008-03-06 | 2009-09-11 | Banyu Pharmaceutical Co., Ltd. | Alkylaminopyridine derivative |
US20110015198A1 (en) | 2008-03-28 | 2011-01-20 | Banyu Pharmaceutical Co., Inc. | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
EP2285419A4 (en) | 2008-05-20 | 2012-05-02 | Neurogesx Inc | LUBRICANT MUTUAL PARACETAMOL PRODRUGS |
EP2301936A1 (en) | 2008-06-19 | 2011-03-30 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
CA2726834A1 (en) * | 2008-06-25 | 2009-12-30 | Actelion Pharmaceuticals Ltd | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds |
EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
EP2319841A1 (en) | 2008-07-30 | 2011-05-11 | Msd K.K. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
EP2161266A1 (en) | 2008-08-22 | 2010-03-10 | EVOTEC Neurosciences GmbH | Benzofuran derivatives as orexin receptor antagonists |
CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010064212A1 (en) | 2008-12-05 | 2010-06-10 | Actelion Pharmaceuticals Ltd | Method for obtaining an optically pure 1,2,3,4 tetrahydro-isoquinoline derivative |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
EP2504316A1 (en) | 2009-11-23 | 2012-10-03 | MSD Oss B.V. | Heterocylic compounds as antagonists of the orexin receptors |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
WO2011138265A2 (en) | 2010-05-03 | 2011-11-10 | Evotec Ag | Indole and indazole derivatives as orexin receptor antagonists |
WO2011138266A1 (en) | 2010-05-03 | 2011-11-10 | Evotec Ag | Indolizine and imidazopyridine derivatives as orexin receptor antagonists |
EP2402322A1 (en) | 2010-07-02 | 2012-01-04 | Actelion Pharmaceuticals Ltd. | 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
EP2677869B1 (en) | 2011-02-25 | 2017-11-08 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
AU2012311599B2 (en) | 2011-09-19 | 2017-07-06 | Eth Zurich | Ror gamma modulators |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
WO2013078413A1 (en) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulators of lipid storage |
AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
HUE040323T2 (hu) | 2012-12-21 | 2019-02-28 | Epizyme Inc | PRMT5-inhibitorok és alkalmazásaik |
AU2014219020A1 (en) | 2013-02-22 | 2015-07-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
EP2781217A1 (en) | 2013-03-18 | 2014-09-24 | ETH Zurich | ROR gamma modulators |
JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法 |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
JP6769963B2 (ja) | 2014-08-29 | 2020-10-14 | ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ | α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤 |
CN105198809A (zh) * | 2015-09-24 | 2015-12-30 | 绍兴文理学院 | 一种2-(1-酰亚胺基甲基)-1,2,3,4-四氢异喹啉衍生物及其合成方法与应用 |
CN105418498A (zh) * | 2015-12-30 | 2016-03-23 | 绍兴文理学院 | 一种1,2,3,4-四氢异喹啉衍生物及其合成方法与应用 |
US20190151304A1 (en) | 2016-05-10 | 2019-05-23 | Inserm (Institut National De La Santé Et De La Rechercjae Médicale | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory |
AU2017342083A1 (en) | 2016-10-14 | 2019-04-11 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
KR20210111248A (ko) | 2018-11-20 | 2021-09-10 | 테스 파마 에스.알.엘. | α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제 |
CN112538100B (zh) * | 2020-12-16 | 2022-06-24 | 河南中医药大学 | 一种从黄柏中提取的具有抗炎活性的异喹啉生物碱苷类化合物及其制备方法与应用 |
WO2023164596A1 (en) * | 2022-02-25 | 2023-08-31 | The Katholieke Universiteit Leuven | Dihydroquinazolinones and related analogs for inhibiting yap/taz-tead |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE204917C (no) | ||||
CA205079A (en) * | 1920-10-26 | Nelson Lionel | Gas producer | |
DE258817C (no) | ||||
DE261158C (no) | ||||
CA110459A (en) * | 1907-12-09 | 1908-02-25 | Charles Albert Keller | Electric furnace |
CA173523A (en) * | 1916-04-01 | 1916-11-28 | Raymond B. Price | Textile material |
CA170679A (en) * | 1916-05-26 | 1916-07-11 | Edwin W. Webb | Car brake |
US3480714A (en) * | 1966-02-07 | 1969-11-25 | Ciba Geigy Corp | N-substituted isoquinolines as antiprotozoal agents |
DD204917A1 (de) * | 1981-12-31 | 1983-12-14 | Gerhard Kempter | Verfahren zur herstellung phenylsubstituierter und benzkondensierter cycloalkylaminoacetanilide |
JPS6153268A (ja) * | 1984-08-24 | 1986-03-17 | Hokuriku Seiyaku Co Ltd | アントラニルアミド誘導体 |
DD261158A1 (de) * | 1987-01-08 | 1988-10-19 | Univ Halle Wittenberg | Verfahren zur herstellung von 2-aminoalkyl-3,4-dihydro-4-oxo-7h-pyrrolo 2.3-d pyrimidinen |
DD258817A1 (de) * | 1987-01-19 | 1988-08-03 | Univ Halle Wittenberg | Verfahren zur herstellung von 2-(aminoalkyl) -pyrimido-4,5'-5,4 pyrrolo 3,2-f 1,4 thiazepinderivaten |
PL168202B1 (pl) | 1991-01-11 | 1996-01-31 | Glaxo Lab Sa | S posób wytwarzania nowych pochodnych akrydyny PL PL |
BR9406897A (pt) * | 1993-06-22 | 1996-03-26 | Knoll Ag | Compostos de tetraidroisoquinolina composiçoes farmaceuticas processo de analgesia ou de tratamento de psicoses doença de parkinson sindrome de leschnyan distúrbio da falta de atençao ou danos cognitivos ou na supressao da dependencia de drogas ou discinesia tardia e uso de um composto |
JPH07267961A (ja) * | 1994-03-30 | 1995-10-17 | Taisho Pharmaceut Co Ltd | ベンゾフロ[3,2−dピリミジン−4−オン誘導体 |
JPH1095766A (ja) | 1996-09-19 | 1998-04-14 | Sanwa Kagaku Kenkyusho Co Ltd | アセトアミド誘導体、及びその用途 |
YU23499A (sh) * | 1996-11-27 | 2001-07-10 | Pfizer Inc. | Inhibitorski amidi apo-b-sekrecije/mtp-a |
AR016817A1 (es) | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
US6372757B1 (en) * | 1998-05-08 | 2002-04-16 | Smithkline Beecham P.L.C. | Phenylurea and phenylthio urea derivatives |
WO2000029399A1 (en) | 1998-11-12 | 2000-05-25 | Boehringer Ingelheim (Canada) Ltd. | Antiherpes compounds |
GB9827467D0 (en) * | 1998-12-15 | 1999-02-10 | Zeneca Ltd | Chemical compounds |
GB9914015D0 (en) * | 1999-06-17 | 1999-08-18 | Zeneca Ltd | Chemical compounds |
GB9914025D0 (en) * | 1999-06-17 | 1999-08-18 | Zeneca Ltd | Chemical compounds |
AU6073300A (en) * | 1999-07-06 | 2001-01-22 | Vertex Pharmaceuticals Incorporated | N-heterocyclic derivatives with neuronal activity |
-
2001
- 2001-03-12 MX MXPA02008797A patent/MXPA02008797A/es active IP Right Grant
- 2001-03-12 DE DE60108236T patent/DE60108236T2/de not_active Expired - Lifetime
- 2001-03-12 IL IL15098601A patent/IL150986A0/xx active IP Right Grant
- 2001-03-12 ES ES01933685T patent/ES2234840T3/es not_active Expired - Lifetime
- 2001-03-12 BR BRPI0109200A patent/BRPI0109200B8/pt not_active IP Right Cessation
- 2001-03-12 US US10/239,693 patent/US6703392B2/en not_active Expired - Lifetime
- 2001-03-12 CA CA002402431A patent/CA2402431C/en not_active Expired - Lifetime
- 2001-03-12 PT PT01933685T patent/PT1274687E/pt unknown
- 2001-03-12 KR KR1020077016214A patent/KR20070087103A/ko active Search and Examination
- 2001-03-12 HU HU0300207A patent/HU227811B1/hu unknown
- 2001-03-12 AU AU2001260113A patent/AU2001260113B2/en not_active Expired
- 2001-03-12 CN CNB018063268A patent/CN100393703C/zh not_active Expired - Lifetime
- 2001-03-12 NZ NZ520624A patent/NZ520624A/xx not_active IP Right Cessation
- 2001-03-12 JP JP2001567703A patent/JP4009460B2/ja not_active Expired - Lifetime
- 2001-03-12 AU AU6011301A patent/AU6011301A/xx active Pending
- 2001-03-12 KR KR1020027011533A patent/KR100842698B1/ko active IP Right Grant
- 2001-03-12 WO PCT/EP2001/002733 patent/WO2001068609A1/en active IP Right Grant
- 2001-03-12 AT AT01933685T patent/ATE286500T1/de active
-
2002
- 2002-07-30 IL IL150986A patent/IL150986A/en unknown
- 2002-08-13 ZA ZA200206467A patent/ZA200206467B/en unknown
- 2002-09-11 NO NO20024339A patent/NO324932B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2001068609A1 (en) | 2001-09-20 |
KR20070087103A (ko) | 2007-08-27 |
HU227811B1 (en) | 2012-03-28 |
DE60108236T2 (de) | 2005-12-22 |
AU2001260113B2 (en) | 2006-04-06 |
US20030176415A1 (en) | 2003-09-18 |
NO20024339L (no) | 2002-09-11 |
PT1274687E (pt) | 2005-04-29 |
DE60108236D1 (de) | 2005-02-10 |
BRPI0109200B1 (pt) | 2015-08-11 |
NZ520624A (en) | 2004-02-27 |
KR20020080465A (ko) | 2002-10-23 |
JP4009460B2 (ja) | 2007-11-14 |
JP2003527374A (ja) | 2003-09-16 |
ES2234840T3 (es) | 2005-07-01 |
ZA200206467B (en) | 2003-11-13 |
ATE286500T1 (de) | 2005-01-15 |
CA2402431C (en) | 2009-10-06 |
HUP0300207A2 (en) | 2003-05-28 |
MXPA02008797A (es) | 2005-09-08 |
HUP0300207A3 (en) | 2005-07-28 |
AU6011301A (en) | 2001-09-24 |
NO20024339D0 (no) | 2002-09-11 |
BRPI0109200B8 (pt) | 2021-05-25 |
IL150986A0 (en) | 2003-02-12 |
WO2001068609B1 (en) | 2002-02-21 |
KR100842698B1 (ko) | 2008-07-01 |
CN100393703C (zh) | 2008-06-11 |
CA2402431A1 (en) | 2001-09-20 |
BR0109200A (pt) | 2003-06-03 |
CN1416420A (zh) | 2003-05-07 |
US6703392B2 (en) | 2004-03-09 |
IL150986A (en) | 2007-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO324932B1 (no) | 1,2,3,4-Tetrahydroisokinolin-derivater, fremgangsmate for fremstilling av slike, farmasoytiske preparater inneholdende slike samt slike forbindelser anvendt til fremstilling av medikament for behandling av sykdommer | |
AU2001260113A1 (en) | 1,2,3,4-tetrahydroisoquinoline derivatives | |
RU2378257C2 (ru) | Замещенные производные 1,2,3,4-тетрагидроизохинолина | |
US7192950B2 (en) | Benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists | |
US20060178515A1 (en) | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | |
ZA200500026B (en) | 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydo-pyrido and 2,3-dihydro-2H-pyrroloÄ2,1-bÜ-quinazolinone derivatives. | |
US7538109B2 (en) | Quinoxalin-3-one derivatives as orexin receptor antagonists | |
EP1274687B1 (en) | 1,2,3,4- tetrahydroisoquinoline derivatives | |
US20060040977A1 (en) | 5-HT7 receptor ligands | |
EP1620409B1 (en) | Quinoxalin-3-one derivatives as orexin receptor antagonists | |
MXPA06009833A (en) | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |